BioMedLib Search Engine
[ goto HOMEPAGE ]
Save time; Find better answers!
Skip to content
Advanced Search
Search History
MeSH Query
Page Format
Clarify the query
Login
Skip to content
Export Citations
Search Results
RSS
Email
Articles' Details
Start new query
Reset All
Refine your query
(more in Advanced-Search):
Search all of MEDLINE
Focus on the recent 5 years
Focus on the current year
Focus on the last 30 days
More choices ...
Focus on articles with free fulltexts
More choices ...
Do simple 'keyword' search (no query expansion)
[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click
here to
RESET
all values
Click
here to
GO BACK
without resetting any value
Advanced Search
Submit one or more of the following items, and they will be searched along with your query in the search box above.
Any submit button will submit all of the items you have changed.
+
Publication-Date
Published in the last:
30 days
60 days
90 days
6 months
12 months
this year
2 years
3 years
5 years
10 years
Or published in the following date range: From (yyyy/mm/dd - month and day are optional)
to ('to' is optional)
+
Full Text
Retrieve articles with hyperlinks to:
full text (either free or subscription)
free full text
subscription full text
no full text link
+
Sort-Order
Sort the retrieved articles by:
relevance
publication date
+
Language
And with languages:
English
French
German
Italian
Japanese
Russian
Spanish
More languages:
Afrikaans
Albanian
Amharic
Arabic
Armenian
Azerbaijani
Bengali
Bosnian
Bulgarian
Catalan
Chinese
Czech
Danish
Dutch
Esperanto
Estonian
Finnish
Georgian
Scottish Gaelic
Greek, Modern
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Kinyarwanda
Korean
Latin
Latvian
Lithuanian
Macedonian
Malayalam
Maori
Malay
Multiple languages
Norwegian
Persian
Polish
Portuguese
Pushto
Romanian
Sanskrit
Serbian
Croatian
Slovak
Slovenian
Swedish
Thai
Turkish
Ukrainian
Undetermined
Urdu
Vietnamese
Welsh
+
Publication-Type
And with publication types:
Clinical Trial
Editorial
Letter
Meta-Analysis
Practice Guideline
Randomized Controlled Trial
Review
More publication types:
Addresses
Bibliography
Biography
Case Reports
Classical Article
Clinical Conference
Clinical Trial, Phase I
Clinical Trial, Phase II
Clinical Trial, Phase III
Clinical Trial, Phase IV
Comment
Comparative Study
Congresses
Consensus Development Conference
Consensus Development Conference, NIH
Controlled Clinical Trial
Corrected and Republished Article
Dictionary
Directory
Duplicate Publication
English Abstract
Evaluation Studies
Festschrift
Government Publications
Guideline
Historical Article
Interactive Tutorial
Interview
Introductory Journal Article
In Vitro
Journal Article
Lectures
Legal Cases
Legislation
Multicenter Study
News
Newspaper Article
Overall
Patient Education Handout
Periodical Index
Portraits
Published Erratum
Retracted Publication
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Retraction of Publication
Scientific Integrity Review
Technical Report
Twin Study
Validation Studies
+
Species
And for:
Humans
Animals
+
Gender
And for:
Male
Female
+
Age
And for these age groups:
Newborn: birth to 1 month
Infant: 1 to 23 months
Preschool child: 2 to 5 years
Child: 6 to 12 years
Adolescent: 13 to 18 years
Adult: 19 to 44 years
Middle aged: 45 to 64 years
Aged: 65+ years
80 and over: 80+ years
+
Title
And for this query matching the titles:
+
Transliterated-Title
And for this query matching the title in original language:
+
Abstract
And for this query matching the abstratcs:
+
Major-Mesh
And for this query matching the MeSH-Major terms:
+
Mesh
And for this query matching any MeSH terms:
+
Journal
And for one or more of these journal abbreviated names:
OR
OR
(see
title abbreviations
)
+
Volume
And with journal volume number:
+
Issue
And with journal issue number:
+
Page
And with page number:
+
ISSN
And with ISSN:
+
Publication-Place
And with journal's country of publication:
+
Author
And for...
all these author names:
AND
AND
(see
help
)
one or more of these author names:
OR
OR
but not having any of these unwanted author names:
NOT
NOT
+
Affiliation
And with affiliation to:
+
Has-Abstract
Find MEDLINE records with the abstract status:
has abstract
does not have abstract
include both record types
include both record types but rank higher the records having abstract (the default BML behavior)
+
PMID
Show me only articles for these PMIDs (PubMed IDs):
+
Semantic-Type
And with semantic types:
A. Entity
A1. Physical Object
A1.1. Organism
A1.1.1. Archaeon
A1.1.2. Bacterium
A1.1.3. Eukaryote
A1.1.3.1. Animal
A1.1.3.1.1. Vertebrate
A1.1.3.1.1.1. Amphibian
A1.1.3.1.1.2. Bird
A1.1.3.1.1.3. Fish
A1.1.3.1.1.4. Mammal
A1.1.3.1.1.4.1. Human
A1.1.3.1.1.5. Reptile
A1.1.3.2. Fungus
A1.1.3.3. Plant
A1.1.4. Virus
A1.2. Anatomical Structure
A1.2.1. Embryonic Structure
A1.2.2. Anatomical Abnormality
A1.2.2.1. Congenital Abnormality
A1.2.2.2. Acquired Abnormality
A1.2.3. Fully Formed Anatomical Structure
A1.2.3.1. Body Part, Organ, or Organ Component
A1.2.3.2. Tissue
A1.2.3.3. Cell
A1.2.3.4. Cell Component
A1.2.3.5. Gene or Genome
A1.3. Manufactured Object
A1.3.1. Medical Device
A1.3.1.1. Drug Delivery Device
A1.3.2. Research Device
A1.3.3. Clinical Drug
A1.4. Substance
A1.4.1. Chemical
A1.4.1.1. Chemical Viewed Functionally
A1.4.1.1.1. Pharmacologic Substance
A1.4.1.1.1.1. Antibiotic
A1.4.1.1.2. Biomedical or Dental Material
A1.4.1.1.3. Biologically Active Substance
A1.4.1.1.3.1. Neuroreactive Substance or Biogenic Amine
A1.4.1.1.3.2. Hormone
A1.4.1.1.3.3. Enzyme
A1.4.1.1.3.4. Vitamin
A1.4.1.1.3.5. Immunologic Factor
A1.4.1.1.3.6. Receptor
A1.4.1.1.4. Indicator, Reagent, or Diagnostic Aid
A1.4.1.1.5. Hazardous or Poisonous Substance
A1.4.1.2. Chemical Viewed Structurally
A1.4.1.2.1. Organic Chemical
A1.4.1.2.1.5. Nucleic Acid, Nucleoside, or Nucleotide
A1.4.1.2.1.6. Organophosphorus Compound
A1.4.1.2.1.7. Amino Acid, Peptide, or Protein
A1.4.1.2.1.8. Carbohydrate
A1.4.1.2.1.9. Lipid
A1.4.1.2.1.9.1. Steroid
A1.4.1.2.1.9.2. Eicosanoid
A1.4.1.2.2. Inorganic Chemical
A1.4.1.2.3. Element, Ion, or Isotope
A1.4.2. Body Substance
A1.4.3. Food
A2. Conceptual Entity
A2.1. Idea or Concept
A2.1.1. Temporal Concept
A2.1.2. Qualitative Concept
A2.1.3. Quantitative Concept
A2.1.4. Functional Concept
A2.1.4.1. Body System
A2.1.5. Spatial Concept
A2.1.5.1. Body Space or Junction
A2.1.5.2. Body Location or Region
A2.1.5.3. Molecular Sequence
A2.1.5.3.1. Nucleotide Sequence
A2.1.5.3.2. Amino Acid Sequence
A2.1.5.3.3. Carbohydrate Sequence
A2.1.5.4. Geographic Area
A2.2. Finding
A2.2.1. Laboratory or Test Result
A2.2.2. Sign or Symptom
A2.3. Organism Attribute
A2.3.1. Clinical Attribute
A2.4. Intellectual Product
A2.4.1. Classification
A2.4.2. Regulation or Law
A2.5. Language
A2.6. Occupation or Discipline
A2.6.1. Biomedical Occupation or Discipline
A2.7. Organization
A2.7.1. Health Care Related Organization
A2.7.2. Professional Society
A2.7.3. Self-help or Relief Organization
A2.8. Group Attribute
A2.9. Group
A2.9.1. Professional or Occupational Group
A2.9.2. Population Group
A2.9.3. Family Group
A2.9.4. Age Group
A2.9.5. Patient or Disabled Group
B. Event
B1. Activity
B1.1. Behavior
B1.1.1. Social Behavior
B1.1.2. Individual Behavior
B1.2. Daily or Recreational Activity
B1.3. Occupational Activity
B1.3.1. Health Care Activity
B1.3.1.1. Laboratory Procedure
B1.3.1.2. Diagnostic Procedure
B1.3.1.3. Therapeutic or Preventive Procedure
B1.3.2. Research Activity
B1.3.2.1. Molecular Biology Research Technique
B1.3.3. Governmental or Regulatory Activity
B1.3.4. Educational Activity
B1.4. Machine Activity
B2. Phenomenon or Process
B2.1. Human-caused Phenomenon or Process
B2.1.1. Environmental Effect of Humans
B2.2. Natural Phenomenon or Process
B2.2.1. Biologic Function
B2.2.1.1. Physiologic Function
B2.2.1.1.1. Organism Function
B2.2.1.1.1.1. Mental Process
B2.2.1.1.2. Organ or Tissue Function
B2.2.1.1.3. Cell Function
B2.2.1.1.4. Molecular Function
B2.2.1.1.4.1. Genetic Function
B2.2.1.2. Pathologic Function
B2.2.1.2.1. Disease or Syndrome
B2.2.1.2.1.1. Mental or Behavioral Dysfunction
B2.2.1.2.1.2. Neoplastic Process
B2.2.1.2.2. Cell or Molecular Dysfunction
B2.2.1.2.3. Experimental Model of Disease
B2.3. Injury or Poisoning
Page Format
Any submit button will submit all of the items you have changed.
[theme]
Use this page design theme:
original
twenty ten
[shown]
Results per page:
5
10
20
50
100
200
500
[expand/collapse]
show these sections expanded by default:
Advanced search
MeSH query
Search history
Page format
Query expansion
Articles details
Export citations
Email
[text size]
use this font size for text:
25%
50%
75%
100%
125%
150%
200%
or enter your choice of font size:
[page width]
use this page width (relative to the default initial value):
25%
50%
75%
100%
125%
150%
200%
or enter your choice of page width:
[highlight color]
use this color to highlight query words in the articles:
red
green
blue
black
purple
yellow
orange
navy
olive
maroon
none
[query history]
maximum number of queries shown in the history section:
[annotate]
Annotate these parts of each article:
title
abstract
both
none
Reset all values
Find best MeSH terms for
Search History
1
anal squamous cell carcinoma 2005:2010[pubdate] *count=100
626 results
Searchbox
Export
PDF
RSS
Email
Delete
Email this search result to the following email address:
[X] Close
Expand the query
'
anal squamous cell carcinoma
' expands to
2 meanings
. Choose the one you intended:
Concept C0349534: anal margin carcinoma;
details
Concept C1412036: anal cancer epidermoid carcinoma;
details
Email the results to the following email address:
Export the checked citations in RIS format (RIS format is used by RefWorks, Endnote, among others).
Items 1 to 100 of about 626
1.
Vietharsdóttir H, Moeller PH, Jóhannsson J, Jónasson JG:
[Anal cancer in Iceland 1987-2003. A population based study].
Laeknabladid
; 2006 May;92(5):365-72
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[
Anal
cancer
in Iceland 1987-2003. A population based study].
[Transliterated title]
Carcinoma
ani á Islandi 1987-2003 -- lýethgrundueth rannsókn.
OBJECTIVE:
Anal
cancer
is a rare disease.
The aim of this study was to describe
anal
cancer
in Iceland in 1987-2003 with respect to incidence, histologic type, treatment, recurrence rate and survival.
MATERIAL AND METHODS: This is a retrospective study in which all malignant
anal
tumours diagnosed in Iceland in the period 1987-2003 were reviewed with respect to patient outcome.
This is a nationwide, population-based study of malignant tumours of the
anal
region.
RESULTS: From 1987-2003 thirty-eight patients were diagnosed with
anal
cancer
, 28 females and 10 males.
The average age at
diagnosis
was 63.4 years.
Age standardized incidence rates for
anal
cancer
in Iceland were 0.3 (+/-0.2) of 100.000 males and 0.9 (+/-0.4) of 100.000 females.
Most patients had
squamous cell carcinoma
(n=30).
The remaining histologic types were malignant melanoma (n=3), adenosquamous
carcinoma
(n=1), adenocarcinoma (n=1), GIST (n=1) and undifferentiated
carcinoma
(n=2).
The duration of symptoms before
diagnosis
ranged from 2 weeks to 96 months (mean value 3.5 months).
Twelve patients had recurrent
cancer
.
The mean value of the time from
diagnosis of
the primary to the recurrent
cancer
was 15.6 months (range, 5.9-117).
Sixteen patients remain with disease and ten have died of
anal
cancer
.
The five year survival rate for patients diagnosed in the years 1987 to 1998 is 75% but
cancer
-specific survival is 82%.
CONCLUSION: Age-standardized incidence for
anal
cancer
in Iceland is similar to other regions.
Average age at
diagnosis
, male-female ratio and prognosis is similar to reports in other studies.
The proportion of adenocarcinoma of the
anus
is lower in Iceland than elsewhere.
[MeSH-major]
Anus
Neoplasms / epidemiology
[MeSH-minor]
Adenocarcinoma / epidemiology. Aged.
Carcinoma
/ epidemiology.
Carcinoma
, Adenosquamous / epidemiology.
Carcinoma
,
Squamous Cell
/ epidemiology. Defecation. Female. Gastrointestinal Hemorrhage / etiology. Humans. Iceland / epidemiology. Incidence. Male. Melanoma / epidemiology. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Pain / etiology. Pruritus / epidemiology. Retrospective Studies. Survival Analysis
Genetic Alliance.
consumer health - Anal Cancer
.
MedlinePlus Health Information.
consumer health - Anal Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16741319.001).
[ISSN]
0023-7213
[Journal-full-title]
Læknablađiđ
[ISO-abbreviation]
Laeknabladid
[Language]
ice
[Publication-type]
English Abstract; Journal Article
[Publication-country]
Iceland
2.
Gagne SE, Jensen R, Polvi A, Da Costa M, Ginzinger D, Efird JT, Holly EA, Darragh T, Palefsky JM:
High-resolution analysis of genomic alterations and human papillomavirus integration in anal intraepithelial neoplasia.
J Acquir Immune Defic Syndr
; 2005 Oct 1;40(2):182-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
High-resolution analysis of genomic alterations and human papillomavirus integration in
anal
intraepithelial neoplasia.
Anal
intraepithelial neoplasia (AIN) is the likely precursor to
anal
cancer
.
AIN is associated with human papillomavirus (HPV) infection, and HPV-associated genomic instability may play an important role in the progression of
squamous
intraepithelial neoplasia to
cancer
.
HPV16 DNA integration or rearrangement correlated with CNAs in host
cell
DNA (P = 0.007).
[MeSH-major]
Anus
Neoplasms / virology.
Carcinoma
in Situ / virology. Genome, Viral. Papillomaviridae / physiology. Virus Integration
MedlinePlus Health Information.
consumer health - Anal Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16186736.001).
[ISSN]
1525-4135
[Journal-full-title]
Journal of acquired immune deficiency syndromes (1999)
[ISO-abbreviation]
J. Acquir. Immune Defic. Syndr.
[Language]
eng
[Grant]
United States / NCRR NIH HHS / RR / 5 M01-RR-00079; United States / NCI NIH HHS / CA / R01CA54053; United States / NCI NIH HHS / CA / U01 CA66529; United States / NCI NIH HHS / CA / U01 CA70019
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
[Publication-country]
United States
3.
Driemel O, Kunkel M, Hullmann M, Kleinsasser N, Staudenmaier R, Müller-Richter U, Reichert TE, Kosmehl H:
[Performance of conventional oral brush biopsies].
HNO
; 2008 Feb;56(2):205-10
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND: This study evaluated the performance of oral brush biopsies using standard morphological analysis and haematoxylin and eosin (HE) staining for detecting oral
squamous cell
carcinomas and their respective precursor lesions PATIENTS AND METHODS: Brush biopsies were obtained in 169 consecutive patients who underwent routine biopsies and histological examination for clinically suspicious oral lesions.
RESULTS: Despite a sufficient number of cells, a definite cytological
diagnosis
could not be established in six cases.
Thus, this technique should not be used for diagnostic proof or to exclude malignant cells in a lesion suspicious for
cancer
.
[MeSH-major]
Biopsy / methods.
Carcinoma
,
Squamous Cell
/ pathology. Mouth Neoplasms / pathology
MedlinePlus Health Information.
consumer health - Biopsy
.
MedlinePlus Health Information.
consumer health - Oral Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Anal Cell Pathol. 2003;25(3):139-46
[
12775918.001
]
[Cites]
Mol Cancer. 2006 Mar 23;5:11
[
16556320.001
]
[Cites]
Dtsch Zahnarztl Z. 1981 Nov;36(11):701-3
[
6946905.001
]
[Cites]
Br J Oral Maxillofac Surg. 1996 Oct;34(5):461-6
[
8909744.001
]
[Cites]
Dtsch Med Wochenschr. 1978 Jan 6;103(1):17-20
[
620647.001
]
[Cites]
Br J Cancer. 2006 Apr 24;94(8):1170-5
[
16622441.001
]
[Cites]
N Engl J Med. 2001 May 24;344(21):1603-7
[
11372013.001
]
[Cites]
Mund Kiefer Gesichtschir. 2007 Jan;11(1):1-9
[
17177045.001
]
[Cites]
J Am Dent Assoc. 1999 Oct;130(10):1445-57
[
10570588.001
]
[Cites]
Geburtshilfe Frauenheilkd. 1991 Jan;51(1):51-3
[
2026300.001
]
[Cites]
Eur J Cancer B Oral Oncol. 1994 Nov;30B(6):405-8
[
7536508.001
]
[Cites]
Dtsch Zahnarztl Z. 1981 Nov;36(11):697-700
[
6946904.001
]
[Cites]
Ann Intern Med. 1949 Oct;31(4):661-74
[
15392502.001
]
[Cites]
Int J Oral Maxillofac Surg. 2000 Dec;29(6):453-7
[
11202330.001
]
[Cites]
Science. 1942 Apr 24;95(2469):438-9
[
17842594.001
]
[Cites]
Anal Cell Pathol. 2001;22(4):211-21
[
11564897.001
]
[Cites]
Acta Cytol. 1963 Mar-Apr;7:107-10
[
13978631.001
]
[Cites]
Oral Oncol. 2004 Sep;40(8):824-8
[
15288838.001
]
[Cites]
Stomatol DDR. 1986 Dec;36(12):712-6
[
2438824.001
]
[Cites]
J Oral Maxillofac Surg. 2006 Apr;64(4):628-35
[
16546642.001
]
[Cites]
J Oral Pathol Med. 2006 Jan;35(1):58-60
[
16393256.001
]
[Cites]
J Dent Res. 1951 Jun;30(3):308-13
[
14841304.001
]
[Cites]
Mund Kiefer Gesichtschir. 2006 Mar;10(2):89-93
[
16485137.001
]
[Cites]
Cytopathology. 2007 Dec;18(6):348-55
[
18031447.001
]
[Cites]
Br J Cancer. 1971 Mar;25(1):21-4
[
5581297.001
]
[Cites]
APMIS. 2005 Mar;113(3):208-12
[
15799765.001
]
[Cites]
J Oral Pathol Med. 2004 Aug;33(7):398-404
[
15250831.001
]
[Cites]
Mund Kiefer Gesichtschir. 2002 Nov;6(6):410-4
[
12447653.001
]
[Cites]
Gen Dent. 2000 Nov-Dec;48(6):656-60
[
12004660.001
]
[Cites]
Head Neck. 2002 Mar;24(3):223-7
[
11891953.001
]
[Cites]
Oral Oncol. 2002 Feb;38(2):125-30
[
11854058.001
]
[Cites]
Int Dent J. 1968 Dec;18(4):708-23
[
5252708.001
]
[Cites]
Oral Oncol. 2004 Sep;40(8):829-34
[
15288839.001
]
[Cites]
Geburtshilfe Frauenheilkd. 1984 Aug;44(8):485-94
[
6566637.001
]
[Cites]
J Indiana Dent Assoc. 2001 Summer;80(2):6-8
[
11693004.001
]
[Cites]
Cytopathology. 1994 Feb;5(1):47-53
[
8173031.001
]
[Cites]
Dtsch Zahnarztl Z. 1966 Jan 1;21(1):145-8
[
5216203.001
]
[Cites]
Mund Kiefer Gesichtschir. 2004 Jul;8(4):229-36
[
15293118.001
]
(PMID = 18214406.001).
[ISSN]
1433-0458
[Journal-full-title]
HNO
[ISO-abbreviation]
HNO
[Language]
ger
[Publication-type]
English Abstract; Evaluation Studies; Journal Article
[Publication-country]
Germany
Advertisement
4.
Varnai AD, Bollmann M, Griefingholt H, Speich N, Schmitt C, Bollmann R, Decker D:
HPV in anal squamous cell carcinoma and anal intraepithelial neoplasia (AIN). Impact of HPV analysis of anal lesions on diagnosis and prognosis.
Int J Colorectal Dis
; 2006 Mar;21(2):135-42
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
HPV in
anal squamous cell carcinoma
and
anal
intraepithelial neoplasia (AIN). Impact of HPV analysis of
anal
lesions on
diagnosis
and prognosis.
BACKGROUND AND AIMS: Majority of cases of
anal squamous cell carcinoma
are human papilloma virus (HPV)-induced and result from
anal
intraepithelial neoplasia (AIN).
This study was conducted to examine methods which may enable the routine
diagnosis of
HPV-induced changes in the
anal
rim and the consequences of such detection especially in view
of a
more sensitive
diagnosis of
AIN.
METHODS: The study included biopsy samples from 87 patients who had been diagnosed with the following disease patterns: 47 invasive
anal carcinoma
, 33 AIN of varying severity and seven condylomatous lesions.
RESULTS: In 38 of 47 cases of
anal carcinoma
, HPV DNA could be detected via PCR (80.9%), the majority of which were HPV 16 (33/38=86.8%).
DISCUSSION: In our series, the clinical
diagnosis of
the invasive
anal carcinoma
had a high sensitivity of 93.6%, with a specificity of 80%.
In this situation, especially with high-risk patients, our findings recommend
anal
HPV screening in combination with
anal
cytology and anoscopy.
CONCLUSION: Based on our results, we urgently recommend for any histological report on excision of
anal
lesions to include a statement whether histological markers of HPV infection were detected.
[MeSH-major]
Alphapapillomavirus / genetics.
Anus
Neoplasms / virology.
Carcinoma
in Situ / virology.
Carcinoma
,
Squamous Cell
/ virology. DNA, Viral / analysis
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Biopsy.
Diagnosis
, Differential. Female. Humans. Male. Middle Aged. Polymerase Chain Reaction. Prognosis. Retrospective Studies
Genetic Alliance.
consumer health - Carcinoma, Squamous Cell
.
MedlinePlus Health Information.
consumer health - Anal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Int J Colorectal Dis. 2007 Oct;22(10):1289
[
16703315.001
]
[Cites]
J Pathol. 1990 Jun;161(2):99-103
[
2199641.001
]
[Cites]
Cancer. 2003 Feb 25;99(1):57-62
[
12589647.001
]
[Cites]
Br J Cancer. 1998 Dec;78(11):1534-8
[
9836490.001
]
[Cites]
Cytopathology. 1998 Feb;9(1):15-22
[
9523124.001
]
[Cites]
Cancer Res. 2002 Dec 1;62(23):7075-82
[
12460929.001
]
[Cites]
Cancer Res. 2003 Mar 15;63(6):1398-404
[
12649205.001
]
[Cites]
AIDS. 1998 Mar 26;12(5):495-503
[
9543448.001
]
[Cites]
J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9
[
9525431.001
]
[Cites]
Swiss Med Wkly. 2003 Jun 28;133(25-26):353-9
[
12947531.001
]
[Cites]
Sao Paulo Med J. 2003 May 5;121(3):128-32
[
12920476.001
]
[Cites]
Cancer Res. 1991 Feb 1;51(3):1014-9
[
1846314.001
]
[Cites]
Int J Cancer. 1990 Aug 15;46(2):203-6
[
2166709.001
]
[Cites]
Eur J Cancer. 2002 Nov;38(17):2229-42
[
12441259.001
]
[Cites]
Br J Cancer. 1997;76(10):1271-8
[
9374370.001
]
[Cites]
Acta Cytol. 1997 Jul-Aug;41(4):1167-70
[
9250316.001
]
[Cites]
Cancer Lett. 1998 Jan 16;123(1):47-52
[
9461017.001
]
[Cites]
Mod Pathol. 2003 Jul;16(7):692-9
[
12861066.001
]
[Cites]
J Clin Microbiol. 1990 Dec;28(12):2739-43
[
2177751.001
]
[Cites]
J Med Microbiol. 2004 Feb;53(Pt 2):125-8
[
14729933.001
]
[Cites]
J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10
[
10995805.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 1999 Feb;8(2):173-8
[
10067816.001
]
[Cites]
BMJ. 1993 Feb 13;306(6875):419-22
[
8461721.001
]
[Cites]
Cytopathology. 2005 Feb;16(1):13-21
[
15859310.001
]
[Cites]
Mod Pathol. 1995 Apr;8(3):270-4
[
7617653.001
]
[Cites]
Scand J Infect Dis. 1996;28(6):629-32
[
9060069.001
]
[Cites]
Dis Colon Rectum. 1987 May;30(5):345-51
[
3568924.001
]
[Cites]
Cancer. 2004 Feb 25;102(1):41-54
[
14968417.001
]
[Cites]
Lancet. 1994 Mar 12;343(8898):636-9
[
7906812.001
]
[Cites]
Cancer. 1986 Aug 1;58(3):611-6
[
3524788.001
]
[Cites]
Dan Med Bull. 2002 Aug;49(3):194-209
[
12238281.001
]
[Cites]
Cancer. 2004 Feb 25;102(1):19-26
[
14968414.001
]
[Cites]
Cancer Res. 1999 Feb 1;59(3):753-7
[
9973228.001
]
[Cites]
J Clin Pathol. 2002 Apr;55(4):244-65
[
11919208.001
]
[Cites]
Dtsch Med Wochenschr. 2003 Sep 19;128(38):1957-62
[
14502448.001
]
[Cites]
N Engl J Med. 1994 Aug 4;331(5):300-2
[
8022440.001
]
[Cites]
Cancer. 1995 Feb 15;75(4):958-67
[
7842416.001
]
[Cites]
Cancer. 2003 Apr 25;99(2):113-7
[
12704691.001
]
[Cites]
Nucleic Acids Res. 1997 Sep 1;25(17):3389-402
[
9254694.001
]
(PMID = 15864603.001).
[ISSN]
0179-1958
[Journal-full-title]
International journal of colorectal disease
[ISO-abbreviation]
Int J Colorectal Dis
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / DNA, Viral
5.
Pepek JM, Willett CG, Czito BG:
Radiation therapy advances for treatment of anal cancer.
J Natl Compr Canc Netw
; 2010 Jan;8(1):123-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Radiation therapy advances for treatment of
anal
cancer
.
Radiation therapy (RT) is established as the primary treatment of
squamous cell carcinoma
of the
anus
.
[MeSH-major]
Anus
Neoplasms / radiotherapy
Genetic Alliance.
consumer health - Anal Cancer
.
MedlinePlus Health Information.
consumer health - Anal Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20064294.001).
[ISSN]
1540-1405
[Journal-full-title]
Journal of the National Comprehensive Cancer Network : JNCCN
[ISO-abbreviation]
J Natl Compr Canc Netw
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Number-of-references]
39
6.
Perk LR, Vosjan MJ, Visser GW, Budde M, Jurek P, Kiefer GE, van Dongen GA:
p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging.
Eur J Nucl Med Mol Imaging
; 2010 Feb;37(2):250-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[MeSH-major]
Antibodies, Monoclonal / chemistry. Antibodies, Monoclonal / pharmacokinetics.
Carcinoma
,
Squamous Cell
/ metabolism. Chelating Agents / chemistry. Deferoxamine / analogs & derivatives. Isothiocyanates / chemistry. Positron-Emission Tomography / methods. Radioisotopes / pharmacokinetics. Zirconium / pharmacokinetics
[MeSH-minor]
Animals.
Cell
Line, Tumor. Female. Humans. Isotope Labeling / methods. Metabolic Clearance Rate. Mice. Mice, Nude. Organ Specificity. Radioimmunodetection / methods. Radiopharmaceuticals / chemical synthesis. Radiopharmaceuticals / pharmacokinetics. Tissue Distribution
Hazardous Substances Data Bank.
DESFERRIOXAMINE
.
Hazardous Substances Data Bank.
ZIRCONIUM, ELEMENTAL
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Nucl Med. 2003 Aug;44(8):1271-81
[
12902418.001
]
[Cites]
Eur J Nucl Med Mol Imaging. 2006 Nov;33(11):1337-45
[
16832633.001
]
[Cites]
J Nucl Med. 2003 Oct;44(10):1663-70
[
14530484.001
]
[Cites]
Mol Imaging. 2003 Jul;2(3):131-7
[
14649056.001
]
[Cites]
Cancer Biother Radiopharm. 2004 Apr;19(2):155-63
[
15186595.001
]
[Cites]
Cancer. 1972 Jan;29(1):117-21
[
4332311.001
]
[Cites]
J Nucl Med. 1982 Oct;23(10):909-14
[
7119886.001
]
[Cites]
J Immunol Methods. 1984 Aug 3;72(1):77-89
[
6086763.001
]
[Cites]
Anal Biochem. 1984 Oct;142(1):68-78
[
6440451.001
]
[Cites]
Cancer Res. 1988 Mar 1;48(5):1189-94
[
3422590.001
]
[Cites]
Int J Cancer. 1989 Jun 15;43(6):1188-94
[
2786509.001
]
[Cites]
Cancer Res. 1993 Sep 15;53(18):4383-90
[
8364934.001
]
[Cites]
Cancer Res. 1995 Feb 15;55(4):878-84
[
7850803.001
]
[Cites]
J Nucl Med. 1996 Feb;37(2):352-62
[
8667076.001
]
[Cites]
J Nucl Med. 1996 Aug;37(8):1384-8
[
8708780.001
]
[Cites]
J Nucl Med. 1997 Jan;38(1):112-8
[
8998164.001
]
[Cites]
Int J Cancer. 1997 May 2;71(3):410-5
[
9139877.001
]
[Cites]
J Nucl Med. 2005 Nov;46(11):1898-906
[
16269605.001
]
[Cites]
Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2133-40
[
16609026.001
]
[Cites]
Nat Rev Immunol. 2006 May;6(5):343-57
[
16622479.001
]
[Cites]
Semin Oncol. 2006 Aug;33(4):369-85
[
16890793.001
]
[Cites]
Phys Med Biol. 2007 Mar 7;52(5):1505-26
[
17301468.001
]
[Cites]
J Nucl Med. 2007 Aug;48(8):1313-9
[
17631557.001
]
[Cites]
Oncologist. 2007 Dec;12(12):1379-89
[
18165614.001
]
[Cites]
Adv Drug Deliv Rev. 2008 Sep15;60(12):1347-70
[
18538888.001
]
[Cites]
Eur J Nucl Med Mol Imaging. 2008 Oct;35(10):1857-67
[
18491091.001
]
[Cites]
J Nucl Med. 2009 Jan;50(1):2-5
[
19091888.001
]
[Cites]
Bioconjug Chem. 2009 May 20;20(5):825-41
[
19125647.001
]
[Cites]
Cancer Biother Radiopharm. 2003 Aug;18(4):655-61
[
14503961.001
]
(PMID = 19763566.001).
[ISSN]
1619-7089
[Journal-full-title]
European journal of nuclear medicine and molecular imaging
[ISO-abbreviation]
Eur. J. Nucl. Med. Mol. Imaging
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Germany
[Chemical-registry-number]
0 / 4-isothiocyanatobenzyl-desferrioxamine; 0 / Antibodies, Monoclonal; 0 / Chelating Agents; 0 / Isothiocyanates; 0 / Radioisotopes; 0 / Radiopharmaceuticals; C6V6S92N3C / Zirconium; J06Y7MXW4D / Deferoxamine
[Other-IDs]
NLM/ PMC2816257
7.
Goldstone SE, Hundert JS, Huyett JW:
Infrared coagulator ablation of high-grade anal squamous intraepithelial lesions in HIV-negative males who have sex with males.
Dis Colon Rectum
; 2007 May;50(5):565-75
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Infrared coagulator ablation of high-grade
anal squamous
intraepithelial lesions in HIV-negative males who have sex with males.
PURPOSE: The incidence of
anal squamous carcinoma
in males who have sex with males is rising.
We reported that infrared coagulation of high-grade
squamous
intraepithelial lesions in HIV-positive males who have sex with males yielded a recurrence rate after the first ablation of 65 percent and 58 percent after a second ablation.
METHODS: We performed a retrospective review of medical records on HIV-negative males who have sex with males who had infrared coagulation ablation of
anal
high-grade
squamous
intraepithelial lesions.
Recurrent high-grade
squamous
intraepithelial lesions were retreated.
HIV-positive patients were twice as likely to have lesions persist and 1.7 times more likely to develop a recurrent high-grade
squamous
intraepithelial lesion.
No patient developed
squamous
-
cell carcinoma
,
anal
stenosis, or had a serious complication.
CONCLUSIONS: Infrared coagulation is a safe and effective office-based procedure for treating
anal
high-grade
squamous
intraepithelial lesions.
Although recurrence was high after the first infrared coagulation, repeated treatment led to resolution of high-grade
squamous
intraepithelial lesions.
[MeSH-major]
Anus
Neoplasms / surgery.
Carcinoma
,
Squamous Cell
/ surgery. HIV Seronegativity. Homosexuality, Male. Infrared Rays / therapeutic use. Light Coagulation / methods. Precancerous Conditions / surgery
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - Anal Cancer
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17380365.001).
[ISSN]
0012-3706
[Journal-full-title]
Diseases of the colon and rectum
[ISO-abbreviation]
Dis. Colon Rectum
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
8.
Hoebers FJ, Pluim D, Hart AA, Verheij M, Balm AJ, Fons G, Rasch CR, Schellens JH, Stalpers LJ, Bartelink H, Begg AC:
Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor.
Cancer Chemother Pharmacol
; 2008 May;61(6):1075-81
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
No evidence
of a
correlation was found between adduct levels in normal tissues and primary tumor biopsies.
[MeSH-minor]
Carcinoma
,
Squamous Cell
/ drug therapy.
Carcinoma
,
Squamous Cell
/ metabolism.
Carcinoma
,
Squamous Cell
/ radiotherapy. Combined Modality Therapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / metabolism. Head and Neck Neoplasms / radiotherapy. Humans. Leukocyte Count. Mouth Mucosa / cytology. Predictive Value of Tests
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
CIS-DIAMINEDICHLOROPLATINUM
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Br J Cancer. 1999 Jan;79(1):82-8
[
10408697.001
]
[Cites]
N Engl J Med. 2006 Sep 7;355(10):983-91
[
16957145.001
]
[Cites]
Int J Cancer. 2006 Aug 15;119(4):750-6
[
16550603.001
]
[Cites]
Anal Biochem. 1999 Nov 1;275(1):30-8
[
10542106.001
]
[Cites]
J Clin Oncol. 2000 Apr;18(7):1458-64
[
10735893.001
]
[Cites]
Int J Cancer. 2000 Mar 20;89(2):160-6
[
10754494.001
]
[Cites]
Lancet. 2000 Mar 18;355(9208):949-55
[
10768432.001
]
[Cites]
Lancet. 2001 Sep 8;358(9284):781-6
[
11564482.001
]
[Cites]
Clin Cancer Res. 2002 Sep;8(9):2992-9
[
12231546.001
]
[Cites]
Clin Pharmacol Ther. 2003 May;73(5):417-26
[
12732842.001
]
[Cites]
N Engl J Med. 2003 Nov 27;349(22):2091-8
[
14645636.001
]
[Cites]
Eur J Cancer Clin Oncol. 1986 Mar;22(3):257-63
[
3709595.001
]
[Cites]
Radiother Oncol. 1986 May;6(1):61-74
[
3715061.001
]
[Cites]
Int J Radiat Biol Relat Stud Phys Chem Med. 1986 Nov;50(5):871-84
[
3490450.001
]
[Cites]
Cancer Res. 1987 Jun 1;47(11):3000-4
[
3552211.001
]
[Cites]
Proc Natl Acad Sci U S A. 1987 Jul;84(14):5024-8
[
3110781.001
]
[Cites]
Cancer Res. 1987 Nov 15;47(22):6134-7
[
3664513.001
]
[Cites]
Carcinogenesis. 1988 Oct;9(10):1909-11
[
2458857.001
]
[Cites]
Cancer Res. 1990 Jun 15;50(12):3556-61
[
2340504.001
]
[Cites]
Cancer Res. 1990 Dec 15;50(24):7887-94
[
2253228.001
]
[Cites]
Cancer. 1991 Jun 1;67(11):2828-32
[
2025848.001
]
[Cites]
Arch Otolaryngol Head Neck Surg. 1993 Jun;119(6):612-7
[
8499090.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 1993 May-Jun;2(3):229-34
[
8318875.001
]
[Cites]
Cancer Res. 1993 Dec 1;53(23):5669-75
[
8242622.001
]
[Cites]
Cancer. 1994 Jun 1;73(11):2843-52
[
7514956.001
]
[Cites]
Br J Cancer. 1995 Mar;71(3):512-7
[
7880732.001
]
[Cites]
Carcinogenesis. 1995 Oct;16(10):2447-53
[
7586150.001
]
[Cites]
Cancer Chemother Pharmacol. 1995;37(1-2):23-31
[
7497593.001
]
[Cites]
Cancer Chemother Pharmacol. 1995;37(1-2):150-4
[
7497585.001
]
[Cites]
Br J Cancer. 1996 Jun;73(12):1569-75
[
8664132.001
]
[Cites]
Int J Cancer. 1996 Nov 15;68(4):452-6
[
8945615.001
]
[Cites]
N Engl J Med. 1998 Jun 18;338(25):1798-804
[
9632446.001
]
[Cites]
Clin Cancer Res. 1996 Jun;2(6):1063-6
[
9816268.001
]
[Cites]
Clin Cancer Res. 1996 Nov;2(11):1829-35
[
9816137.001
]
[Cites]
N Engl J Med. 1999 Apr 15;340(15):1154-61
[
10202166.001
]
[Cites]
Int J Cancer. 2006 Apr 15;118(8):1963-71
[
16287073.001
]
(PMID = 17639394.001).
[ISSN]
0344-5704
[Journal-full-title]
Cancer chemotherapy and pharmacology
[ISO-abbreviation]
Cancer Chemother. Pharmacol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / DNA Adducts; Q20Q21Q62J / Cisplatin
[Other-IDs]
NLM/ PMC2270367
9.
Zuo QP, Li B, Pei Q, Li Z, Liu SK:
A highly selective fluorescent probe for detection of biological samples thiol and its application in living cells.
J Fluoresc
; 2010 Nov;20(6):1307-13
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
This fluorescent molecular probe consists
of a
thiol reaction moiety bound to a coumarin fluorophore.
[MeSH-major]
Carcinoma
,
Squamous Cell
/ chemistry. Fluorescent Dyes / chemistry. Sulfhydryl Compounds / analysis. Tongue Neoplasms / chemistry
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Am Chem Soc. 2003 Jul 2;125(26):7802-3
[
12822989.001
]
[Cites]
Clin Chem. 1990 Dec;36(12):2137-8
[
2253363.001
]
[Cites]
Chem Commun (Camb). 2009 Aug 14;(30):4530-2
[
19617973.001
]
[Cites]
J Am Chem Soc. 2007 Aug 29;129(34):10322-3
[
17672463.001
]
[Cites]
Angew Chem Int Ed Engl. 2005 May 6;44(19):2922-5
[
15818626.001
]
[Cites]
Org Lett. 2008 Jan 3;10(1):37-40
[
18062694.001
]
[Cites]
Anal Biochem. 2007 Dec 1;371(1):71-81
[
17727809.001
]
[Cites]
Spectrochim Acta A Mol Biomol Spectrosc. 2001 Oct;57(12):2403-7
[
11767834.001
]
[Cites]
J Pharm Biomed Anal. 2008 Dec 15;48(5):1375-80
[
18926658.001
]
[Cites]
N Engl J Med. 1997 Jul 24;337(4):230-6
[
9227928.001
]
[Cites]
Anal Chim Acta. 2008 Jul 14;620(1-2):120-6
[
18558132.001
]
[Cites]
Chem Commun (Camb). 2003 Jan 7;(1):146-7
[
12611008.001
]
[Cites]
Bioelectrochemistry. 2004 Jun;63(1-2):19-24
[
15110242.001
]
[Cites]
Angew Chem Int Ed Engl. 2008;47(41):7883-7
[
18781571.001
]
[Cites]
Anal Chem. 2007 Nov 15;79(22):8769-73
[
17924649.001
]
[Cites]
Anal Chem. 2000 Dec 1;72(23):5755-60
[
11128932.001
]
[Cites]
Cancer Lett. 2004 May 28;208(2):143-53
[
15142672.001
]
[Cites]
Org Lett. 2009 Nov 5;11(21):4918-21
[
19788282.001
]
[Cites]
Chem Commun (Camb). 2004 Aug 7;(15):1762-3
[
15278174.001
]
[Cites]
Angew Chem Int Ed Engl. 2009;48(22):4034-7
[
19388016.001
]
[Cites]
Org Lett. 2007 Aug 16;9(17 ):3375-7
[
17645349.001
]
[Cites]
Bioorg Med Chem Lett. 2008 Apr 1;18(7):2246-9
[
18358719.001
]
[Cites]
Clin Chem. 1998 Aug;44(8 Pt 2):1833-43
[
9702993.001
]
[Cites]
J Nutr. 2006 Jun;136(6 Suppl):1682S-1693S
[
16702340.001
]
[Cites]
N Engl J Med. 2002 Feb 14;346(7):476-83
[
11844848.001
]
[Cites]
J Chromatogr. 1985 Feb 27;338(1):209-12
[
4019645.001
]
[Cites]
Anal Chem. 2001 Dec 15;73(24):5972-8
[
11791568.001
]
[Cites]
Anal Chem. 2002 Mar 15;74(6):1349-54
[
11922303.001
]
[Cites]
Eur J Biochem. 2000 Aug;267(16):4904-11
[
10931172.001
]
[Cites]
Talanta. 2003 Aug 29;60(6):1229-38
[
18969150.001
]
[Cites]
J Fluoresc. 2009 Jul;19(4):593-9
[
19050997.001
]
[Cites]
Neurosci Lett. 1990 Mar 2;110(1-2):216-20
[
2325885.001
]
[Cites]
Amino Acids. 2009 Jul;37(2):395-400
[
18695935.001
]
[Cites]
Chem Commun (Camb). 2005 Jul 7;(25):3189-91
[
15968367.001
]
[Cites]
Chemistry. 2009;15(20):5096-103
[
19343759.001
]
[Cites]
Anal Chim Acta. 2008 Oct 10;627(2):254-7
[
18809081.001
]
[Cites]
J Clin Invest. 1960 Nov;39(11):1633-8
[
16695834.001
]
(PMID = 20473559.001).
[ISSN]
1573-4994
[Journal-full-title]
Journal of fluorescence
[ISO-abbreviation]
J Fluoresc
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / Fluorescent Dyes; 0 / Sulfhydryl Compounds
10.
Patel H, Polanco-Echeverry G, Segditsas S, Volikos E, McCart A, Lai C, Guenther T, Zaitoun A, Sieber O, Ilyas M, Northover J, Silver A:
Activation of AKT and nuclear accumulation of wild type TP53 and MDM2 in anal squamous cell carcinoma.
Int J Cancer
; 2007 Dec 15;121(12):2668-73
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Activation of AKT and nuclear accumulation of wild type TP53 and MDM2 in
anal squamous cell carcinoma
.
Human papilloma virus (HPV) infection is considered as an important aetiological factor for
anal squamous cell carcinoma
(ASCC) but is not sufficient for tumour progression.
This
carcinoma
is poorly understood at the molecular level.
[MeSH-major]
Anus
Neoplasms / genetics. Biomarkers, Tumor / genetics.
Carcinoma
,
Squamous Cell
/ genetics. Mutation. Papillomaviridae / isolation & purification. Proto-Oncogene Proteins c-akt / genetics. Proto-Oncogene Proteins c-mdm2 / genetics. Tumor Suppressor Protein p53 / genetics
Genetic Alliance.
consumer health - Carcinoma, Squamous Cell
.
MedlinePlus Health Information.
consumer health - Anal Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
(c) 2007 Wiley-Liss, Inc.
(PMID = 17721920.001).
[ISSN]
1097-0215
[Journal-full-title]
International journal of cancer
[ISO-abbreviation]
Int. J. Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Tumor Suppressor Protein p53; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / PIK3CA protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
11.
Houvenaeghel G, Ghouti L, Moutardier V, Buttarelli M, Lelong B, Delpero JR:
Rectus abdominis myocutaneous flap in radical oncopelvic surgery: a safe and useful procedure.
Eur J Surg Oncol
; 2005 Dec;31(10):1185-90
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
RESULTS: Between 1989 and 1998, 46 patients underwent pelvi-perineal reconstruction with RAM flaps after radical pelvic surgery for
carcinoma
of the cervix (n=22),
anal carcinoma
(n=11), rectal
carcinoma
(n=7), or other pelvic tumours types (n=6).
MedlinePlus Health Information.
consumer health - Surgery
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16126359.001).
[ISSN]
0748-7983
[Journal-full-title]
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
[ISO-abbreviation]
Eur J Surg Oncol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
12.
Kovar JL, Volcheck WM, Chen J, Simpson MA:
Purification method directly influences effectiveness of an epidermal growth factor-coupled targeting agent for noninvasive tumor detection in mice.
Anal Biochem
; 2007 Feb 1;361(1):47-54
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Binding of IRDye 800CW EGF to intact A431 human
epidermoid
carcinoma
cells was quantified in a microplate assay.
This is the first study to directly correlate targeting agent signal strength in whole
cell
binding, In-
Cell
Western, and in vivo near-infrared imaging.
[MeSH-major]
Carcinoma
,
Squamous Cell
/
diagnosis
. Epidermal Growth Factor
[MeSH-minor]
Animals.
Cell
Line, Tumor. Chromatography, Gel. Chromatography, High Pressure Liquid. Coloring Agents. Humans. Indicators and Reagents. Mice. Mice, Nude. Mice, SCID. Receptor, Epidermal Growth Factor. Sensitivity and Specificity. Spectrometry, Fluorescence / methods. Transplantation, Heterologous
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Nat Rev Mol Cell Biol. 2002 Aug;3(8):600-14
[
12154371.001
]
[Cites]
Am J Pathol. 2002 Sep;161(3):849-57
[
12213713.001
]
[Cites]
Amino Acids. 2002;23(1-3):301-8
[
12373551.001
]
[Cites]
Clin Cancer Res. 2002 Nov;8(11):3438-44
[
12429632.001
]
[Cites]
Lung Cancer. 2003 Aug;41 Suppl 1:S9-14
[
12867057.001
]
[Cites]
Curr Opin Chem Biol. 2003 Oct;7(5):626-34
[
14580568.001
]
[Cites]
Cancer Res. 2003 Nov 15;63(22):7870-5
[
14633715.001
]
[Cites]
Mol Imaging. 2003 Oct;2(4):303-12
[
14717329.001
]
[Cites]
Nat Biotechnol. 2004 Feb;22(2):198-203
[
14704683.001
]
[Cites]
Mol Cancer Ther. 2004 Apr;3(4):481-8
[
15078992.001
]
[Cites]
Mol Imaging. 2004 Jan;3(1):9-23
[
15142408.001
]
[Cites]
Science. 1977 Dec 23;198(4323):1264-7
[
929199.001
]
[Cites]
EMBO J. 1987 Mar;6(3):605-10
[
3034598.001
]
[Cites]
Am J Pathol. 2006 Oct;169(4):1415-26
[
17003496.001
]
[Cites]
Nat Biotechnol. 2001 Apr;19(4):327-31
[
11283589.001
]
[Cites]
Nat Biotechnol. 2005 Mar;23(3):313-20
[
15765087.001
]
[Cites]
Mol Imaging. 2004 Oct;3(4):343-51
[
15802051.001
]
[Cites]
Anal Biochem. 2005 Mar 1;338(1):136-42
[
15707944.001
]
[Cites]
Cancer Res. 2004 Nov 1;64(21):8009-14
[
15520209.001
]
[Cites]
Biochemistry. 1993 Nov 16;32(45):12039-45
[
8218281.001
]
[Cites]
Curr Opin Oncol. 1993 May;5(3):474-80
[
8494908.001
]
[Cites]
Annu Rev Biophys Biophys Chem. 1991;20:1-28
[
1867711.001
]
[Cites]
Cancer Treat Res. 2002;107:247-58
[
11775453.001
]
[Cites]
Bioconjug Chem. 2005 Nov-Dec;16(6):1433-41
[
16287239.001
]
[Cites]
Mol Imaging. 2005 Oct-Dec;4(4):439-47
[
16285906.001
]
[Cites]
J Biomed Opt. 2005 Jul-Aug;10(4):41205
[
16178629.001
]
[Cites]
Drugs Today (Barc). 2005 Feb;41(2):107-27
[
15821783.001
]
(PMID = 17188228.001).
[ISSN]
0003-2697
[Journal-full-title]
Analytical biochemistry
[ISO-abbreviation]
Anal. Biochem.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / R01 CA106584
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Coloring Agents; 0 / Indicators and Reagents; 62229-50-9 / Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
[Other-IDs]
NLM/ NIHMS16673; NLM/ PMC1866276
13.
Burgi A, Brodine S, Wegner S, Milazzo M, Wallace MR, Spooner K, Blazes DL, Agan BK, Armstrong A, Fraser S, Crum NF:
Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals.
Cancer
; 2005 Oct 1;104(7):1505-11
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Cancer
incidence rates were race specific and were adjusted for age; these were compared with national rates using logistic regression to assess predictors of NADC development.
The most frequent NADCs were
skin
carcinomas (basal
cell
and
squamous cell
), Hodgkin disease, and
anal carcinoma
.
The results showed that there were higher rates of melanoma, basal and
squamous cell
skin
carcinomas,
anal carcinoma
, prostate
carcinoma
, and Hodgkin disease among the HIV-infected cohort compared with age-adjusted rates for the general United States population.
A low CD4 nadir or CD4 count at
diagnosis
(< 200 cells/mL) was not predictive of NADCs.
CONCLUSIONS: The most frequent NADCs were primary
skin
malignancies.
Melanoma, basal and
squamous cell
skin
carcinomas,
anal carcinoma
, prostate
carcinoma
, and Hodgkin disease occurred at higher rates among HIV-infected individuals.
[MeSH-minor]
Adult. Age Distribution. Aged. Analysis of Variance. Cohort Studies. Comorbidity. Female. HIV Infections /
diagnosis
. HIV Infections / epidemiology. Humans. Incidence. Male. Middle Aged. Multivariate Analysis. Probability. Prognosis. Retrospective Studies. Risk Factors. Severity of Illness Index. Sex Distribution. Survival Analysis. United States / epidemiology
Genetic Alliance.
consumer health - AIDS-HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16104038.001).
[ISSN]
0008-543X
[Journal-full-title]
Cancer
[ISO-abbreviation]
Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
[Publication-country]
United States
14.
Li M, Gray W, Zhang H, Chung CH, Billheimer D, Yarbrough WG, Liebler DC, Shyr Y, Slebos RJ:
Comparative shotgun proteomics using spectral count data and quasi-likelihood modeling.
J Proteome Res
; 2010 Aug 6;9(8):4295-305
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Comparative shotgun proteomics using spectral count data and quasi-likelihood modeling.
Shotgun proteomics provides the most powerful analytical platform for global inventory of complex proteomes using liquid chromatography-tandem mass spectrometry (LC-MS/MS) and allows a global analysis of protein changes.
Nevertheless, sampling of complex proteomes by current shotgun proteomics platforms is incomplete, and this contributes to variability in assessment of peptide and protein inventories by spectral counting approaches.
Thus, shotgun proteomics data pose challenges in comparing proteomes from different biological states.
We developed an analysis strategy using quasi-likelihood Generalized Linear Modeling (GLM), included in a graphical interface software package (QuasiTel) that reads standard output from protein assemblies created by IDPicker, an HTML-based user interface to query shotgun proteomic data sets.
This approach was compared to four other statistical analysis strategies: Student t test, Wilcoxon rank test, Fisher's Exact test, and Poisson-based GLM.
We analyzed the performance of these tests to identify differences in protein levels based on spectral counts in a shotgun data set in which equimolar amounts of 48 human proteins were spiked at different levels into whole yeast lysates.
Both GLM approaches and the Fisher Exact test performed adequately, each with their unique limitations.
We subsequently compared the proteomes of normal tonsil epithelium and HNSCC using this approach and identified 86 proteins with differential spectral counts between normal tonsil epithelium and HNSCC.
We selected 18 proteins from this comparison for verification of protein levels between the individual normal and tumor tissues using liquid chromatography-multiple reaction monitoring mass spectrometry (LC-MRM-MS).
This analysis confirmed the magnitude and direction of the protein expression differences in all 6 proteins for which reliable data could be obtained.
Our analysis demonstrates that shotgun proteomic data sets from different tissue phenotypes are sufficiently rich in quantitative information and that statistically significant differences in proteins spectral counts reflect the underlying biology of the samples.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Biometrics. 2001 Jun;57(2):620-4
[
11414592.001
]
[Cites]
J Proteome Res. 2010 Feb 5;9(2):761-76
[
19921851.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
[
11553815.001
]
[Cites]
Nature. 2002 Jan 31;415(6871):530-6
[
11823860.001
]
[Cites]
Histopathology. 2002 May;40(5):403-39
[
12010363.001
]
[Cites]
Anal Chem. 2002 Jul 1;74(13):3076-83
[
12141667.001
]
[Cites]
Dis Markers. 2002;18(2):99-105
[
12364816.001
]
[Cites]
Nat Biotechnol. 2003 Mar;21(3):262-7
[
12610573.001
]
[Cites]
J Proteome Res. 2003 Nov-Dec;2(6):643-9
[
14692458.001
]
[Cites]
Am J Pathol. 2004 Jan;164(1):35-42
[
14695316.001
]
[Cites]
Anal Chem. 2004 Jul 15;76(14):4193-201
[
15253663.001
]
[Cites]
Bioinformatics. 2004 Aug 4;20 Suppl 1:i31-9
[
15262778.001
]
[Cites]
Nat Biotechnol. 2004 Aug;22(8):985-92
[
15258593.001
]
[Cites]
Biometrics. 1991 Jun;47(2):383-401
[
1912253.001
]
[Cites]
J Invest Dermatol. 1992 Sep;99(3):299-305
[
1512466.001
]
[Cites]
Biochem J. 1994 Sep 1;302 ( Pt 2):363-71
[
8092987.001
]
[Cites]
Science. 1995 Oct 20;270(5235):467-70
[
7569999.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 1995 Dec;4(8):871-6
[
8634660.001
]
[Cites]
J Invest Dermatol. 1997 Feb;108(2):200-4
[
9008234.001
]
[Cites]
Cancer Lett. 2005 Jul 8;225(1):151-7
[
15922867.001
]
[Cites]
Anal Chem. 2005 Oct 1;77(19):6218-24
[
16194081.001
]
[Cites]
Mol Cell Proteomics. 2005 Oct;4(10):1487-502
[
15979981.001
]
[Cites]
Nat Biotechnol. 2006 Aug;24(8):971-83
[
16900146.001
]
[Cites]
J Proteome Res. 2006 Nov;5(11):2909-18
[
17081042.001
]
[Cites]
BMC Genomics. 2006;7:278
[
17074082.001
]
[Cites]
Cardiovasc Res. 2007 Jan 1;73(1):19-25
[
17045254.001
]
[Cites]
J Proteome Res. 2007 Feb;6(2):654-61
[
17269722.001
]
[Cites]
J Proteome Res. 2007 Sep;6(9):3549-57
[
17676885.001
]
[Cites]
J Proteome Res. 2007 Oct;6(10):3962-75
[
17711321.001
]
[Cites]
J Proteome Res. 2008 Mar;7(3):845-54
[
18198819.001
]
[Cites]
Mol Cell Proteomics. 2008 Dec;7(12):2373-85
[
18644780.001
]
[Cites]
J Proteome Res. 2008 Dec;7(12):5286-94
[
18939861.001
]
[Cites]
Proteomics. 2009 Apr;9(8):2193-201
[
19337991.001
]
[Cites]
Nat Biotechnol. 2009 Jul;27(7):633-41
[
19561596.001
]
[Cites]
J Oral Pathol Med. 2009 Jul;38(6):530-4
[
19222712.001
]
[Cites]
J Proteome Res. 2009 Aug;8(8):3872-81
[
19522537.001
]
[Cites]
Bioinformatics. 2010 Feb 1;26(3):363-9
[
20007255.001
]
[Cites]
Mol Cell Proteomics. 2010 Feb;9(2):242-54
[
19858499.001
]
[ErratumIn]
J Proteome Res. 2010 Nov 5;9(11):6090
(PMID = 20586475.001).
[ISSN]
1535-3907
[Journal-full-title]
Journal of proteome research
[ISO-abbreviation]
J. Proteome Res.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / U24 CA126479; United States / NCI NIH HHS / CA / 1U24CA126479
[Publication-type]
Comparative Study; Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Proteins
[Other-IDs]
NLM/ PMC2920032
15.
Lê LH, Chetty R, Moore MJ:
Epidermal growth factor receptor expression in anal canal carcinoma.
Am J Clin Pathol
; 2005 Jul;124(1):20-3
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Epidermal growth factor receptor expression in
anal
canal
carcinoma
.
Most
anal
canal carcinomas (ACCs) are
squamous cell
carcinomas (SCCs).
Therefore, we obtained archived pathology samples from ACC biopsies and examined the frequency and level of expression of EGFR and other
cell
surface and
cell
cycle markers.
[MeSH-major]
Anal
Canal / pathology.
Anus
Neoplasms / metabolism. Biomarkers, Tumor / analysis.
Carcinoma
,
Squamous Cell
/ metabolism. Receptor, Epidermal Growth Factor / biosynthesis
MedlinePlus Health Information.
consumer health - Anal Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15923158.001).
[ISSN]
0002-9173
[Journal-full-title]
American journal of clinical pathology
[ISO-abbreviation]
Am. J. Clin. Pathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
16.
Jahan I, Fujimoto J, Alam SM, Sato E, Tamaya T:
Role of protease activated receptor-2 in lymph node metastasis of uterine cervical cancers.
BMC Cancer
; 2008;8:301
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[MeSH-major]
Carcinoma
,
Squamous Cell
/ genetics.
Carcinoma
,
Squamous Cell
/ pathology. Receptor, PAR-2 / metabolism. Uterine Cervical Neoplasms / genetics. Uterine Cervical Neoplasms / pathology
MedlinePlus Health Information.
consumer health - Cervical Cancer
.
International Agency for Research on Cancer - Screening Group.
diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Int J Oncol. 2003 Jul;23(1):61-6
[
12792776.001
]
[Cites]
J Histochem Cytochem. 1998 Feb;46(2):157-64
[
9446822.001
]
[Cites]
J Biol Chem. 2004 May 14;279(20):20927-34
[
15010475.001
]
[Cites]
Int J Oncol. 2004 Jun;24(6):1401-6
[
15138580.001
]
[Cites]
Mol Cancer Res. 2004 Jul;2(7):395-402
[
15280447.001
]
[Cites]
Oncol Rep. 2004 Nov;12(5):1013-6
[
15492786.001
]
[Cites]
Arch Pathol Lab Med. 1985 Aug;109(8):716-21
[
3893381.001
]
[Cites]
Cancer. 1986 Apr 15;57(8):1584-93
[
2418947.001
]
[Cites]
J Cell Biol. 2000 Mar 20;148(6):1267-81
[
10725339.001
]
[Cites]
J Neural Transm (Vienna). 2001;108(2):125-40
[
11314768.001
]
[Cites]
Pharmacol Rev. 2001 Jun;53(2):245-82
[
11356985.001
]
[Cites]
Am J Pathol. 2001 Jun;158(6):2031-41
[
11395381.001
]
[Cites]
Br J Cancer. 2001 Sep 1;85(5):772-9
[
11531266.001
]
[Cites]
Life Sci. 2002 Feb 8;70(12):1359-67
[
11883712.001
]
[Cites]
FEBS Lett. 2002 Jul 17;523(1-3):85-9
[
12123809.001
]
[Cites]
Arterioscler Thromb Vasc Biol. 2002 Sep 1;22(9):1421-6
[
12231560.001
]
[Cites]
Cancer. 2003 Feb 1;97(3):703-13
[
12548614.001
]
[Cites]
Gynecol Oncol. 1987 Jun;27(2):150-8
[
3570054.001
]
[Cites]
Anal Biochem. 1987 Apr;162(1):156-9
[
2440339.001
]
[Cites]
Semin Diagn Pathol. 1990 Aug;7(3):173-89
[
2218146.001
]
[Cites]
Cancer Metastasis Rev. 1992 Mar;11(1):31-44
[
1511495.001
]
[Cites]
Gynecol Oncol. 1998 May;69(2):157-64
[
9600824.001
]
[Cites]
Int J Pancreatol. 1998 Oct;24(2):97-102
[
9816542.001
]
[Cites]
Cancer Lett. 1999 May 3;139(1):109-13
[
10408902.001
]
[Cites]
Cancer Res. 2006 Jan 1;66(1):307-14
[
16397244.001
]
[Cites]
J Surg Oncol. 2006 Feb 1;93(2):139-44
[
16425301.001
]
[Cites]
Am J Pathol. 2006 Jul;169(1):268-78
[
16816379.001
]
[Cites]
J Biol Chem. 2000 Feb 18;275(7):4592-8
[
10671485.001
]
[Cites]
Eur J Biochem. 1995 Aug 15;232(1):84-9
[
7556175.001
]
[Cites]
Biochem J. 1996 Mar 15;314 ( Pt 3):1009-16
[
8615752.001
]
[Cites]
J Pharmacol Exp Ther. 2003 Nov;307(2):437-42
[
12966163.001
]
(PMID = 18937843.001).
[ISSN]
1471-2407
[Journal-full-title]
BMC cancer
[ISO-abbreviation]
BMC Cancer
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / RNA, Messenger; 0 / Receptor, PAR-2
[Other-IDs]
NLM/ PMC2587477
17.
Charnley N, Choudhury A, Chesser P, Cooper RA, Sebag-Montefiore D:
Effective treatment of anal cancer in the elderly with low-dose chemoradiotherapy.
Br J Cancer
; 2005 Apr 11;92(7):1221-5
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Effective treatment of
anal
cancer
in the elderly with low-dose chemoradiotherapy.
Chemoradiotherapy (CRT) is accepted as the standard initial treatment for
squamous cell anal
cancer
.
This paper reports the results
of a
modified regimen for this group of patients.
In all, 16 patients with biopsy-proven
squamous cell carcinoma
of the
anal
canal or
margin
and performance status or co-morbidity precluding the use of full-dose CRT were included in this protocol.
Patients received a dose of 30 Gy to the gross tumour volume plus 3 cm
margin
in all directions.
Only one patient experienced any grade 3 toxicity (
skin
).
This is a well-tolerated regimen for elderly/poor performance patients with
anal
cancer
, which can achieve high rates of local control and survival.
[MeSH-major]
Antimetabolites, Antineoplastic / therapeutic use.
Anus
Neoplasms / drug therapy.
Anus
Neoplasms / radiotherapy.
Carcinoma
,
Squamous Cell
/ drug therapy.
Carcinoma
,
Squamous Cell
/ radiotherapy. Fluorouracil / therapeutic use. Frail Elderly
Genetic Alliance.
consumer health - Anal Cancer
.
MedlinePlus Health Information.
consumer health - Anal Cancer
.
Hazardous Substances Data Bank.
FLUOROURACIL
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Int J Radiat Oncol Biol Phys. 1996 Jan 1;34(1):65-9
[
12118566.001
]
[Cites]
Cancer. 1997 Oct 15;80(8):1387-92
[
9338461.001
]
[Cites]
J Clin Oncol. 2004 Aug 1;22(15):2978-81
[
15210736.001
]
[Cites]
Dis Colon Rectum. 1974 May-Jun;17(3):354-6
[
4830803.001
]
[Cites]
Nephron. 1976;16(1):31-41
[
1244564.001
]
[Cites]
Dis Colon Rectum. 1977 Nov-Dec;20(8):677-8
[
923397.001
]
[Cites]
Dis Colon Rectum. 1982 Nov-Dec;25(8):778-82
[
7172946.001
]
[Cites]
Am J Med. 1985 Feb;78(2):211-5
[
3918441.001
]
[Cites]
Radiother Oncol. 1985 Feb;3(2):145-50
[
3920734.001
]
[Cites]
Dis Colon Rectum. 1987 May;30(5):324-33
[
3568920.001
]
[Cites]
Dis Colon Rectum. 1987 Jul;30(7):495-502
[
3109860.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1115-25
[
1938508.001
]
[Cites]
Cancer. 1993 Mar 1;71(5):1736-40
[
8448738.001
]
[Cites]
Radiology. 1994 May;191(2):569-72
[
8153343.001
]
[Cites]
J Clin Oncol. 1996 Sep;14(9):2527-39
[
8823332.001
]
[Cites]
Lancet. 1996 Oct 19;348(9034):1049-54
[
8874455.001
]
[Cites]
J Clin Oncol. 1997 May;15(5):2040-9
[
9164216.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1101-5
[
9169819.001
]
[Cites]
Br J Cancer. 2003 May 6;88(9):1352-7
[
12778060.001
]
(PMID = 15798772.001).
[ISSN]
0007-0920
[Journal-full-title]
British journal of cancer
[ISO-abbreviation]
Br. J. Cancer
[Language]
eng
[Publication-type]
Clinical Trial; Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
[Other-IDs]
NLM/ PMC2361984
18.
Cranston RD, Hart SD, Gornbein JA, Hirschowitz SL, Cortina G, Moe AA:
The prevalence, and predictive value, of abnormal anal cytology to diagnose anal dysplasia in a population of HIV-positive men who have sex with men.
Int J STD AIDS
; 2007 Feb;18(2):77-80
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The prevalence, and predictive value, of abnormal
anal
cytology to diagnose
anal
dysplasia in a population of HIV-positive men who have sex with men.
Due to the increasing incidence of
anal
cancer
in HIV-positive men who have sex with men, and the potential to detect and treat high-grade
anal
dysplasia--the putative
anal
cancer
precursor--we have introduced an
anal
cytology screening service.
Patients with abnormal
anal
cytology have follow-up high-resolution anoscopy (HRA) with biopsy of lesions clinically suspicious for high-grade dysplasia.
One hundred and sixty-four (67%) men had abnormal
anal
cytology, and 93 of them had follow-up HRA and
anal
biopsy.
The positive predictive value for any
anal
cytological abnormality to predict any degree of
anal
dysplasia was 95.7+/-2.1%, and for any
anal
cytological abnormality to predict high-grade
anal
dysplasia was 55.9+/-5.1%.
Abnormal
anal
cytology was highly predicative of
anal
dysplasia on biopsy.
[MeSH-major]
Anal
Canal / pathology.
Anus
Neoplasms.
Carcinoma
,
Squamous Cell
. HIV Infections / complications. Homosexuality, Male
[MeSH-minor]
AIDS-Related Opportunistic Infections /
diagnosis
. AIDS-Related Opportunistic Infections / epidemiology. Adult. Aged. Biopsy. Cytological Techniques. Humans. Male. Middle Aged. Predictive Value of Tests. Prevalence
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - Anal Cancer
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17331275.001).
[ISSN]
0956-4624
[Journal-full-title]
International journal of STD & AIDS
[ISO-abbreviation]
Int J STD AIDS
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
19.
de Veld DC, Bakker Schut TC, Skurichina M, Witjes MJ, Van der Wal JE, Roodenburg JL, Sterenborg HJ:
Autofluorescence and Raman microspectroscopy of tissue sections of oral lesions.
Lasers Med Sci
; 2005;19(4):203-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Cluster analysis was applied to find any relationship between spectral shape and lesion type or
cell
layer.
No clustering with regard to lesion type or
cell
layer was observed.
Raman spectra allowed for reliable classification into
cell
layers, but differences between lesion types were not significant in this study.
[MeSH-minor]
Carcinoma
,
Squamous Cell
/ pathology. Cluster Analysis. Connective Tissue / pathology. Epithelium / pathology. Freeze Drying. Humans. Keratins / metabolism. Mouth Neoplasms / pathology
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Gastrointest Endosc Clin N Am. 2003 Apr;13(2):279-96
[
12916660.001
]
[Cites]
Phys Med Biol. 2000 Feb;45(2):R1-59
[
10701500.001
]
[Cites]
J Biomed Opt. 2001 Jan;6(1):41-51
[
11178579.001
]
[Cites]
Int J Cancer. 2003 Dec 20;107(6):1047-52
[
14601068.001
]
[Cites]
Lasers Surg Med. 1992;12(1):63-78
[
1614265.001
]
[Cites]
Photochem Photobiol. 1998 Jul;68(1):123-32
[
9679458.001
]
[Cites]
J Invest Dermatol. 2002 Jul;119(1):64-9
[
12164926.001
]
[Cites]
Am J Obstet Gynecol. 2002 Mar;186(3):374-82
[
11904594.001
]
[Cites]
Gastrointest Endosc. 2003 Mar;57(3):396-402
[
12612529.001
]
[Cites]
J Biomed Opt. 2004 Sep-Oct;9(5):940-50
[
15447015.001
]
[Cites]
Arterioscler Thromb Vasc Biol. 2001 Oct;21(10):1630-5
[
11597937.001
]
[Cites]
Photochem Photobiol. 1997 Oct;66(4):418-23
[
9337612.001
]
[Cites]
Photochem Photobiol. 1996 May;63(5):662-71
[
8628758.001
]
[Cites]
J Am Paraplegia Soc. 1994 Oct;17(4):161-4
[
7869057.001
]
[Cites]
J Pathol. 2003 Aug;200(5):602-9
[
12898596.001
]
[Cites]
Head Neck. 1998 Sep;20(6):556-62
[
9702544.001
]
[Cites]
Anal Chem. 2000 Dec 15;72(24):6010-8
[
11140770.001
]
[Cites]
Br J Cancer. 2003 Jul 7;89(1):106-8
[
12838309.001
]
[Cites]
Technol Cancer Res Treat. 2003 Aug;2(4):327-32
[
12892515.001
]
[Cites]
Biopolymers. 2001;62(4):185-92
[
11391568.001
]
(PMID = 15772873.001).
[ISSN]
0268-8921
[Journal-full-title]
Lasers in medical science
[ISO-abbreviation]
Lasers Med Sci
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
68238-35-7 / Keratins
20.
Harris AT, Rennie A, Waqar-Uddin H, Wheatley SR, Ghosh SK, Martin-Hirsch DP, Fisher SE, High AS, Kirkham J, Upile T:
Raman spectroscopy in head and neck cancer.
Head Neck Oncol
; 2010 Oct 05;2:26
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Raman spectroscopy in head and neck
cancer
.
In recent years there has been much interest in the use of optical diagnostics in
cancer
detection.
Early
diagnosis of cancer
affords early intervention and greatest chance of cure.
Raman has been used successfully in key health areas such as cardiovascular diseases, and dental care but there is a paucity of literature on Raman spectroscopy in Head and Neck
cancer
.
Following the introduction of health care targets for
cancer
, and with an ever-aging population the need for rapid
cancer
detection has never been greater.
Raman spectroscopy could confer great patient benefit with early, rapid and accurate
diagnosis
.
It could reduce the need for whole pathological specimen examination, in theatre it could help to determine
margin
status, and finally peripheral blood
diagnosis
may be an achievable target.
MedlinePlus Health Information.
consumer health - Head and Neck Cancer
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Phys Med Biol. 2000 Feb;45(2):R1-59
[
10701500.001
]
[Cites]
Eur J Med Res. 2010 Mar 30;15(3):131-4
[
20452899.001
]
[Cites]
Laryngoscope. 2000 Oct;110(10 Pt 1):1756-63
[
11037840.001
]
[Cites]
Br J Dermatol. 2002 Mar;146(3):448-57
[
11952545.001
]
[Cites]
J Biomed Opt. 2003 Jan;8(1):121-47
[
12542388.001
]
[Cites]
Lasers Surg Med. 2003;32(3):210-4
[
12605428.001
]
[Cites]
Gastrointest Endosc. 2003 Mar;57(3):396-402
[
12612529.001
]
[Cites]
Photochem Photobiol. 2003 Aug;78(2):197-204
[
12945589.001
]
[Cites]
Anal Chem. 2003 Dec 1;75(23):6679-86
[
14640745.001
]
[Cites]
J Invest Dermatol. 2004 Feb;122(2):443-9
[
15009728.001
]
[Cites]
Gynecol Oncol. 2004 Apr;93(1):59-68
[
15047215.001
]
[Cites]
J Cell Biochem. 2004 Aug 15;92(6):1180-92
[
15258901.001
]
[Cites]
Bioinformatics. 2005 Apr 1;21(7):860-8
[
15513990.001
]
[Cites]
Lasers Surg Med. 2005 Sep;37(3):192-200
[
16127671.001
]
[Cites]
Biopolymers. 2006 Feb 15;81(3):179-93
[
16231284.001
]
[Cites]
Oral Oncol. 2006 Mar;42(3):221-8
[
16140566.001
]
[Cites]
Cancer Res. 2006 Mar 15;66(6):3317-22
[
16540686.001
]
[Cites]
J Biomed Opt. 2006 Mar-Apr;11(2):021003
[
16674178.001
]
[Cites]
Bioinformatics. 2006 Oct 15;22(20):2565-6
[
16882648.001
]
[Cites]
Biochem Soc Trans. 2007 Jun;35(Pt 3):544-9
[
17511648.001
]
[Cites]
Int J Nanomedicine. 2007;2(4):785-98
[
18203445.001
]
[Cites]
Analyst. 2008 Oct;133(10):1416-23
[
18810290.001
]
[Cites]
Biopolymers. 2009 Jul;91(7):539-46
[
19226625.001
]
[Cites]
Head Neck Oncol. 2009;1:25
[
19594907.001
]
[Cites]
Head Neck Oncol. 2009;1:34
[
19761601.001
]
[Cites]
Head Neck Oncol. 2009;1:38
[
19863815.001
]
[Cites]
Oral Oncol. 2009 Dec;45(12):1006-10
[
19828359.001
]
[Cites]
Int J Gynecol Cancer. 2010 Feb;20(2):283-7
[
20134271.001
]
[Cites]
Expert Rev Anticancer Ther. 2010 Mar;10(3):321-9
[
20214513.001
]
[Cites]
Anal Chem. 2000 Aug 15;72(16):3771-5
[
10959962.001
]
(PMID = 20923567.001).
[ISSN]
1758-3284
[Journal-full-title]
Head & neck oncology
[ISO-abbreviation]
Head Neck Oncol
[Language]
ENG
[Grant]
United Kingdom / Cancer Research UK / /
[Publication-type]
Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't; Review
[Publication-country]
England
[Other-IDs]
NLM/ PMC2958871
21.
Wang L, Xue L, Yan H, Li J, Lu Y:
Effects of ROCK inhibitor, Y-27632, on adhesion and mobility in esophageal squamous cell cancer cells.
Mol Biol Rep
; 2010 Apr;37(4):1971-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Effects of ROCK inhibitor, Y-27632, on adhesion and mobility in esophageal
squamous cell
cancer
cells.
However, little is known the effect of ROCK on
cell
adhesion and mobility in esophageal
squamous cell
cancer
(ESCC), one of the most diagnosed cancers in China.
All these findings indicate that ROCK signaling pathway plays an important role in
cell
adhesion and mobility, suggesting that it may be used as a potential target for therapy of ESCC.
[MeSH-major]
Amides / pharmacology.
Carcinoma
,
Squamous Cell
/ pathology.
Cell
Movement / drug effects. Esophageal Neoplasms / pathology. Protein Kinase Inhibitors / pharmacology. Pyridines / pharmacology. rho-Associated Kinases / antagonists & inhibitors
[MeSH-minor]
Cell
Adhesion / drug effects.
Cell
Line, Tumor. Humans
Genetic Alliance.
consumer health - Esophageal Cancer
.
MedlinePlus Health Information.
consumer health - Esophageal Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Hepatol Res. 2008 Aug;38(8):810-7
[
18507693.001
]
[Cites]
Am J Physiol Cell Physiol. 2008 Jul;295(1):C38-49
[
18463228.001
]
[Cites]
Exp Cell Res. 2008 Oct 15;314(17):3162-74
[
18694745.001
]
[Cites]
Mol Cancer Res. 2008 Sep;6(9):1410-20
[
18819929.001
]
[Cites]
World J Gastroenterol. 2008 May 21;14(19):3054-8
[
18494058.001
]
[Cites]
J Craniomaxillofac Surg. 2007 Jan;35(1):1-9
[
17296306.001
]
[Cites]
Invest Ophthalmol Vis Sci. 2007 Dec;48(12):5549-57
[
18055804.001
]
[Cites]
Am J Physiol Cell Physiol. 2006 Oct;291(4):C668-77
[
16641163.001
]
[Cites]
Am J Respir Cell Mol Biol. 1999 Jun;20(6):1190-200
[
10340938.001
]
[Cites]
Invest Ophthalmol Vis Sci. 2003 Aug;44(8):3317-25
[
12882776.001
]
[Cites]
Ann N Y Acad Sci. 2005 Nov;1056:405-12
[
16387705.001
]
[Cites]
J Biol Chem. 2009 May 29;284(22):15147-57
[
19293150.001
]
[Cites]
Int J Oncol. 2008 Sep;33(3):585-93
[
18695890.001
]
[Cites]
Int J Cancer. 1996 Jun 21;69(3):225-35
[
8682592.001
]
[Cites]
J Pharmacol Exp Ther. 2008 Dec;327(3):777-88
[
18791066.001
]
[Cites]
World J Gastroenterol. 2008 Oct 7;14(37):5665-73
[
18837082.001
]
[Cites]
Acta Biochim Biophys Sin (Shanghai). 2006 May;38(5):318-26
[
16680372.001
]
[Cites]
Neoplasia. 2008 Dec;10(12):1444-58
[
19048123.001
]
[Cites]
Jpn J Cancer Res. 2000 Aug;91(8):811-6
[
10965022.001
]
[Cites]
J Cell Biol. 2008 Nov 17;183(4):697-710
[
19015318.001
]
[Cites]
Cancer Lett. 2009 Nov 1;284(2):122-30
[
19303207.001
]
[Cites]
Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11305-10
[
18685096.001
]
[Cites]
Cancer Lett. 2007 Aug 18;253(2):236-48
[
17360108.001
]
[Cites]
Gut. 2009 Aug;58(8):1121-7
[
19398441.001
]
[Cites]
Biol Pharm Bull. 2008 Sep;31(9):1802-5
[
18758081.001
]
[Cites]
Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1500-9
[
16565385.001
]
[Cites]
Trends Cell Biol. 2005 Mar;15(3):138-45
[
15752977.001
]
[Cites]
J Pineal Res. 2009 Jan;46(1):15-21
[
18482340.001
]
[Cites]
Kobe J Med Sci. 2007;53(3):125-34
[
17684444.001
]
[Cites]
Mol Cancer Res. 2005 Aug;3(8):425-33
[
16123138.001
]
[Cites]
Anal Biochem. 1976 May 7;72:248-54
[
942051.001
]
[Cites]
Histopathology. 2008 Apr;52(5):560-8
[
18312357.001
]
[Cites]
J Biol Chem. 2006 Oct 6;281(40):29614-24
[
16882662.001
]
[Cites]
Lab Invest. 2007 Nov;87(11):1149-58
[
17876296.001
]
[Cites]
Cancer Lett. 2005 Jan 31;218(1):69-79
[
15639342.001
]
(PMID = 19649725.001).
[ISSN]
1573-4978
[Journal-full-title]
Molecular biology reports
[ISO-abbreviation]
Mol. Biol. Rep.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / Amides; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 138381-45-0 / Y 27632; EC 2.7.11.1 / rho-Associated Kinases
22.
Driemel O, Dahse R, Berndt A, Pistner H, Hakim SG, Zardi L, Reichert TE, Kosmehl H:
High-molecular tenascin-C as an indicator of atypical cells in oral brush biopsies.
Clin Oral Investig
; 2007 Mar;11(1):93-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[MeSH-major]
Biomarkers, Tumor / analysis. Biopsy / methods.
Carcinoma
,
Squamous Cell
/ pathology. Mouth Neoplasms / pathology. Tenascin / analysis
MedlinePlus Health Information.
consumer health - Biopsy
.
MedlinePlus Health Information.
consumer health - Oral Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Anal Cell Pathol. 2003;25(3):139-46
[
12775918.001
]
[Cites]
Int J Biochem Cell Biol. 2004 Jun;36(6):986-90
[
15094113.001
]
[Cites]
Br J Cancer. 2006 Apr 24;94(8):1170-5
[
16622441.001
]
[Cites]
Int J Mol Med. 2000 May;5(5):505-10
[
10762653.001
]
[Cites]
Cancer. 2001 Sep 15;92(6):1419-26
[
11745218.001
]
[Cites]
J Am Dent Assoc. 1999 Oct;130(10):1445-57
[
10570588.001
]
[Cites]
J Oral Pathol Med. 2006 Sep;35(8):520; author reply 520-2
[
16918607.001
]
[Cites]
Int J Cancer. 2002 Aug 20;100(6):719-22
[
12209613.001
]
[Cites]
Int J Cancer. 1997 Jul 17;72(2):236-40
[
9219826.001
]
[Cites]
Int J Cancer. 1992 Nov 11;52(5):688-92
[
1385335.001
]
[Cites]
Oncology. 2003;64(3):245-50
[
12697965.001
]
[Cites]
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003 Sep;96(3):252
[
14515857.001
]
[Cites]
Anal Cell Pathol. 2001;22(4):211-21
[
11564897.001
]
[Cites]
Biochem Cell Biol. 1997;75(6):759-69
[
9599665.001
]
[Cites]
J Pathol. 2003 Jul;200(4):429-47
[
12845611.001
]
[Cites]
J Pathol. 2004 Jul;203(3):771-9
[
15221936.001
]
[Cites]
Int J Cancer. 1998 Mar 2;75(5):680-7
[
9495234.001
]
[Cites]
Oral Oncol. 2004 Sep;40(8):824-8
[
15288838.001
]
[Cites]
J Oral Pathol Med. 2006 Jan;35(1):58-60
[
16393256.001
]
[Cites]
Cancer Res. 2002 Jun 1;62(11):3289-97
[
12036947.001
]
[Cites]
Cytopathology. 2007 Dec;18(6):348-55
[
18031447.001
]
[Cites]
J Oral Pathol Med. 1994 Nov;23(10):446-50
[
7532219.001
]
[Cites]
J Oral Pathol Med. 2004 Aug;33(7):398-404
[
15250831.001
]
[Cites]
Histochem Cell Biol. 2006 Jul;126(1):125-31
[
16344911.001
]
[Cites]
Oral Oncol. 2004 Sep;40(8):829-34
[
15288839.001
]
[Cites]
J Cancer Res Clin Oncol. 2001 May;127(5):286-92
[
11355143.001
]
[Cites]
Oral Oncol. 2002 Jun;38(4):332-6
[
12076695.001
]
[Cites]
J Pathol. 1999 Dec;189(4):475-80
[
10629546.001
]
[Cites]
Gen Dent. 2002 Nov-Dec;50(6):500-3
[
12572180.001
]
[Cites]
Mund Kiefer Gesichtschir. 2004 Jul;8(4):229-36
[
15293118.001
]
(PMID = 17111122.001).
[ISSN]
1432-6981
[Journal-full-title]
Clinical oral investigations
[ISO-abbreviation]
Clin Oral Investig
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Germany
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Tenascin
23.
Seth A, Agarwal A:
Apoptotic count as a guide for histological grading of carcinoma esophagus: a light microscopic study.
J Lab Physicians
; 2009 Jan;1(1):11-4
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Apoptotic count as a guide for histological grading of
carcinoma
esophagus: a light microscopic study.
AIMS: The study aims to find out if a correlation between apoptotic count and histological grading exists in
squamous cell carcinoma
of the esophagus, and also to review the literature on such a relationship in the context of some other tumors.
SETTINGS AND DESIGN: Cases of
squamous cell carcinoma
of the esophagus who presented at a tertiary care center over a period of one year were reviewed.
MATERIALS AND METHODS: The endoscopic biopsy specimens of 56 patients of
squamous cell carcinoma
of esophagus were fixed in 10% buffered formalin, processed for routine paraffin sections, sections taken, stained by hematoxylin and eosin and examined under light microscope, using 40× objective and 10× eyepiece.
CONCLUSIONS: Grading of
squamous cell carcinoma
of esophagus, solely on the basis of apoptotic count can be used in the first place or to corroborate conventional histological grading done on the basis of morphology.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Anticancer Res. 2000 May-Jun;20(3B):2123-8
[
10928164.001
]
[Cites]
Am J Surg Pathol. 1997 Jan;21(1):88-101
[
8990145.001
]
[Cites]
Indian J Pathol Microbiol. 2001 Jul;44(3):257-9
[
12024908.001
]
[Cites]
Surgery. 2006 Dec;140(6):899-905; discussion 905-6
[
17188136.001
]
[Cites]
Mod Pathol. 2007 Oct;20(10):1036-44
[
17643097.001
]
[Cites]
Br J Cancer. 1972 Aug;26(4):239-57
[
4561027.001
]
[Cites]
Stroke. 1995 Jul;26(7):1252-7; discussion 1257-8
[
7541573.001
]
[Cites]
Int J Cancer. 1995 Jun 9;61(6):826-31
[
7790118.001
]
[Cites]
Arch Pathol Lab Med. 1997 Jan;121(1):54-8
[
9111093.001
]
[Cites]
J Cell Biol. 1997 Aug 25;138(4):901-11
[
9265655.001
]
[Cites]
Anal Quant Cytol Histol. 2002 Apr;24(2):73-80
[
12026053.001
]
[Cites]
Int J Oral Maxillofac Surg. 2005 Dec;34(8):900-6
[
15907374.001
]
[Cites]
Cancer Res. 1995 May 1;55(9):1811-6
[
7728743.001
]
[Cites]
Nature. 1996 Jan 4;379(6560):19-20
[
8538735.001
]
[Cites]
Histopathology. 1995 Nov;27(5):469-72
[
8575739.001
]
[Cites]
Blood. 1996 Mar 15;87(6):2470-5
[
8630413.001
]
[Cites]
Indian J Pathol Microbiol. 2000 Jul;43(3):271-5
[
11218671.001
]
(PMID = 21938242.001).
[ISSN]
0974-2727
[Journal-full-title]
Journal of laboratory physicians
[ISO-abbreviation]
J Lab Physicians
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
India
[Other-IDs]
NLM/ PMC3167958
[Keywords]
NOTNLM ; Apoptotic count / histological grading / squamous cell carcinoma esophagus
24.
Kreuter A, Potthoff A, Brockmeyer NH, Gambichler T, Swoboda J, Stücker M, Schmitt M, Pfister H, Wieland U, German Competence Network HIV/AIDS:
Anal carcinoma in human immunodeficiency virus-positive men: results of a prospective study from Germany.
Br J Dermatol
; 2010 Jun;162(6):1269-77
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Anal carcinoma
in human immunodeficiency virus-positive men: results
of a
prospective study from Germany.
BACKGROUND:
Anal
intraepithelial neoplasia (AIN), a human papillomavirus (HPV)-associated potential precursor lesion of
anal
cancer
, is frequent among human immunodeficiency virus (HIV)-positive men who have sex with men (MSM).
There is a paucity of data published on the progression of high-grade AIN to invasive
cancer
as well as on clinical and virological characteristics comparing
anal
margin
and
anal
canal
carcinoma
.
OBJECTIVES: To search for
anal carcinoma
and AIN in a large series of HIV-positive MSM, to assess treatment response of
anal carcinoma
, and to analyse lesional HPV spectrum of
anal
cancers.
METHODS: Detection of
anal carcinoma
and AIN was performed using cytology, high-resolution anoscopy, and histology in case of abnormal findings.
Additionally, HPV analyses for 36 high- and low-risk α-HPV types were performed in patients with
anal carcinoma
.
Of these, 116 (26·0%) patients had normal findings, 163 (36·5%) had low-grade AIN, 156 (35·0%) had high-grade AIN, and 11 (2·5%) had
anal carcinoma
as evidenced by the highest grade of cytology/histology.
Five patients with
anal
cancer
, who had refused treatment of their precancerous lesions, had progressed from high-grade AIN to invasive
cancer
within a median time of 8·6 months.
All
anal
cancers carried high-risk α-HPV types.
All five
squamous cell
carcinomas (SCCs) of the
anal
canal were HPV16 positive.
In contrast, only one of the four
anal
margin
SCCs were HPV16 positive (HPV31, HPV33 and HPV33 + HPV68 were found in the other three
anal
margin
SCCs).
In contrast to
the cancer
biopsies, a broad spectrum of surface high- and low-risk HPV types was found in
anal
swabs of the patients.
Surgical excision resulted in long-term disease control of all
anal
margin
carcinomas, whereas combined chemoradiotherapy in carcinomas of the
anal
canal was associated with high recurrence rates, high toxicity, and high mortality.
CONCLUSIONS:
Anal carcinoma
and AIN are frequent in HIV-positive men, even in patients participating in
anal
cancer
prevention programmes.
High-grade dysplasia in these patients can progress to invasive
cancer
within a short period of time.
Anal
margin
carcinoma
and
anal
canal
carcinoma
differ substantially in their lesional HPV spectrum, prognosis and treatment response.
[MeSH-major]
Anus
Neoplasms / virology.
Carcinoma
in Situ / virology.
Carcinoma
,
Squamous Cell
/ virology. HIV Seropositivity / complications. Papillomaviridae / isolation & purification
MedlinePlus Health Information.
consumer health - Anal Cancer
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
© 2010 The Authors. Journal Compilation © 2010 British Association of Dermatologists.
(PMID = 20184584.001).
[ISSN]
1365-2133
[Journal-full-title]
The British journal of dermatology
[ISO-abbreviation]
Br. J. Dermatol.
[Language]
eng
[Databank-accession-numbers]
ClinicalTrials.gov/ NCT00365729
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Antineoplastic Agents
25.
García Sar D, Montes-Bayón M, Blanco González E, Sierra LM, Aguado L, Comendador MA, Koellensperger G, Hann S, Sanz-Medel A:
Quantitative profiling of in vivo generated cisplatin-DNA adducts using different isotope dilution strategies.
Anal Chem
; 2009 Dec 1;81(23):9553-60
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
In this regard, two novel sensitive and selective strategies are proposed here to quantify cisplatin-DNA adducts generated in Drosophila melanogaster larvae and in head and neck
squamous cell carcinoma
cultures.
Two different strategies, based on isotope dilution analysis (IDA), have been attempted and evaluated for quantification: species-unspecific (the postcolumn addition
of a
194Pt-enriched solution) and the species-specific (by means
of a
synthesized isotopically enriched cisplatin (194Pt) adduct).
Species-specific spiking before enzymatic digestion provided accurate and precise analytical results to clearly differentiate between Drosophila samples and
carcinoma cell
cultures exposed to different cisplatin concentrations.
[MeSH-minor]
Animals. Base Sequence.
Cell
Line, Tumor. Drosophila melanogaster / metabolism. Humans. Indicator Dilution Techniques. Isotopes. Mass Spectrometry. Oligodeoxyribonucleotides / genetics. Oligodeoxyribonucleotides / metabolism
FlyBase.
FlyBase
.
Hazardous Substances Data Bank.
CIS-DIAMINEDICHLOROPLATINUM
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19886652.001).
[ISSN]
1520-6882
[Journal-full-title]
Analytical chemistry
[ISO-abbreviation]
Anal. Chem.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / DNA Adducts; 0 / Isotopes; 0 / Oligodeoxyribonucleotides; Q20Q21Q62J / Cisplatin
26.
Hwang HJ, Bestani C, Jiménez R, Masciángioli G, Gutiérrez A, Cartelli C, Rafailovici L, Barugel M, Rodríguez G, Méndez G:
[Treatment of patients with squamous cell carcinoma of the anal canal in the last 20 years in a gastroenterology hospital].
Acta Gastroenterol Latinoam
; 2005;35(2):94-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Treatment of patients with
squamous cell carcinoma
of the
anal
canal in the last 20 years in a gastroenterology hospital].
[Transliterated title]
El tratamiento
de
los pacientes con
carcinoma
epidermoide
del
canal
anal
en los últimos 20 años en nuestro hospital.
Anal
cancers compromise only 1.5% of all digestive tumors.
OBJECTIVE: To collect and analyze clinical data from the medical records of all consecutive patients with
squamous cell carcinoma
of the
anal
canal (SCCAC) treated by the Oncology Section in 20 years.
[MeSH-major]
Anus
Neoplasms / therapy.
Carcinoma
,
Squamous Cell
/ therapy
Genetic Alliance.
consumer health - Carcinoma, Squamous Cell
.
MedlinePlus Health Information.
consumer health - Anal Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16127985.001).
[ISSN]
0300-9033
[Journal-full-title]
Acta gastroenterologica Latinoamericana
[ISO-abbreviation]
Acta Gastroenterol. Latinoam.
[Language]
spa
[Publication-type]
English Abstract; Journal Article
[Publication-country]
Argentina
27.
Chou YP, Saito Y, Matsuda T, Nakajima T, Mashimo Y, Moriya Y, Shimoda T:
Novel diagnostic methods for early-stage squamous cell carcinoma of the anal canal successfully resected by endoscopic submucosal dissection.
Endoscopy
; 2009;41 Suppl 2:E283-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Novel diagnostic methods for early-stage
squamous cell carcinoma
of the
anal
canal successfully resected by endoscopic submucosal dissection.
[MeSH-major]
Anus
Neoplasms /
diagnosis
.
Carcinoma
,
Squamous Cell
/
diagnosis
. Colonoscopy / methods. Dissection / methods. Intestinal Mucosa / surgery
Genetic Alliance.
consumer health - Carcinoma, Squamous Cell
.
MedlinePlus Health Information.
consumer health - Anal Cancer
.
MedlinePlus Health Information.
consumer health - Colonoscopy
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19866431.001).
[ISSN]
1438-8812
[Journal-full-title]
Endoscopy
[ISO-abbreviation]
Endoscopy
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Germany
28.
Baudis M:
Genomic imbalances in 5918 malignant epithelial tumors: an explorative meta-analysis of chromosomal CGH data.
BMC Cancer
; 2007;7:226
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Related average imbalance patterns were found for clinically distinct entities, e.g. hepatocellular carcinomas (
ca
.) and ductal breast
ca
., as well as for histologically related entities (
squamous cell
ca
. of different sites).
[MeSH-major]
Carcinoma
/ genetics. Chromosome Aberrations. Chromosome Mapping
COS Scholar Universe.
author profiles
.
SciCrunch.
BioSharing: Resource: Registry
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Hum Genet. 1988 Nov;80(3):235-46
[
3192213.001
]
[Cites]
Science. 1992 Oct 30;258(5083):818-21
[
1359641.001
]
[Cites]
Br J Cancer. 1999 Dec;81(8):1410-8
[
10604741.001
]
[Cites]
Int J Oncol. 2000 Feb;16(2):383-99
[
10639584.001
]
[Cites]
Am J Pathol. 2000 Mar;156(3):871-8
[
10702404.001
]
[Cites]
J Pathol. 2000 Nov;192(3):301-6
[
11054712.001
]
[Cites]
Am J Pathol. 2001 Feb;158(2):399-406
[
11159178.001
]
[Cites]
N Engl J Med. 2001 Mar 15;344(11):783-92
[
11248153.001
]
[Cites]
Bioinformatics. 2001 Dec;17(12):1228-9
[
11751233.001
]
[Cites]
Anal Cell Pathol. 2001;23(1):29-37
[
11790857.001
]
[Cites]
Blood. 2002 Feb 15;99(4):1381-7
[
11830490.001
]
[Cites]
Cancer Genet Cytogenet. 2002 May;135(1):63-90
[
12072205.001
]
[Cites]
Anal Cell Pathol. 2002;24(2-3):77-87
[
12446957.001
]
[Cites]
Int J Cancer. 2003 Jul 1;105(4):494-8
[
12712440.001
]
[Cites]
Clin Cancer Res. 2003 May;9(5):1808-14
[
12738738.001
]
[Cites]
Pathologica. 2003 Apr;95(2):71-82
[
12768875.001
]
[Cites]
Proc Natl Acad Sci U S A. 2004 Jan 27;101(4):1039-44
[
14730057.001
]
[Cites]
Blood Rev. 2004 Jun;18(2):115-36
[
15010150.001
]
[Cites]
BMC Cancer. 2004 Feb 6;4:5
[
15018632.001
]
[Cites]
Neoplasia. 2004 Mar-Apr;6(2):143-9
[
15140403.001
]
[Cites]
Genes Chromosomes Cancer. 2004 Aug;40(4):342-8
[
15188458.001
]
[Cites]
Cytogenet Genome Res. 2004;106(1):43-8
[
15218240.001
]
[Cites]
Cancer Genet Cytogenet. 2004 Aug;153(1):1-9
[
15325087.001
]
[Cites]
J Korean Med Sci. 2004 Oct;19(5):682-7
[
15483344.001
]
[Cites]
Nature. 1972 May 5;237(5349):33-4
[
4113130.001
]
[Cites]
Clin Genet. 1972;3(3):169-79
[
4115505.001
]
[Cites]
Nature. 1973 Jun 1;243(5405):290-3
[
4126434.001
]
[Cites]
Hum Genet. 1993 Feb;90(6):584-9
[
8383093.001
]
[Cites]
Trends Genet. 1993 Apr;9(4):138-41
[
8516849.001
]
[Cites]
Hum Mol Genet. 1993 Nov;2(11):1907-14
[
8281155.001
]
[Cites]
Am J Pathol. 1994 Aug;145(2):356-64
[
7519827.001
]
[Cites]
Cancer Res. 1994 Sep 1;54(17):4813-7
[
8062283.001
]
[Cites]
Cancer Genet Cytogenet. 1995 Jul 15;82(2):140-5
[
7664243.001
]
[Cites]
Blood. 1996 Jan 1;87(1):25-9
[
8547649.001
]
[Cites]
Nat Genet. 1996 Apr;12(4):368-75
[
8630489.001
]
[Cites]
Exp Clin Endocrinol Diabetes. 1996;104 Suppl 4:101-4
[
8981013.001
]
[Cites]
Cytogenet Cell Genet. 1996;75(1):17-21
[
8995481.001
]
[Cites]
Nat Genet. 1997 Apr;15(4):406-10
[
9090389.001
]
[Cites]
J Neuropathol Exp Neurol. 1997 Sep;56(9):999-1008
[
9291941.001
]
[Cites]
Genes Chromosomes Cancer. 1997 Dec;20(4):372-6
[
9408753.001
]
[Cites]
Genes Chromosomes Cancer. 1997 Dec;20(4):399-407
[
9408757.001
]
[Cites]
Genes Chromosomes Cancer. 1998 Feb;21(2):172-5
[
9491330.001
]
[Cites]
Am J Pathol. 1998 May;152(5):1107-23
[
9588877.001
]
[Cites]
Am J Hum Genet. 1998 Aug;63(2):625-37
[
9683604.001
]
[Cites]
Nat Genet. 1998 Oct;20(2):207-11
[
9771718.001
]
[Cites]
Genes Chromosomes Cancer. 1998 Dec;23(4):307-16
[
9824203.001
]
[Cites]
Nat Genet. 1999 Sep;23(1):41-6
[
10471496.001
]
[Cites]
Clin Gastroenterol Hepatol. 2006 Oct;4(10):1283-91
[
16979954.001
]
[Cites]
Oncogene. 2006 Nov 23;25(55):7324-32
[
16751803.001
]
[Cites]
J Pathol. 2007 Jan;211(1):18-25
[
17072825.001
]
[Cites]
Lung Cancer. 2006 Dec;54(3):293-301
[
17011066.001
]
[Cites]
Oncogene. 2007 Feb 8;26(6):934-44
[
16862168.001
]
[Cites]
Bioinformatics. 2007 Feb 15;23(4):450-7
[
17150994.001
]
[Cites]
Best Pract Res Clin Endocrinol Metab. 2007 Mar;21(1):1-14
[
17382262.001
]
[Cites]
Prostate. 2007 May 15;67(7):692-700
[
17342750.001
]
[Cites]
Int J Cancer. 2007 Jun 15;120(12):2734-8
[
17354231.001
]
[Cites]
Pathologe. 2007 Nov;28(6):464-73
[
17882420.001
]
[Cites]
Ugeskr Laeger. 2008 Jan 28;170(5):328-30
[
18252159.001
]
[Cites]
Hum Genet. 1988 Nov;80(3):224-34
[
3192212.001
]
[Cites]
Am J Pathol. 1999 Sep;155(3):683-94
[
10487825.001
]
[Cites]
Am J Hum Genet. 1960 Sep;12:250-76
[
14430808.001
]
[Cites]
Thyroid. 2004 Dec;14(12):1061-4
[
15650359.001
]
[Cites]
Cancer Res. 2005 Feb 1;65(3):822-7
[
15705879.001
]
[Cites]
Acta Pharmacol Sin. 2005 Jun;26(6):659-65
[
15916730.001
]
[Cites]
Int J Oncol. 2005 Sep;27(3):593-606
[
16077907.001
]
[Cites]
Genes Chromosomes Cancer. 2006 Jan;45(1):11-9
[
16130125.001
]
[Cites]
Biotechniques. 2006 Mar;40(3):269-70, 272
[
16568815.001
]
[Cites]
BMC Cancer. 2006;6:96
[
16620391.001
]
[Cites]
Cancer Genet Cytogenet. 2006 Jun;167(2):103-8
[
16737908.001
]
[Cites]
Genes Chromosomes Cancer. 2006 Aug;45(8):721-30
[
16688744.001
]
[Cites]
Clin Cancer Res. 2006 Jul 1;12(13):3961-70
[
16818693.001
]
[Cites]
Cell Oncol. 2006;28(3):71-84
[
16823176.001
]
[Cites]
Oncogene. 2006 Jul 27;25(32):4399-412
[
16547504.001
]
[Cites]
Bioinformatics. 2006 Aug 15;22(16):1971-8
[
16705014.001
]
[Cites]
Cytogenet Genome Res. 2006;115(1):16-22
[
16974079.001
]
[Cites]
J Invest Dermatol. 2006 Oct;126(10):2308-15
[
16728973.001
]
(PMID = 18088415.001).
[ISSN]
1471-2407
[Journal-full-title]
BMC cancer
[ISO-abbreviation]
BMC Cancer
[Language]
eng
[Publication-type]
Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Other-IDs]
NLM/ PMC2225423
29.
Dietz A, Boehm A, Horn IS, Kruber P, Bechmann I, Golusinski W, Niederwieser D, Dollner R, Remmerbach TW, Wittekind C, Dietzsch S, Hildebrandt G, Wichmann G:
Assay-based response evaluation in head and neck oncology: requirements for better decision making.
Eur Arch Otorhinolaryngol
; 2010 Apr;267(4):483-94
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
This article gives an overview on different current strategies of assay-based response evaluation in head and neck
squamous cell
carcinomas (HNSCC) and critically summarizes their role and needs for future clinical evaluation.
Moreover, the outcome is difficult to predict due to heterogeneity
of a
tumor's response, impaired late functional outcome, and increased late toxicity if simultaneously applied to radiation.
Unfortunately, predictive information on response characteristics
of a
given tumor before starting the therapy is not available in daily routine, although heterogeneity in response
of a
given tumor entity to treatments has been known for decades.
[MeSH-major]
Carcinoma
,
Squamous Cell
/ therapy. Combined Modality Therapy / methods. Decision Making. Head and Neck Neoplasms / therapy
MedlinePlus Health Information.
consumer health - Head and Neck Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Eur Arch Otorhinolaryngol. 2010 Apr;267(4):481-2
[
20052588.001
]
[Cites]
Cancer. 2009 Aug 1;115(15):3483-8
[
19536900.001
]
[Cites]
Cancer Biother Radiopharm. 1998 Apr;13(2):81-7
[
10850344.001
]
[Cites]
BMC Cancer. 2006 Mar 06;6:52
[
16515711.001
]
[Cites]
Br J Cancer. 2008 Sep 2;99(5):760-7
[
18728667.001
]
[Cites]
Cancer Genomics Proteomics. 2007 May-Jun;4(3):175-86
[
17878521.001
]
[Cites]
Int J Cancer. 2007 Apr 15;120(8):1731-8
[
17236202.001
]
[Cites]
Eur Arch Otorhinolaryngol. 2008 Jul;265 Suppl 1:S3-12
[
18535834.001
]
[Cites]
J Natl Cancer Inst. 1990 Apr 4;82(7):582-8
[
2313735.001
]
[Cites]
Cancer Res. 1995 Nov 1;55(21):4837-43
[
7585517.001
]
[Cites]
Cancer Res. 1985 Nov;45(11 Pt 1):5436-41
[
4053017.001
]
[Cites]
Mol Vis. 2008 Sep 15;14:1705-12
[
18806879.001
]
[Cites]
Nat Rev Mol Cell Biol. 2000 Dec;1(3):233-6
[
11252900.001
]
[Cites]
J Natl Cancer Inst. 1990 Jan 17;82(2):117-24
[
2152944.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2009 Apr 1;73(5):1293-303
[
19306746.001
]
[Cites]
Cancer Res. 2008 Jun 1;68(11):4311-20
[
18519691.001
]
[Cites]
Anticancer Res. 2006 Mar-Apr;26(2B):1651-5
[
16619587.001
]
[Cites]
Radiother Oncol. 2003 Aug;68(2):163-70
[
12972311.001
]
[Cites]
Oral Oncol. 2007 Sep;43(8):749-56
[
17112769.001
]
[Cites]
Recent Results Cancer Res. 1984;94:197-201
[
6494580.001
]
[Cites]
Cancer Res. 1984 Jun;44(6):2309-12
[
6202397.001
]
[Cites]
Eur Arch Otorhinolaryngol. 2009 Aug;266(8):1291-300
[
18972123.001
]
[Cites]
Anticancer Res. 2008 Mar-Apr;28(2A):949-55
[
18507041.001
]
[Cites]
Arch Otolaryngol Head Neck Surg. 2008 May;134(5):536-8
[
18490577.001
]
[Cites]
Anticancer Res. 2004 Jan-Feb;24(1):325-31
[
15015616.001
]
[Cites]
Head Neck. 2008 Dec;30(12):1636-42
[
18642286.001
]
[Cites]
Radiother Oncol. 2009 Jul;92(1):4-14
[
19446902.001
]
[Cites]
Oncology. 1992;49(5):343-6
[
1528569.001
]
[Cites]
Int J Cancer. 1991 May 30;48(3):423-7
[
2040537.001
]
[Cites]
Am J Surg. 1980 Oct;140(4):527-30
[
7425237.001
]
[Cites]
Anticancer Res. 1991 May-Jun;11(3):1301-4
[
1909515.001
]
[Cites]
J Clin Oncol. 2005 May 20;23(15):3645-6; author reply 3646-8
[
15908688.001
]
[Cites]
J Natl Cancer Inst. 1990 Jan 17;82(2):96-101
[
2403594.001
]
[Cites]
Head Neck. 2002 May;24(5):437-42
[
12001073.001
]
[Cites]
Br J Cancer. 1992 Jan;65(1):27-32
[
1310250.001
]
[Cites]
Cancer Res. 1983 Apr;43(4):1926-31
[
6339044.001
]
[Cites]
Mol Pharmacol. 2000 Dec;58(6):1563-9
[
11093797.001
]
[Cites]
Cancer Res. 1987 Mar 1;47(5):1297-301
[
3469013.001
]
[Cites]
J Cell Biochem Suppl. 1996;24:173-85
[
8806100.001
]
[Cites]
J Clin Oncol. 2004 Sep 1;22(17):3631-8
[
15289488.001
]
[Cites]
J Cell Biochem. 2009 May 1;107(1):179-88
[
19277990.001
]
[Cites]
Gynecol Oncol. 1995 Jun;57(3):294-8
[
7774832.001
]
[Cites]
Toxicol Appl Pharmacol. 2000 Apr 15;164(2):134-42
[
10764626.001
]
[Cites]
Strahlenther Onkol. 2009 Jun;185(6):371-8
[
19506820.001
]
[Cites]
J Natl Cancer Inst. 1996 Jul 3;88(13):890-9
[
8656441.001
]
[Cites]
J Natl Cancer Inst. 2009 Apr 1;101(7):498-506
[
19318632.001
]
[Cites]
Cancer Chemother Pharmacol. 2010 May;65(6):1153-63
[
19771432.001
]
[Cites]
Pancreas. 2004 Jan;28(1):38-44
[
14707728.001
]
[Cites]
Eur J Cancer. 1980 May;16(5):647-54
[
7389791.001
]
[Cites]
Acta Otolaryngol. 1987 May-Jun;103(5-6):529-36
[
2441566.001
]
[Cites]
J Clin Lab Anal. 1991;5(2):133-43
[
2023059.001
]
[Cites]
Anticancer Drugs. 1998 Jan;9(1):51-7
[
9491792.001
]
[Cites]
N Engl J Med. 1991 Jun 13;324(24):1685-90
[
2034244.001
]
[Cites]
Radiother Oncol. 1995 Nov;37(2):87-99
[
8747932.001
]
[Cites]
Endocr Relat Cancer. 2002 Sep;9(3):171-82
[
12237245.001
]
[Cites]
Arch Otolaryngol. 1983 Nov;109(11):709-14
[
6314953.001
]
[Cites]
Cancer Res. 2000 Dec 1;60(23):6730-6
[
11118059.001
]
[Cites]
Cancer Lett. 2005 Jun 1;223(1):57-66
[
15890237.001
]
[Cites]
Cancer Treat Rev. 1984 Mar;11 Suppl A:131-7
[
6733715.001
]
[Cites]
Oral Oncol. 1998 Jan;34(1):30-8
[
9659517.001
]
[Cites]
Radiother Oncol. 2008 Oct;89(1):33-7
[
18621428.001
]
[Cites]
Oral Oncol. 2008 Dec;44(12):1100-9
[
18487078.001
]
[Cites]
J Clin Oncol. 2008 Jul 20;26(21):3582-9
[
18559875.001
]
[Cites]
Arch Otolaryngol Head Neck Surg. 2004 Aug;130(8):943-7
[
15313864.001
]
[Cites]
Lancet. 2000 Sep 2;356(9232):827-8
[
11022932.001
]
[Cites]
Science. 1977 Jul 29;197(4302):461-3
[
560061.001
]
[Cites]
Biochem Biophys Res Commun. 1992 Aug 31;187(1):164-70
[
1381586.001
]
[Cites]
Int J Gynecol Cancer. 2006 Jan-Feb;16(1):194-201
[
16445633.001
]
[Cites]
Free Radic Biol Med. 2001 Jun 15;30(12):1418-25
[
11390187.001
]
[Cites]
Onkologie. 2009 May;32(5):264-72
[
19420973.001
]
[Cites]
N Engl J Med. 2003 Nov 27;349(22):2091-8
[
14645636.001
]
[Cites]
Curr Opin Obstet Gynecol. 2009 Feb;21(1):39-43
[
19125002.001
]
[Cites]
Int J Gynecol Cancer. 2007 May-Jun;17(3):601-6
[
17504374.001
]
[Cites]
J Clin Oncol. 2008 Jun 10;26(17):2846-53
[
18539963.001
]
[Cites]
Arch Otolaryngol Head Neck Surg. 1991 Jan;117(1):83-6
[
1986767.001
]
[Cites]
Head Neck. 1990 Sep-Oct;12(5):406-10
[
2211101.001
]
[Cites]
Onkologie. 2004 Jun;27(3):310-5
[
15249723.001
]
[Cites]
Eur J Cancer. 1990;26(7):834-8
[
2145907.001
]
(PMID = 20052589.001).
[ISSN]
1434-4726
[Journal-full-title]
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
[ISO-abbreviation]
Eur Arch Otorhinolaryngol
[Language]
eng
[Publication-type]
Evaluation Studies; Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / Antineoplastic Agents
30.
Haubner R, Weber WA, Beer AJ, Vabuliene E, Reim D, Sarbia M, Becker KF, Goebel M, Hein R, Wester HJ, Kessler H, Schwaiger M:
Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD.
PLoS Med
; 2005 Mar;2(3):e70
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Noninvasive visualization of the activated alphavbeta3 integrin in
cancer
patients by positron emission tomography and [18F]Galacto-RGD.
BACKGROUND: The integrin alphavbeta3 plays an important role in angiogenesis and tumor
cell
metastasis, and is currently being evaluated as a target for new therapeutic approaches.
Moreover, using the A431 human
squamous cell carcinoma
model we demonstrate that this approach is sensitive enough to visualize alphavbeta3 expression resulting exclusively from the tumor vasculature.
[MeSH-minor]
Animals. Blotting, Western.
Carcinoma
,
Squamous Cell
/ radionuclide imaging. Humans. Immunohistochemistry. Melanoma / radionuclide imaging. Mice. Neoplasms / blood supply. Neoplasms / pathology. Neovascularization, Pathologic. Positron-Emission Tomography. Sensitivity and Specificity.
Skin
Neoplasms / radionuclide imaging. Transplantation, Heterologous
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Nucl Med. 1999 Jun;40(6):1061-71
[
10452325.001
]
[Cites]
Clin Cancer Res. 1998 Nov;4(11):2625-34
[
9829725.001
]
[Cites]
J Nucl Med. 2005 Jan;46(1):184-9
[
15632051.001
]
[Cites]
J Nucl Med. 1999 Nov;40(11):1771-7
[
10565769.001
]
[Cites]
Adv Cancer Res. 2000;79:1-38
[
10818676.001
]
[Cites]
Clin Cancer Res. 2000 Aug;6(8):3056-61
[
10955784.001
]
[Cites]
Magn Reson Med. 2000 Sep;44(3):433-9
[
10975896.001
]
[Cites]
J Nucl Med. 2001 Feb;42(2):326-36
[
11216533.001
]
[Cites]
Cancer Res. 2001 Mar 1;61(5):1781-5
[
11280722.001
]
[Cites]
Eur J Nucl Med. 2001 Feb;28(2):136-43
[
11303882.001
]
[Cites]
Semin Oncol. 2001 Oct;28(5 Suppl 16):94-104
[
11706401.001
]
[Cites]
Eur J Nucl Med Mol Imaging. 2002 Jan;29(1):28-38
[
11807604.001
]
[Cites]
Int J Cancer. 2002 Apr 10;98(5):690-7
[
11920637.001
]
[Cites]
Science. 2002 Jun 28;296(5577):2404-7
[
12089446.001
]
[Cites]
Cell. 2002 Sep 6;110(5):599-11
[
12230977.001
]
[Cites]
Bioconjug Chem. 2002 Sep-Oct;13(5):1021-30
[
12236784.001
]
[Cites]
Calcif Tissue Int. 2002 Oct;71(4):293-9
[
12154391.001
]
[Cites]
Expert Opin Biol Ther. 2002 Dec;2(8):953-66
[
12517273.001
]
[Cites]
Nat Rev Cancer. 2002 Feb;2(2):83-90
[
12635171.001
]
[Cites]
Nat Rev Cancer. 2002 Feb;2(2):91-100
[
12635172.001
]
[Cites]
Cancer Biother Radiopharm. 2002 Dec;17(6):641-6
[
12537667.001
]
[Cites]
Clin Exp Metastasis. 2003;20(3):203-13
[
12741679.001
]
[Cites]
Chemistry. 2003 Jun 16;9(12):2717-25
[
12772286.001
]
[Cites]
Q J Nucl Med. 2003 Sep;47(3):189-99
[
12897710.001
]
[Cites]
Curr Opin Investig Drugs. 2003 Jun;4(6):741-5
[
12901235.001
]
[Cites]
Angiogenesis. 2002;5(4):237-56
[
12906317.001
]
[Cites]
Cancer Res. 2003 Sep 15;63(18):5838-43
[
14522907.001
]
[Cites]
Oral Oncol. 2004 Feb;40(2):228-30
[
14693249.001
]
[Cites]
Bioconjug Chem. 2004 Jan-Feb;15(1):61-9
[
14733584.001
]
[Cites]
Nucl Med Biol. 2004 Jan;31(1):11-9
[
14741566.001
]
[Cites]
Nuklearmedizin. 2004 Feb;43(1):26-32
[
14978538.001
]
[Cites]
Curr Pharm Des. 2004;10(13):1439-55
[
15134568.001
]
[Cites]
J Nucl Med. 2004 May;45(5):892-902
[
15136641.001
]
[Cites]
J Nucl Med. 2004 Oct;45(10):1776-83
[
15471848.001
]
[Cites]
Anal Biochem. 1976 May 7;72:248-54
[
942051.001
]
[Cites]
J Biol Chem. 1987 Dec 25;262(36):17703-11
[
2447074.001
]
[Cites]
Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5819-23
[
1712106.001
]
[Cites]
FEBS Lett. 1991 Oct 7;291(1):50-4
[
1718779.001
]
[Cites]
Eur J Immunol. 2004 Jun;34(6):1608-16
[
15162430.001
]
[Cites]
Cancer Biother Radiopharm. 2004 Apr;19(2):231-44
[
15186604.001
]
[Cites]
Eur J Nucl Med Mol Imaging. 2004 Aug;31(8):1081-9
[
15118844.001
]
[Cites]
Mol Imaging. 2004 Apr;3(2):96-104
[
15296674.001
]
[Cites]
Mol Imaging Biol. 2004 Sep-Oct;6(5):350-9
[
15380745.001
]
[Cites]
J Clin Invest. 1992 Jun;89(6):2018-22
[
1376331.001
]
[Cites]
Science. 1994 Apr 22;264(5158):569-71
[
7512751.001
]
[Cites]
Am J Pathol. 1994 Jun;144(6):1188-94
[
7515558.001
]
[Cites]
Cell. 1994 Dec 30;79(7):1157-64
[
7528107.001
]
[Cites]
J Clin Invest. 1995 Oct;96(4):1815-22
[
7560073.001
]
[Cites]
Eur J Nucl Med. 1995 Dec;22(12):1420-32
[
8586089.001
]
[Cites]
Science. 1998 Jan 16;279(5349):377-80
[
9430587.001
]
[Cites]
Nat Med. 1998 May;4(5):623-6
[
9585240.001
]
[Cites]
J Med Chem. 1999 Aug 12;42(16):3033-40
[
10447947.001
]
(PMID = 15783258.001).
[ISSN]
1549-1676
[Journal-full-title]
PLoS medicine
[ISO-abbreviation]
PLoS Med.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Integrin alphaVbeta3; 0 / Peptides, Cyclic; 0 / fluorogalacto-RGD; X2RN3Q8DNE / Galactose
[Other-IDs]
NLM/ PMC1069665
31.
Saarilahti K, Arponen P, Vaalavirta L, Tenhunen M:
The effect of intensity-modulated radiotherapy and high dose rate brachytherapy on acute and late radiotherapy-related adverse events following chemoradiotherapy of anal cancer.
Radiother Oncol
; 2008 Jun;87(3):383-90
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The effect of intensity-modulated radiotherapy and high dose rate brachytherapy on acute and late radiotherapy-related adverse events following chemoradiotherapy of
anal
cancer
.
BACKGROUND AND PURPOSE: To investigate acute and late radiotherapy-related adverse events following intensity-modulated radiotherapy (IMRT) and high dose rate (HDR) brachytherapy of
anal
cancer
.
MATERIALS AND METHODS: Fifty-nine consecutive patients treated by chemoradiotherapy for
anal squamous cell
cancer
were evaluated for acute and late radiotherapy-related adverse events.
RESULTS: A significant reduction in
skin
and mucosal eruptions in the female genital area (P=0.04) and in radiotherapy-associated > grade 2 diarrhoea (P=0.004) was observed in patients treated by IMRT.
A correlation between the equivalent dose in 2Gy fractions (EQD2) at the wall of
anal
canal opposite to the tumour and radiation proctitis was observed.
CONCLUSIONS: IMRT significantly reduces acute radiotherapy-associated adverse events in patients treated by chemoradiotherapy for
anal
cancer
.
[MeSH-major]
Anus
Neoplasms / radiotherapy. Brachytherapy / adverse effects.
Carcinoma
,
Squamous Cell
/ radiotherapy. Radiotherapy, Intensity-Modulated / adverse effects
[MeSH-minor]
Adult. Aged. Aged, 80 and over.
Carcinoma
, Basal
Cell
/ drug therapy.
Carcinoma
, Basal
Cell
/ radiotherapy. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Radiation Injuries. Radiotherapy Dosage
Genetic Alliance.
consumer health - Anal Cancer
.
MedlinePlus Health Information.
consumer health - Anal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18501454.001).
[ISSN]
0167-8140
[Journal-full-title]
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
[ISO-abbreviation]
Radiother Oncol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Ireland
32.
Otto SD, Lee L, Buhr HJ, Frericks B, Höcht S, Kroesen AJ:
Staging anal cancer: prospective comparison of transanal endoscopic ultrasound and magnetic resonance imaging.
J Gastrointest Surg
; 2009 Jul;13(7):1292-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Staging
anal
cancer
: prospective comparison of transanal endoscopic ultrasound and magnetic resonance imaging.
PURPOSE: The staging of
anal
cancer
is extremely important for therapy and prognosis.
METHODS: Forty-five
anal
cancer
patients underwent endoscopic ultrasound and magnetic resonance imaging.
Cancer
patients were correctly identified with 100% sensitivity (45/45) by endoscopic ultrasound and with 88.9% (40/45) sensitivity by magnetic resonance imaging.
[MeSH-major]
Anus
Neoplasms / diagnostic imaging.
Anus
Neoplasms / pathology. Endosonography. Magnetic Resonance Imaging. Neoplasm Staging / methods
[MeSH-minor]
Adenocarcinoma / diagnostic imaging. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Biopsy, Needle.
Carcinoma
,
Squamous Cell
/ diagnostic imaging.
Carcinoma
,
Squamous Cell
/ pathology. Cohort Studies. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Invasiveness / diagnostic imaging. Neoplasm Invasiveness / pathology. Prospective Studies. Sensitivity and Specificity
Genetic Alliance.
consumer health - Anal Cancer
.
MedlinePlus Health Information.
consumer health - Anal Cancer
.
MedlinePlus Health Information.
consumer health - MRI Scans
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
World J Gastroenterol. 2008 Jun 14;14 (22):3504-10
[
18567078.001
]
[Cites]
Surg Endosc. 2008 Nov;22(11):2412-5
[
18622554.001
]
[Cites]
Int J Colorectal Dis. 2000 Nov;15(5-6):282-90
[
11151431.001
]
[Cites]
Endoscopy. 1995 Sep;27(7):469-79
[
8565885.001
]
[Cites]
Surg Endosc. 2000 Nov;14 (11):1005-9
[
11116406.001
]
[Cites]
Lancet. 1996 Oct 19;348(9034):1049-54
[
8874455.001
]
[Cites]
World J Gastroenterol. 2007 Feb 14;13(6):895-900
[
17352019.001
]
[Cites]
Dis Colon Rectum. 2002 Jan;45(1):16-22
[
11786758.001
]
[Cites]
Dis Colon Rectum. 1986 Apr;29(4):234-42
[
3512199.001
]
[Cites]
Int J Colorectal Dis. 1991 Aug;6(3):152-7
[
1744487.001
]
[Cites]
Clin Radiol. 2005 Oct;60(10):1111-9
[
16179172.001
]
[Cites]
J Clin Oncol. 1997 May;15(5):2040-9
[
9164216.001
]
[Cites]
Int J Colorectal Dis. 1992 Sep;7(3):122-4
[
1402307.001
]
[Cites]
Int J Colorectal Dis. 2007 Oct;22(10 ):1261-8
[
17294198.001
]
[Cites]
Int J Colorectal Dis. 1991 Feb;6(1):2-4
[
2033348.001
]
[Cites]
Dis Colon Rectum. 1978 Mar;21(2):89-91
[
648293.001
]
[Cites]
Cancer Invest. 2006 Aug-Sep;24(5):535-44
[
16939964.001
]
[Cites]
AJR Am J Roentgenol. 2006 Jan;186(1):144-8
[
16357394.001
]
[Cites]
Radiology. 2004 Sep;232(3):773-83
[
15273331.001
]
[Cites]
Eur J Radiol. 2007 Mar;61(3):480-9
[
17188828.001
]
[Cites]
N Engl J Med. 2003 Jun 19;348(25):2491-9
[
12815134.001
]
[Cites]
Int J Colorectal Dis. 2007 Nov;22(11):1347-52
[
17643251.001
]
[Cites]
N Engl J Med. 2000 Mar 16;342(11):792-800
[
10717015.001
]
[Cites]
Endoscopy. 2001 Mar;33(3):231-6
[
11293755.001
]
[Cites]
Int J Colorectal Dis. 2007 Feb;22(2):191-9
[
16799791.001
]
[Cites]
Cancer. 1999 Apr 15;85(8):1686-93
[
10223561.001
]
[Cites]
Int J Colorectal Dis. 1992 Dec;7(4):192-6
[
1293239.001
]
[Cites]
Dis Colon Rectum. 1974 Mar-Apr;17(2):181-7
[
4819268.001
]
[Cites]
Radiol Med. 2003 Oct;106(4):329-37
[
14612825.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):794-800
[
17379452.001
]
[Cites]
Dis Colon Rectum. 1981 Mar-Apr;24(2):73-5
[
7215078.001
]
[Cites]
Radiology. 2007 Jan;242(1):137-43
[
17090719.001
]
[Cites]
J Ultrasound Med. 2006 Jan;25(1):57-73
[
16371556.001
]
[Cites]
J Clin Oncol. 1996 Sep;14(9):2527-39
[
8823332.001
]
[Cites]
Radiology. 1990 May;175(2):494-8
[
2326475.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):92-102
[
15629599.001
]
[Cites]
CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
[
17237035.001
]
(PMID = 19365694.001).
[ISSN]
1873-4626
[Journal-full-title]
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
[ISO-abbreviation]
J. Gastrointest. Surg.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
United States
33.
Alvarez J, de Pokomandy A, Rouleau D, Ghattas G, Vézina S, Coté P, Allaire G, Hadjeres R, Franco EL, Coutlée F, HIPVIRG Study Group:
Episomal and integrated human papillomavirus type 16 loads and anal intraepithelial neoplasia in HIV-seropositive men.
AIDS
; 2010 Sep 24;24(15):2355-63
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Episomal and integrated human papillomavirus type 16 loads and
anal
intraepithelial neoplasia in HIV-seropositive men.
OBJECTIVES: To assess levels of episomal and integrated human papillomavirus type 16 (HPV-16) loads in HIV-seropositive men who have sex with men (MSM) in
anal
infection and to study the association between episomal and integrated HPV-16 loads and
anal
intraepithelial neoplasia (AIN).
Overall, 135 (54.7%) men provided 665 HPV-16-positive
anal
samples.
RESULTS: The HPV-16 DNA forms in
anal
samples were characterized as episomal only in 627 samples (94.3%), mixed in 22 samples (3.3%) and integrated only in nine samples (1.4%).
HPV-16 episomal load [odds ratio (OR) = 1.5, 95% confidence interval (CI) 1.1-2.1], number of HPV types (OR = 1.4, 95% CI 1.1-1.8) and current smoking (OR = 4.8, 95% CI 1.3-18.6) were associated with high-grade AIN (AIN-2,3) after adjusting for age and CD4
cell
counts.
[MeSH-major]
Anus
Neoplasms / immunology.
Carcinoma
,
Squamous Cell
/ immunology. HIV Seropositivity / immunology. Human papillomavirus 16 / immunology. Papillomavirus Infections / immunology. Plasmids / immunology
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - Anal Cancer
.
COS Scholar Universe.
author profiles
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20706109.001).
[ISSN]
1473-5571
[Journal-full-title]
AIDS (London, England)
[ISO-abbreviation]
AIDS
[Language]
eng
[Grant]
Canada / Canadian Institutes of Health Research / /
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / DNA, Viral
[Investigator]
Allaire G; Baril JG; Boissonnault M; Charest L; Charron MA; Coté S; Coté P; Coutlée F; de Pokomandy A; Dion H; Dufresne S; Falutz J; Fortin C; Franco EL; Ghattas G; Gilmore N; Gorska I; Hadjeres R; Junod P; Klein M; Lalonde R; Laplante F; Leblanc R; Legault D; Lessard B; Longpré D; McLeod J; Maziade JP; Murphy D; Nguyen VK; O'Brien R; Phaneuf D; Rouleau D; Routy JP; Szabo J; Tessier D; Thomas R; Toma E; Tremblay C; Trépanier JM; Trottier B; Tsoukas C; Turner H; Vezina S
34.
Guix M, Faber AC, Wang SE, Olivares MG, Song Y, Qu S, Rinehart C, Seidel B, Yee D, Arteaga CL, Engelman JA:
Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.
J Clin Invest
; 2008 Jul;118(7):2609-19
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Acquired resistance to EGFR tyrosine kinase inhibitors in
cancer
cells is mediated by loss of IGF-binding proteins.
We investigated mechanisms of acquired resistance to the EGFR TKI gefitinib by generating gefitinib-resistant (GR) A431
squamous
cancer
cells.
Inhibition of IGFIR signaling disrupted the association of IRS-1 with PI3K and restored the ability of gefitinib to downregulate PI3K/Akt signaling and to inhibit GR
cell
growth.
Addition of recombinant IGFBP-3 restored the ability of gefitinib to downregulate PI3K/Akt signaling and to inhibit
cell
growth.
COS Scholar Universe.
author profiles
.
Faculty of 1000.
commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine.
(subscription/membership/fee required).
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
N Engl J Med. 2005 Feb 24;352(8):786-92
[
15728811.001
]
[Cites]
Science. 2004 Jun 4;304(5676):1497-500
[
15118125.001
]
[Cites]
J Clin Oncol. 2005 Apr 10;23(11):2493-501
[
15710947.001
]
[Cites]
J Clin Oncol. 2005 Apr 10;23(11):2513-20
[
15738541.001
]
[Cites]
J Natl Cancer Inst. 2005 May 4;97(9):643-55
[
15870435.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 May 24;102(21):7665-70
[
15897464.001
]
[Cites]
Clin Cancer Res. 2005 Jun 1;11(11):4182-90
[
15930355.001
]
[Cites]
PLoS Med. 2005 Mar;2(3):e73
[
15737014.001
]
[Cites]
Mol Cell Biol. 2004 Aug;24(16):7275-83
[
15282325.001
]
[Cites]
J Clin Oncol. 2004 Aug 15;22(16):3238-47
[
15310767.001
]
[Cites]
Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11
[
15329413.001
]
[Cites]
J Clin Invest. 1985 Oct;76(4):1643-8
[
4056043.001
]
[Cites]
Anal Biochem. 1986 Apr;154(1):138-43
[
2422981.001
]
[Cites]
J Natl Cancer Inst. 1992 Sep 2;84(17):1336-41
[
1379645.001
]
[Cites]
Nat Med. 1999 Jul;5(7):810-6
[
10395327.001
]
[Cites]
Cancer Res. 2004 Nov 1;64(21):7711-23
[
15520175.001
]
[Cites]
Int J Cancer. 2005 Jan 10;113(2):316-28
[
15386423.001
]
[Cites]
N Engl J Med. 2005 Jul 14;353(2):123-32
[
16014882.001
]
[Cites]
N Engl J Med. 2005 Jul 14;353(2):133-44
[
16014883.001
]
[Cites]
Eur J Cancer. 2005 Jul;41(11):1515-27
[
15979304.001
]
[Cites]
J Clin Oncol. 2005 Oct 1;23(28):6829-37
[
15998907.001
]
[Cites]
Cancer Cell. 2005 Oct;8(4):287-97
[
16226704.001
]
[Cites]
N Engl J Med. 2005 Nov 10;353(19):2012-24
[
16282176.001
]
[Cites]
Cell. 2006 May 19;125(4):733-47
[
16647110.001
]
[Cites]
Nat Rev Genet. 2006 Aug;7(8):606-19
[
16847462.001
]
[Cites]
J Clin Invest. 2006 Oct;116(10):2695-706
[
16906227.001
]
[Cites]
Clin Cancer Res. 2006 Oct 1;12(19):5764-9
[
17020982.001
]
[Cites]
Clin Cancer Res. 2006 Nov 1;12(21):6494-501
[
17085664.001
]
[Cites]
J Biol Chem. 2006 Dec 29;281(52):40183-92
[
17082181.001
]
[Cites]
Science. 2007 May 18;316(5827):1039-43
[
17463250.001
]
[Cites]
Cancer Res. 2007 Jun 15;67(12):5779-88
[
17575145.001
]
[Cites]
Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4637-40
[
17671156.001
]
[Cites]
Cancer Res. 2007 Aug 15;67(16):7807-14
[
17699786.001
]
[Cites]
Cancer Cell. 2007 Oct;12(4):395-402
[
17936563.001
]
[Cites]
Cancer Biol Ther. 2007 Apr;6(4):534-40
[
17457048.001
]
[Cites]
Int J Cancer. 2008 Feb 1;122(3):558-66
[
17918155.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20932-7
[
18093943.001
]
[Cites]
Oncogene. 2008 Apr 3;27(15):2137-47
[
17952116.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3788-93
[
15731348.001
]
[Cites]
J Cell Physiol. 2000 Apr;183(1):1-9
[
10699960.001
]
[Cites]
Blood. 2002 Oct 15;100(8):3041-4
[
12351420.001
]
[Cites]
Cancer Res. 2002 Oct 15;62(20):5749-54
[
12384534.001
]
[Cites]
Oncogene. 2003 May 8;22(18):2812-22
[
12743604.001
]
[Cites]
Methods. 2003 Jul;30(3):256-68
[
12798140.001
]
[Cites]
J Clin Oncol. 2003 Jun 15;21(12):2237-46
[
12748244.001
]
[Cites]
JAMA. 2003 Oct 22;290(16):2149-58
[
14570950.001
]
[Cites]
Cancer Cell. 2004 Mar;5(3):231-9
[
15050915.001
]
[Cites]
N Engl J Med. 2004 May 20;350(21):2129-39
[
15118073.001
]
[CommentIn]
J Clin Invest. 2008 Jul;118(7):2389-92
[
18568082.001
]
(PMID = 18568074.001).
[ISSN]
0021-9738
[Journal-full-title]
The Journal of clinical investigation
[ISO-abbreviation]
J. Clin. Invest.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / R01 CA080195; United States / NCI NIH HHS / CA / P50 CA98131; United States / NCI NIH HHS / CA / P30 CA68485; United States / NCI NIH HHS / CA / R01 CA80195; United States / NCI NIH HHS / CA / P50 CA098131; United States / NCI NIH HHS / CA / K08 CA120060; United States / NCI NIH HHS / CA / P30 CA068485; United States / NCI NIH HHS / CA / R00 CA125892; United States / NCI NIH HHS / CA / K08 CA120060-01; United States / NCI NIH HHS / CA / P50 CA127003
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Adaptor Proteins, Signal Transducing; 0 / IRS1 protein, human; 0 / Insulin Receptor Substrate Proteins; 0 / Insulin-Like Growth Factor Binding Protein 3; 0 / Insulin-Like Growth Factor Binding Protein 4; 0 / Insulin-Like Growth Factor Binding Proteins; 0 / Irs1 protein, mouse; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 67763-96-6 / Insulin-Like Growth Factor I; 67763-97-7 / Insulin-Like Growth Factor II; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-3; EC 2.7.10.1 / Receptor, IGF Type 1; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; S65743JHBS / gefitinib
[Other-IDs]
NLM/ PMC2430495
35.
Das P, Cantor SB, Parker CL, Zampieri JB, Baschnagel A, Eng C, Delclos ME, Krishnan S, Janjan NA, Crane CH:
Long-term quality of life after radiotherapy for the treatment of anal cancer.
Cancer
; 2010 Feb 15;116(4):822-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Long-term quality of life after radiotherapy for the treatment of
anal
cancer
.
BACKGROUND: Radiotherapy is the current standard of care for patients with localized
squamous cell
cancer of
the
anal
canal.
METHODS: Questionnaires were mailed to 80 patients treated with definitive radiotherapy, with or without concurrent chemotherapy, for
anal
cancer
, with a minimum 2-year interval after the completion of radiotherapy.
The questionnaire included the Functional Assessment
of Cancer
Therapy-Colorectal (FACT-C), the Medical Outcomes Study (MOS) Sexual Problems Scale, and questions regarding demographic characteristics and comorbidities.
The median total FACT-C score was 108 (range, 47-128),
of a
maximum (best possible) score of 136.
The median score on the MOS Sexual Problems Scale was 67 (range, 0-100),
of a
maximum (worst possible) score of 100.
CONCLUSIONS: Patients treated with radiotherapy for
anal
cancer
reported acceptable overall QoL scores, but poor sexual function scores.
[MeSH-major]
Anus
Neoplasms / psychology.
Anus
Neoplasms / radiotherapy.
Carcinoma
,
Squamous Cell
/ psychology.
Carcinoma
,
Squamous Cell
/ radiotherapy. Quality of Life
Genetic Alliance.
consumer health - Anal Cancer
.
MedlinePlus Health Information.
consumer health - Anal Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20041481.001).
[ISSN]
0008-543X
[Journal-full-title]
Cancer
[ISO-abbreviation]
Cancer
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / CA16672
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
36.
Krengli M, Milia ME, Turri L, Mones E, Bassi MC, Cannillo B, Deantonio L, Sacchetti G, Brambilla M, Inglese E:
FDG-PET/CT imaging for staging and target volume delineation in conformal radiotherapy of anal carcinoma.
Radiat Oncol
; 2010;5:10
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
FDG-PET/CT imaging for staging and target volume delineation in conformal radiotherapy of
anal carcinoma
.
BACKGROUND: FDG-PET/CT imaging has an emerging role in staging and treatment planning of various tumor locations and a number of literature studies show that also the
carcinoma
of the
anal
canal may benefit from this diagnostic approach.
We analyzed the potential impact of FDG-PET/CT in stage definition and target volume delineation of patients affected by
carcinoma
of the
anal
canal and candidates for curative radiotherapy.
METHODS: Twenty seven patients with biopsy proven
anal carcinoma
were enrolled.
Pathology was
squamous cell carcinoma
in 20 cases, cloacogenic
carcinoma
in 3, adenocarcinoma in 2, and basal
cell carcinoma
in 2.
CONCLUSIONS: FDG-PET/CT has a potential relevant impact in staging and target volume delineation of the
carcinoma
of the
anal
canal.
[MeSH-major]
Anus
Neoplasms / pathology.
Carcinoma
/ pathology. Neoplasm Staging / methods. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Conformal
MedlinePlus Health Information.
consumer health - Anal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Radiother Oncol. 2001 Oct;61(1):15-22
[
11578724.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):824-30
[
19117696.001
]
[Cites]
Dis Colon Rectum. 1974 May-Jun;17(3):354-6
[
4830803.001
]
[Cites]
Lancet. 1996 Oct 19;348(9034):1049-54
[
8874455.001
]
[Cites]
J Clin Oncol. 1997 May;15(5):2040-9
[
9164216.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):893-900
[
15936575.001
]
[Cites]
Mol Imaging Biol. 2005 Jul-Aug;7(4):309-13
[
16028002.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):720-5
[
16626889.001
]
[Cites]
Technol Cancer Res Treat. 2007 Feb;6(1):31-6
[
17241098.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):155-62
[
17707268.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1423-6
[
17931795.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):180-6
[
17996387.001
]
[Cites]
Med Phys. 2008 Apr;35(4):1207-13
[
18491512.001
]
[Cites]
Radiother Oncol. 2008 Jun;87(3):376-82
[
18453023.001
]
[Cites]
Br J Cancer. 2009 Mar 10;100(5):693-700
[
19259091.001
]
[Cites]
Strahlenther Onkol. 2009 Apr;185(4):254-9
[
19370429.001
]
[Cites]
Br J Radiol. 2009 Jun;82(978):509-13
[
19153180.001
]
[Cites]
Cancer. 2004 Jul 15;101(2):281-8
[
15241824.001
]
(PMID = 20137093.001).
[ISSN]
1748-717X
[Journal-full-title]
Radiation oncology (London, England)
[ISO-abbreviation]
Radiat Oncol
[Language]
eng
[Publication-type]
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
[Other-IDs]
NLM/ PMC2851594
37.
Huang Y, Sen T, Nagpal J, Upadhyay S, Trink B, Ratovitski E, Sidransky D:
ATM kinase is a master switch for the Delta Np63 alpha phosphorylation/degradation in human head and neck squamous cell carcinoma cells upon DNA damage.
Cell Cycle
; 2008 Sep 15;7(18):2846-55
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
ATM kinase is a master switch for the Delta Np63 alpha phosphorylation/degradation in human head and neck
squamous cell carcinoma
cells upon DNA damage.
Genetic Alliance.
consumer health - Carcinoma, Squamous Cell
.
MedlinePlus Health Information.
consumer health - Head and Neck Cancer
.
PhosphoSitePlus.
gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource
.
Hazardous Substances Data Bank.
CIS-DIAMINEDICHLOROPLATINUM
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cell Cycle. 2007 Feb 1;6(3):305-11
[
17224650.001
]
[Cites]
Cell Cycle. 2007 Feb 1;6(3):300-4
[
17264676.001
]
[Cites]
Cell Cycle. 2007 Feb 1;6(3):274-85
[
17264681.001
]
[Cites]
Cell Cycle. 2007 Feb 1;6(3):240-5
[
17297296.001
]
[Cites]
Cell Cycle. 2007 Feb 1;6(3):246-54
[
17297308.001
]
[Cites]
Cell Cycle. 2007 Apr 15;6(8):931-42
[
17457059.001
]
[Cites]
J Clin Invest. 2007 May;117(5):1370-80
[
17446929.001
]
[Cites]
Cell Cycle. 2007 May 2;6(9):1062-71
[
17426453.001
]
[Cites]
Cell Cycle. 2006 Nov 1;5(21):2489-94
[
17106255.001
]
[Cites]
Cancer Res. 2007 Jul 1;67(13):6325-32
[
17616691.001
]
[Cites]
Cell Cycle. 2007 Aug 1;6(15):1831-6
[
17671427.001
]
[Cites]
Mol Cell Biol. 2000 May;20(9):3224-33
[
10757806.001
]
[Cites]
Proc Natl Acad Sci U S A. 2000 May 9;97(10):5462-7
[
10805802.001
]
[Cites]
Oncogene. 2000 Jun 22;19(27):3126-30
[
10871867.001
]
[Cites]
J Biol Chem. 2000 Jul 28;275(30):22719-27
[
10801797.001
]
[Cites]
Cancer Res. 2000 Aug 1;60(15):4016-20
[
10945600.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1817-22
[
11172034.001
]
[Cites]
Nat Biotechnol. 2001 Apr;19(4):375-8
[
11283598.001
]
[Cites]
Oncogene. 2001 Apr 5;20(15):1803-15
[
11313928.001
]
[Cites]
Eur J Biochem. 2001 May;268(10):2764-72
[
11358490.001
]
[Cites]
Mol Pharmacol. 2001 Sep;60(3):405-15
[
11502869.001
]
[Cites]
Apoptosis. 2007 Oct;12(10):1847-55
[
17636382.001
]
[Cites]
Cell Cycle. 2007 Oct 1;6(19):2339-40
[
17914283.001
]
[Cites]
Cell Cycle. 2007 Dec 15;6(24):3114-31
[
18075315.001
]
[Cites]
Science. 2008 Mar 7;319(5868):1352-5
[
18323444.001
]
[Cites]
Cell Cycle. 2008 May 1;7(9):1231-7
[
18418053.001
]
[Cites]
Cell Cycle. 2008 May 15;7(10):1353-9
[
18418074.001
]
[Cites]
Cell Cycle. 2004 Jan;3(1):80-9
[
14657672.001
]
[Cites]
J Biol Chem. 2003 Dec 19;278(51):51408-14
[
14555649.001
]
[Cites]
Oncogene. 2004 Mar 11;23(10):1829-37
[
14647429.001
]
[Cites]
Annu Rev Biochem. 2004;73:39-85
[
15189136.001
]
[Cites]
Nat Rev Cancer. 2004 Oct;4(10):793-805
[
15510160.001
]
[Cites]
Methods Enzymol. 1991;200:3-37
[
1835513.001
]
[Cites]
J Biol Chem. 1995 Sep 8;270(36):21396-403
[
7545671.001
]
[Cites]
Eur J Biochem. 1997 Jan 15;243(1-2):518-26
[
9030780.001
]
[Cites]
Eur J Biochem. 1997 Jan 15;243(1-2):527-36
[
9030781.001
]
[Cites]
Science. 1998 Sep 11;281(5383):1674-7
[
9733514.001
]
[Cites]
Mol Cell. 1998 Sep;2(3):305-16
[
9774969.001
]
[Cites]
Cancer Res. 1999 Jun 15;59(12):2781-6
[
10383130.001
]
[Cites]
J Virol. 2004 Dec;78(24):13501-11
[
15564461.001
]
[Cites]
Cancer Res. 2004 Dec 15;64(24):9152-9
[
15604286.001
]
[Cites]
Cell Cycle. 2004 Oct;3(10):1285-95
[
15467455.001
]
[Cites]
J Invest Dermatol. 1999 Dec;113(6):1099-105
[
10594758.001
]
[Cites]
J Biol Chem. 1999 Dec 31;274(53):37538-43
[
10608806.001
]
[Cites]
Electrophoresis. 1999 Dec;20(18):3551-67
[
10612281.001
]
[Cites]
J Biol Chem. 2000 Mar 17;275(11):7803-10
[
10713094.001
]
[Cites]
J Biol Chem. 2001 Aug 24;276(34):31819-24
[
11431470.001
]
[Cites]
Curr Opin Chem Biol. 2001 Oct;5(5):591-602
[
11578935.001
]
[Cites]
J Biol Chem. 2001 Nov 9;276(45):41717-24
[
11546792.001
]
[Cites]
Nat Biotechnol. 2002 Mar;20(3):301-5
[
11875433.001
]
[Cites]
Nature. 2002 Apr 4;416(6880):560-4
[
11932750.001
]
[Cites]
Exp Cell Res. 2002 Jun 10;276(2):194-200
[
12027449.001
]
[Cites]
Cancer Cell. 2002 May;1(4):369-79
[
12086851.001
]
[Cites]
Neoplasia. 2002 Sep-Oct;4(5):400-8
[
12192598.001
]
[Cites]
Cell Cycle. 2002 May-Jun;1(3):162-8
[
12429926.001
]
[Cites]
Anal Chem. 2002 Nov 1;74(21):5593-9
[
12433093.001
]
[Cites]
Mol Cell Biol. 2003 Apr;23(7):2264-76
[
12640112.001
]
[Cites]
J Biol Chem. 2003 Apr 4;278(14):12207-13
[
12519769.001
]
[Cites]
Cancer Res. 2003 May 15;63(10):2351-7
[
12750249.001
]
[Cites]
Laryngoscope. 2003 Jun;113(6):936-9
[
12782800.001
]
[Cites]
Oncogene. 2003 Jun 5;22(23):3635-44
[
12789272.001
]
[Cites]
Prog Cell Cycle Res. 2003;5:235-48
[
14593718.001
]
[Cites]
Cell Cycle. 2004 Nov;3(11):1358-62
[
15492512.001
]
[Cites]
Cancer Res. 2005 Feb 1;65(3):758-66
[
15705872.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 Apr 5;102(14):5056-61
[
15788536.001
]
[Cites]
Nat Cell Biol. 2005 May;7(5):493-500
[
15834407.001
]
[Cites]
Cell Cycle. 2005 May;4(5):710-6
[
15846104.001
]
[Cites]
J Biol Chem. 2005 Jul 8;280(27):25485-90
[
15899889.001
]
[Cites]
EMBO J. 2005 Jul 6;24(13):2458-71
[
15944736.001
]
[Cites]
Mol Cancer. 2005;4(1):25
[
16033649.001
]
[Cites]
Oncogene. 2005 Oct 20;24(46):6970-5
[
16007154.001
]
[Cites]
Int J Mol Med. 2005 Dec;16(6):1065-70
[
16273287.001
]
[Cites]
Cell Cycle. 2005 Oct;4(10):1313-5
[
16123597.001
]
[Cites]
Cell Cycle. 2005 Oct;4(10):1440-7
[
16177572.001
]
[Cites]
Neuron. 2005 Dec 8;48(5):743-56
[
16337913.001
]
[Cites]
Nat Cell Biol. 2006 Jan;8(1):37-45
[
16327781.001
]
[Cites]
Cancer Cell. 2006 Jan;9(1):1-2
[
16413463.001
]
[Cites]
Cancer Cell. 2006 Jan;9(1):45-56
[
16413471.001
]
[Cites]
Methods Enzymol. 2005;405:82-115
[
16413312.001
]
[Cites]
Curr Opin Genet Dev. 2006 Feb;16(1):38-44
[
16359856.001
]
[Cites]
Cell Cycle. 2006 Jun;5(12):1342-7
[
16760655.001
]
[Cites]
Laryngoscope. 2006 Aug;116(8):1390-6
[
16885742.001
]
[Cites]
Laryngoscope. 2006 Aug;116(8):1409-16
[
16885745.001
]
[Cites]
Cancer Res. 2006 Aug 15;66(16):7870-9
[
16912160.001
]
[Cites]
Development. 2006 Dec;133(23):4783-92
[
17079275.001
]
(PMID = 18769144.001).
[ISSN]
1551-4005
[Journal-full-title]
Cell cycle (Georgetown, Tex.)
[ISO-abbreviation]
Cell Cycle
[Language]
ENG
[Grant]
United States / NIDCR NIH HHS / DE / DE013561-08; United States / NIDCR NIH HHS / DE / R01 DE013561; United States / NIDCR NIH HHS / DE / R01 DE013561-08
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Protein Kinase Inhibitors; 0 / RNA, Small Interfering; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 1114-81-4 / Phosphothreonine; 17885-08-4 / Phosphoserine; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Ribosomal Protein S6 Kinases, 70-kDa; EC 2.7.11.22 / CDK2 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 2; Q20Q21Q62J / Cisplatin
[Other-IDs]
NLM/ NIHMS280819; NLM/ PMC3069617
38.
Kagawa R, Yamaguchi T, Furuta R:
Histological features of human papilloma virus 16 and its association with the development and progression of anal squamous cell carcinoma.
Surg Today
; 2006;36(10):885-91
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Histological features of human papilloma virus 16 and its association with the development and progression of
anal squamous cell carcinoma
.
PURPOSE: To investigate the development of
anal squamous cell carcinoma
(SCC) and the expression patterns of human papillomavirus (HPV).
The expression patterns of HPV in
the cancer
cell
nuclei was investigated by in situ hybridization (ISH) using HPV probes.
RESULTS: Amplification of DMD genes was confirmed in 8 of 20 patients with
anal
SCC, suggesting that tumor DNA was preserved in these patients.
In two patients with
carcinoma
in situ (CIS),
the cancer
cells showed only a diffuse pattern (DP), and in two patients with invasive
cancer
,
the cancer
cell
showed only an oligo-dot pattern (OP).
In one patient with lesions ranging from CIS to invasive
cancer
, the histologic features varied in each area, from DP to OP.
CONCLUSIONS: These findings show that HPV16 infection is closely involved in the development of
anal
SCC and suggest that the change in the genome occurs at the stage of microinvasive
cancer
.
[MeSH-major]
Anus
Neoplasms / pathology.
Carcinoma
,
Squamous Cell
/ pathology. DNA, Viral / genetics. Human papillomavirus 16 / genetics. Papillomavirus Infections / pathology
Genetic Alliance.
consumer health - Carcinoma, Squamous Cell
.
MedlinePlus Health Information.
consumer health - Anal Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Front Biosci. 2002 Mar 01;7:e77-84
[
11861218.001
]
[Cites]
Br J Cancer. 2002 Jul 1;87(1):61-4
[
12085257.001
]
[Cites]
Science. 1990 Apr 6;248(4951):76-9
[
2157286.001
]
[Cites]
Am J Surg Pathol. 1986 Jan;10(1):1-8
[
3006523.001
]
[Cites]
Int J Cancer. 1990 Jul 15;46(1):8-11
[
2163992.001
]
[Cites]
Nucleic Acids Res. 1988 Dec 9;16(23):11141-56
[
3205741.001
]
[Cites]
Jpn J Cancer Res. 1991 May;82(5):524-31
[
1648051.001
]
[Cites]
EMBO J. 1984 May;3(5):1151-7
[
6329740.001
]
[Cites]
Proc Natl Acad Sci U S A. 1983 Jun;80(12):3812-5
[
6304740.001
]
[Cites]
J Clin Pathol. 1997 Aug;50(8):625-34
[
9301544.001
]
[Cites]
World J Gastroenterol. 1998 Aug;4(4):298-302
[
11819303.001
]
[Cites]
J Exp Clin Cancer Res. 1999 Mar;18(1):47-52
[
10374676.001
]
[Cites]
Cancer. 1992 Oct 1;70(7):1967-73
[
1326398.001
]
[Cites]
Ann Intern Med. 2003 Mar 18;138(6):453-9
[
12639077.001
]
[Cites]
Int J Cancer. 1983 Nov 15;32(5):563-5
[
6315601.001
]
[Cites]
Curr Opin Investig Drugs. 2004 Dec;5(12):1247-61
[
15648945.001
]
[Cites]
Science. 1989 Feb 17;243(4893):934-7
[
2537532.001
]
[Cites]
Obstet Gynecol. 2004 Oct;104(4):751-5
[
15458897.001
]
(PMID = 16998682.001).
[ISSN]
0941-1291
[Journal-full-title]
Surgery today
[ISO-abbreviation]
Surg. Today
[Language]
eng
[Publication-type]
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
[Publication-country]
Japan
[Chemical-registry-number]
0 / DNA, Viral
39.
Du Y, Li Z, Li L, Chen ZG, Sun SY, Chen P, Shin DM, Khuri FR, Fu H:
Distinct growth factor-induced dynamic mass redistribution (DMR) profiles for monitoring oncogenic signaling pathways in various cancer cells.
J Recept Signal Transduct Res
; 2009;29(3-4):182-94
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Distinct growth factor-induced dynamic mass redistribution (DMR) profiles for monitoring oncogenic signaling pathways in various
cancer
cells.
Targeting dysregulated signaling pathways in tumors has led to the development
of a
novel class of signal transduction inhibitors, including inhibitors of the epidermal growth factor (EGF) receptor (EGFR).
Here we report the application
of a
label-free optical biosensor to reveal the rapid response
of cancer
cells to EGF, expressed as a dynamic mass redistribution (DMR) signal.
In response to EGF,
squamous cell carcinoma
of the head and neck cells exhibited a rapid rise in DMR signal, whereas lung adenocarcinoma cells showed a biphasic DMR profile, suggesting a
cell
type-dependent DMR response.
The assay can also be used for
cell
-based high-throughput screening of EGF pathway inhibitors, as demonstrated by its robust performance in a 384-well plate format (Z' > 0.5).
[MeSH-minor]
Antineoplastic Agents / isolation & purification. Antineoplastic Agents / pharmacology.
Cell
Line, Tumor. Epidermal Growth Factor / pharmacology. Erlotinib Hydrochloride. Humans. Protein Kinase Inhibitors / pharmacology. Quinazolines / pharmacology
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
FEBS Lett. 2005 Aug 1;579(19):4175-80
[
16038906.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):991-1002
[
14967461.001
]
[Cites]
Med Res Rev. 2006 Sep;26(5):569-94
[
16788977.001
]
[Cites]
Conf Proc IEEE Eng Med Biol Soc. 2005;1:666-9
[
17282270.001
]
[Cites]
Gene. 2006 Jan 17;366(1):2-16
[
16377102.001
]
[Cites]
Cancer. 2008 Jul 1;113(1):97-107
[
18473353.001
]
[Cites]
Adv Cancer Res. 1998;74:49-139
[
9561267.001
]
[Cites]
Oncology (Williston Park). 2006 Apr;20(5 Suppl 2):15-25
[
16736979.001
]
[Cites]
Nat Rev Cancer. 2002 Jul;2(7):489-501
[
12094235.001
]
[Cites]
EMBO J. 2000 Jul 3;19(13):3159-67
[
10880430.001
]
[Cites]
J Biomol Screen. 1999;4(2):67-73
[
10838414.001
]
[Cites]
Cancer Control. 2007 Jul;14(3):295-304
[
17615536.001
]
[Cites]
Oncology (Williston Park). 2006 Feb;20(2):153-61; discussion 162, 166, 169 passim
[
16562649.001
]
[Cites]
Cell. 2000 Jan 7;100(1):57-70
[
10647931.001
]
[Cites]
Anal Chem. 2005 Sep 1;77(17):5720-5
[
16131087.001
]
[Cites]
Assay Drug Dev Technol. 2006 Oct;4(5):583-95
[
17115929.001
]
[Cites]
Eur J Cancer. 2007 Jan;43(1):35-45
[
17098420.001
]
[Cites]
Cancer Res. 1996 Aug 1;56(15):3540-5
[
8758924.001
]
[Cites]
Biophys J. 2006 Sep 1;91(5):1925-40
[
16766609.001
]
[Cites]
Nat Rev Cancer. 2005 May;5(5):341-54
[
15864276.001
]
[Cites]
Annu Rev Pharmacol Toxicol. 2004;44:195-217
[
14744244.001
]
[Cites]
Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37
[
11252954.001
]
[Cites]
J Biol Chem. 1988 Mar 5;263(7):3496-500
[
2830286.001
]
[Cites]
Annu Rev Biochem. 1998;67:481-507
[
9759495.001
]
[Cites]
Cancer Res. 1997 Nov 1;57(21):4838-48
[
9354447.001
]
[Cites]
Cancer Res. 2002 Dec 15;62(24):7350-6
[
12499279.001
]
[Cites]
Biotechnol J. 2008 Apr;3(4):484-95
[
18412175.001
]
[Cites]
Clin Lung Cancer. 2007 Feb;8 Suppl 2:S79-85
[
17382029.001
]
[Cites]
Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4249s-4253s
[
15217968.001
]
[Cites]
Oncol Rep. 2008 Jan;19(1):65-71
[
18097577.001
]
[Cites]
Semin Thorac Cardiovasc Surg. 2008 Fall;20(3):217-23
[
19038731.001
]
[Cites]
Cancer Res. 2002 Oct 15;62(20):5749-54
[
12384534.001
]
[Cites]
ScientificWorldJournal. 2008;8:909-19
[
18836658.001
]
[Cites]
J Natl Cancer Inst. 1998 Jun 3;90(11):824-32
[
9625170.001
]
(PMID = 19604037.001).
[ISSN]
1532-4281
[Journal-full-title]
Journal of receptor and signal transduction research
[ISO-abbreviation]
J. Recept. Signal Transduct. Res.
[Language]
eng
[Grant]
United States / NHGRI NIH HHS / HG / U54 HG003918; United States / NCI NIH HHS / CA / 5 P50 CA128613; United States / NCI NIH HHS / CA / P01 CA116676-04; United States / NHGRI NIH HHS / HG / 5U54 HG003918; United States / NHGRI NIH HHS / HG / U54 HG003918-03; United States / NCI NIH HHS / CA / P01 CA116676; United States / NCI NIH HHS / CA / T32 CA160040; United States / NCI NIH HHS / CA / P50 CA128613-03; United States / NCI NIH HHS / CA / P50 CA128613
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 62229-50-9 / Epidermal Growth Factor; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
[Other-IDs]
NLM/ NIHMS142951; NLM/ PMC3746742
40.
Kreuter A, Brockmeyer NH, Pfister H, Altmeyer P, Wieland U, Competence Network HIV/AIDS:
Human papillomavirus type 26-associated periungual squamous cell carcinoma in situ in a HIV-infected patient with concomitant penile and anal intraepithelial neoplasia.
J Am Acad Dermatol
; 2005 Oct;53(4):737-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Human papillomavirus type 26-associated periungual
squamous cell carcinoma
in situ in a HIV-infected patient with concomitant penile and
anal
intraepithelial neoplasia.
[MeSH-major]
Anus
Neoplasms / epidemiology.
Carcinoma
in Situ / epidemiology.
Carcinoma
,
Squamous Cell
/ virology. HIV Infections / epidemiology. HIV-1. Nail Diseases / epidemiology. Papillomaviridae. Papillomavirus Infections / epidemiology. Penile Neoplasms / epidemiology.
Skin
Neoplasms / epidemiology
Genetic Alliance.
consumer health - Carcinoma, Squamous Cell
.
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - Anal Cancer
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - Nail Diseases
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16198810.001).
[ISSN]
1097-6787
[Journal-full-title]
Journal of the American Academy of Dermatology
[ISO-abbreviation]
J. Am. Acad. Dermatol.
[Language]
eng
[Publication-type]
Case Reports; Letter; Research Support, Non-U.S. Gov't
[Publication-country]
United States
41.
Engstrom PF, Arnoletti JP, Benson AB 3rd, Berlin JD, Berry JM, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J Jr, Fuchs C, Grem JL, Knol JA, Leong LA, Lin E, Mulcahy MF, Rohren E, Ryan DP, Saltz L, Shibata D, Skibber JM, Small W, Sofocleous C, Thomas J, Venook AP, Willett C, NCCN:
NCCN clinical practice guidelines in oncology. Anal carcinoma.
J Natl Compr Canc Netw
; 2010 Jan;8(1):106-20
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
NCCN clinical practice guidelines in oncology.
Anal carcinoma
.
[MeSH-major]
Anus
Neoplasms / pathology
MedlinePlus Health Information.
consumer health - Anal Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20064293.001).
[ISSN]
1540-1405
[Journal-full-title]
Journal of the National Comprehensive Cancer Network : JNCCN
[ISO-abbreviation]
J Natl Compr Canc Netw
[Language]
eng
[Publication-type]
Journal Article; Practice Guideline
[Publication-country]
United States
42.
Fernández-Fernández FJ, Buño-Ramilo B, Alvarez-Fernández JC, Brage-Gómez MS, Nogueira C:
[Paraneoplastic hypercalcemia associated with a rectal epidermoid tumor in a patient with a long-standing anal fistula].
Gastroenterol Hepatol
; 2010 Aug-Sep;33(7):551-3
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Paraneoplastic hypercalcemia associated with a rectal
epidermoid
tumor in a patient with a long-standing
anal
fistula].
[Transliterated title]
Hipercalcemia paraneoplásica asociada a una tumoración epidermoide rectal en una paciente con fístula
anal
de
larga duración.
[MeSH-major]
Carcinoma
,
Squamous Cell
/ complications. Hypercalcemia / etiology. Paraneoplastic Syndromes / etiology. Rectal Fistula / complications. Rectal Neoplasms / complications
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20381202.001).
[ISSN]
0210-5705
[Journal-full-title]
Gastroenterología y hepatología
[ISO-abbreviation]
Gastroenterol Hepatol
[Language]
spa
[Publication-type]
Case Reports; Letter
[Publication-country]
Spain
43.
Bacchiocchi R, Rubini C, Pierpaoli E, Borghetti G, Procacci P, Nocini PF, Santarelli A, Rocchetti R, Ciavarella D, Lo Muzio L, Fazioli F:
Prognostic value analysis of urokinase-type plasminogen activator receptor in oral squamous cell carcinoma: an immunohistochemical study.
BMC Cancer
; 2008;8:220
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Prognostic value analysis of urokinase-type plasminogen activator receptor in oral
squamous cell carcinoma
: an immunohistochemical study.
BACKGROUND: Oral
squamous cell carcinoma
(OSCC) represents the most common oral malignancy.
Among tumour progression biomarkers, already known for their involvement in other neoplasia, a crucial role is ascribed to the urokinase-type plasminogen activator receptor (uPAR), which plays a multiple role in extracellular proteolysis,
cell
migration and tissue remodelling not only as a receptor for the zymogen pro-uPA but also as a component for
cell
adhesion and as a chemoattractant.
[MeSH-major]
Carcinoma
,
Squamous Cell
/
diagnosis
. Gene Expression Regulation, Neoplastic. Immunohistochemistry / methods. Mouth Neoplasms /
diagnosis
. Prognosis. Receptors,
Cell
Surface / metabolism
Genetic Alliance.
consumer health - Carcinoma, Squamous Cell
.
Genetic Alliance.
consumer health - Oral squamous cell carcinoma
.
MedlinePlus Health Information.
consumer health - Oral Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Head Neck. 2000 Aug;22(5):498-504
[
10897110.001
]
[Cites]
Br J Oral Maxillofac Surg. 2007 Dec;45(8):623-7
[
17590247.001
]
[Cites]
Cancer. 2002 Dec 15;95(12):2524-33
[
12467066.001
]
[Cites]
Int J Oral Maxillofac Surg. 2003 Jun;32(3):233-45
[
12767868.001
]
[Cites]
Anal Quant Cytol Histol. 2004 Feb;26(1):15-21
[
15032076.001
]
[Cites]
FEBS Lett. 1991 Aug 19;288(1-2):233-6
[
1715292.001
]
[Cites]
Eur J Cancer. 1991;27(11):1445-8
[
1660294.001
]
[Cites]
Int J Cancer. 1993 Apr 22;54(1):73-80
[
8386710.001
]
[Cites]
Lancet. 1994 Aug 6;344(8919):401-2
[
7914317.001
]
[Cites]
Cancer Res. 1994 Sep 1;54(17):4671-5
[
8062262.001
]
[Cites]
Cancer. 1996 Mar 15;77(6):1035-43
[
8635120.001
]
[Cites]
Immunol Today. 1997 Sep;18(9):415-7
[
9293155.001
]
[Cites]
In Vivo. 1998 Jan-Feb;12(1):135-42
[
9575435.001
]
[Cites]
Oral Oncol. 1998 Jan;34(1):58-62
[
9659521.001
]
[Cites]
Clin Cancer Res. 1995 Oct;1(10):1079-87
[
9815897.001
]
[Cites]
Laryngorhinootologie. 1999 Mar;78(3):131-8
[
10226980.001
]
[Cites]
Int J Cancer. 2006 Jun 15;118(12):2948-56
[
16395714.001
]
[Cites]
J Biol Chem. 2006 May 12;281(19):13021-9
[
16510444.001
]
[Cites]
Br J Oral Maxillofac Surg. 2006 Dec;44(6):515-9
[
16356605.001
]
[Cites]
Biochem J. 2007 Oct 15;407(2):153-9
[
17880283.001
]
[Cites]
J Biol Chem. 2000 Aug 4;275(31):23869-76
[
10791952.001
]
(PMID = 18673553.001).
[ISSN]
1471-2407
[Journal-full-title]
BMC cancer
[ISO-abbreviation]
BMC Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / PLAUR protein, human; 0 / Receptors, Cell Surface; 0 / Receptors, Urokinase Plasminogen Activator
[Other-IDs]
NLM/ PMC2527016
44.
Sueda K, Ikenaga M, Miyazaki M, Yasui M, Mishima H, Tsujie M, Omiya H, Miyamoto A, Hirao M, Takami K, Fujitani K, Nakamori S, Yoshida K, Tsujinaka T:
[A case of squamous cell carcinoma of the anal cancer with associated human immunodeficiency virus].
Gan To Kagaku Ryoho
; 2010 Nov;37(12):2656-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[A case of
squamous cell carcinoma
of the
anal
cancer
with associated human immunodeficiency virus].
He presented with an
anal
tumor with bilateral inguinal nodal metastasis and pain in
the anus
; the tumor was diagnosed as stage IIIb (cA1N2M0).
However, CT performed 2 years after
the diagnosis
showed a recurrence in the hilar and mediastinal lymph node.
The patient developed non-hematologic toxicity and died within 3 years of the
diagnosis
.
We report a case of
squamous cell carcinoma
of the
anus
with associated HIV infection.
[MeSH-major]
Anus
Neoplasms / complications.
Anus
Neoplasms / therapy.
Carcinoma
,
Squamous Cell
/ complications.
Carcinoma
,
Squamous Cell
/ therapy. HIV Seropositivity / complications
Genetic Alliance.
consumer health - Carcinoma, Squamous Cell
.
Genetic Alliance.
consumer health - Anal Cancer
.
MedlinePlus Health Information.
consumer health - Anal Cancer
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
Hazardous Substances Data Bank.
CIS-DIAMINEDICHLOROPLATINUM
.
Hazardous Substances Data Bank.
MITOMYCIN C
.
Hazardous Substances Data Bank.
FLUOROURACIL
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 21224670.001).
[ISSN]
0385-0684
[Journal-full-title]
Gan to kagaku ryoho. Cancer & chemotherapy
[ISO-abbreviation]
Gan To Kagaku Ryoho
[Language]
jpn
[Publication-type]
Case Reports; English Abstract; Journal Article
[Publication-country]
Japan
[Chemical-registry-number]
0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
45.
Planque C, Kulasingam V, Smith CR, Reckamp K, Goodglick L, Diamandis EP:
Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines.
Mol Cell Proteomics
; 2009 Dec;8(12):2746-58
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Identification of five candidate lung
cancer
biomarkers by proteomics analysis of conditioned media of four lung
cancer
cell
lines.
Detection of lung
cancer
at an early stage is necessary for successful therapy and improved survival rates.
We performed a bottom-up proteomics analysis using a two-dimensional LC-MS/MS strategy on the conditioned media of four lung
cancer
cell
lines of different histological backgrounds (non-small
cell
lung
cancer
: H23 (adenocarcinoma), H520 (
squamous cell carcinoma
), and H460 (large
cell carcinoma
); small
cell
lung
cancer
: H1688) to identify secreted or membrane-bound proteins that could be useful as novel lung
cancer
biomarkers.
We also identified known or putative lung
cancer
tumor markers such as
squamous cell carcinoma
antigen, carcinoembryonic antigen, chromogranin A, creatine kinase BB, progastrin-releasing peptide, neural
cell
adhesion molecule, and tumor M2-PK.
To select the most promising candidates for validation, we performed tissue specificity assays, functional classifications, literature searches for association to
cancer
, and a comparison of our proteome with the proteome of lung-related diseases and serum.
Five novel lung
cancer
candidates, ADAM-17, osteoprotegerin, pentraxin 3, follistatin, and tumor necrosis factor receptor superfamily member 1A were preliminarily validated in the serum of patients with lung
cancer
and healthy controls.
Our results demonstrate the utility of this
cell
culture proteomics approach to identify secreted and shed proteins that are potentially useful as serological markers for lung
cancer
.
[MeSH-minor]
ADAM Proteins / metabolism. Animals. CHO Cells.
Cell
Line, Tumor. Chromatography, Liquid. Cricetinae. Cricetulus. Extracellular Space / metabolism. Humans. Mass Spectrometry. Membrane Proteins / metabolism. Neoplasm Proteins / chemistry. Neoplasm Proteins / classification. Neoplasm Proteins / metabolism. Proteome / chemistry. Proteome / metabolism. Reproducibility of Results
Genetic Alliance.
consumer health - Lung Cancer
.
MedlinePlus Health Information.
consumer health - Lung Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Proteomics. 2006 Dec;6(23):6354-69
[
17133372.001
]
[Cites]
Clin Cancer Res. 2006 Dec 1;12(23):7009-17
[
17145822.001
]
[Cites]
CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
[
17237035.001
]
[Cites]
J Biol Chem. 2007 Jan 26;282(4):2405-22
[
17110383.001
]
[Cites]
J Proteome Res. 2007 Mar;6(3):1083-92
[
17284061.001
]
[Cites]
J Proteome Res. 2007 Dec;6(12):4615-23
[
17973440.001
]
[Cites]
Cancer. 2007 Dec 15;110(12):2793-8
[
17941001.001
]
[Cites]
Clin Cancer Res. 2008 Feb 1;14(3):660-7
[
18245525.001
]
[Cites]
Clin Cancer Res. 2008 Mar 1;14(5):1355-62
[
18316555.001
]
[Cites]
Clin Cancer Res. 2008 Apr 15;14(8):2326-33
[
18413821.001
]
[Cites]
Ann Oncol. 2008 Jun;19(6):1075-81
[
18238782.001
]
[Cites]
J Proteome Res. 2008 Aug;7(8):3329-38
[
18578523.001
]
[Cites]
Biol Chem. 2008 Jun;389(6):781-6
[
18627302.001
]
[Cites]
J Biol Chem. 2007 Mar 16;282(11):8325-31
[
17227756.001
]
[Cites]
Clin Cancer Res. 2007 Apr 15;13(8):2335-43
[
17438092.001
]
[Cites]
Am J Physiol Lung Cell Mol Physiol. 2007 May;292(5):L1039-49
[
17277044.001
]
[Cites]
Cancer Sci. 2007 Aug;98(8):1265-74
[
17537172.001
]
[Cites]
J Proteome Res. 2007 Jul;6(7):2859-65
[
17567164.001
]
[Cites]
Endocrinology. 1999 Nov;140(11):5303-9
[
10537161.001
]
[Cites]
Anticancer Res. 2000 Nov-Dec;20(6D):5053-8
[
11326667.001
]
[Cites]
Lung Cancer. 2001 May;32(2):137-44
[
11325484.001
]
[Cites]
Anticancer Res. 2001 Mar-Apr;21(2B):1241-6
[
11396194.001
]
[Cites]
Electrophoresis. 2001 Oct;22(17):3629-38
[
11699900.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5
[
11707567.001
]
[Cites]
Clin Cancer Res. 2002 Jul;8(7):2306-10
[
12114435.001
]
[Cites]
Anal Chem. 2002 Oct 15;74(20):5383-92
[
12403597.001
]
[Cites]
Eur Respir J. 2003 Mar;21(3):414-20
[
12661994.001
]
[Cites]
Nature. 2003 Oct 30;425(6961):905
[
14586448.001
]
[Cites]
Anal Chem. 2003 Sep 1;75(17):4646-58
[
14632076.001
]
[Cites]
Cancer Res. 2004 Jan 1;64(1):347-55
[
14729644.001
]
[Cites]
Mol Cell Proteomics. 2004 Apr;3(4):399-409
[
14726492.001
]
[Cites]
Biomarkers. 2004 Jan-Feb;9(1):56-70
[
15204311.001
]
[Cites]
Proteomics. 2004 Jul;4(7):1985-8
[
15221759.001
]
[Cites]
Clin Chem. 2007 Aug;53(8):1423-32
[
17573418.001
]
[Cites]
Mol Cell Proteomics. 2007 Aug;6(8):1406-15
[
17495049.001
]
[Cites]
Mol Cell Proteomics. 2007 Nov;6(11):1997-2011
[
17656355.001
]
[Cites]
Lung. 2008 Sep-Oct;186(5):323-6
[
18663529.001
]
[Cites]
J Proteome Res. 2006 Oct;5(10):2743-53
[
17022645.001
]
[Cites]
Clin Biochem. 2004 Sep;37(9):823-9
[
15329323.001
]
[Cites]
Oncogene. 2004 Sep 23;23(44):7366-77
[
15326482.001
]
[Cites]
Cancer. 2004 Oct 15;101(8):1794-802
[
15386310.001
]
[Cites]
Int J Cancer. 2004 Dec 20;112(6):927-33
[
15386364.001
]
[Cites]
Neoplasma. 1991;38(2):129-35
[
1645850.001
]
[Cites]
Neoplasma. 1991;38(6):645-51
[
1766488.001
]
[Cites]
Hum Pathol. 1992 Mar;23(3):312-6
[
1313391.001
]
[Cites]
J Biol Chem. 1992 Nov 5;267(31):22190-7
[
1429570.001
]
[Cites]
Cancer. 1993 Jul 15;72(2):418-25
[
8391379.001
]
[Cites]
Int J Cancer Suppl. 1994;8:49-52
[
7515029.001
]
[Cites]
Endocrinology. 1996 Feb;137(2):486-94
[
8593793.001
]
[Cites]
Br J Cancer. 1996 May;73(10):1227-32
[
8630283.001
]
[Cites]
Exp Cell Res. 1996 Sep 15;227(2):230-9
[
8831561.001
]
[Cites]
Prostate. 1997 Aug 1;32(3):214-20
[
9254901.001
]
[Cites]
J Clin Endocrinol Metab. 1997 Nov;82(11):3851-8
[
9360551.001
]
[Cites]
Proteomics. 2005 Apr;5(6):1714-28
[
15800970.001
]
[Cites]
J Proteome Res. 2005 Jul-Aug;4(4):1073-85
[
16083256.001
]
[Cites]
J Proteome Res. 2005 Jul-Aug;4(4):1274-86
[
16083277.001
]
[Cites]
Proteomics. 2005 Jul;5(11):2949-59
[
15996010.001
]
[Cites]
Proteomics. 2005 Aug;5(13):3475-90
[
16047398.001
]
[Cites]
Mol Cell Proteomics. 2005 Sep;4(9):1251-64
[
15951573.001
]
[Cites]
Mol Cell Proteomics. 2005 Oct;4(10):1480-6
[
15970581.001
]
[Cites]
Mol Cell Proteomics. 2005 Nov;4(11):1826-30
[
16103422.001
]
[Cites]
Respir Res. 2005;6:118
[
16236163.001
]
[Cites]
Tumour Biol. 2006;27(1):8-16
[
16340245.001
]
[Cites]
Cancer Cell. 2006 Jul;10(1):39-50
[
16843264.001
]
[Cites]
Proteomics. 2006 Aug;6(15):4390-401
[
16819730.001
]
[Cites]
Lung Cancer. 2006 Oct;54(1):87-94
[
16876904.001
]
[Cites]
Lung Cancer. 2006 Oct;54(1):95-102
[
16890323.001
]
[Cites]
Mol Cell Proteomics. 2006 Oct;5(10):1727-44
[
16887931.001
]
[Cites]
Mol Cell Proteomics. 2006 Oct;5(10):1921-6
[
16896060.001
]
(PMID = 19776420.001).
[ISSN]
1535-9484
[Journal-full-title]
Molecular & cellular proteomics : MCP
[ISO-abbreviation]
Mol. Cell Proteomics
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Culture Media, Conditioned; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / Proteome; EC 3.4.24.- / ADAM Proteins; EC 3.4.24.- / tumor necrosis factor-alpha convertase
[Other-IDs]
NLM/ PMC2816016
46.
Kreuter A, Potthoff A, Brockmeyer NH, Gambichler T, Stücker M, Altmeyer P, Swoboda J, Pfister H, Wieland U, German Competence Network HIV/AIDS:
Imiquimod leads to a decrease of human papillomavirus DNA and to a sustained clearance of anal intraepithelial neoplasia in HIV-infected men.
J Invest Dermatol
; 2008 Aug;128(8):2078-83
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Imiquimod leads to a decrease of human papillomavirus DNA and to a sustained clearance of
anal
intraepithelial neoplasia in HIV-infected men.
Anal
intraepithelial neoplasia (AIN), a human papillomavirus (HPV)-associated precursor lesion of
anal carcinoma
, is highly prevalent in HIV-infected men having sex with men (MSM).
Standardized follow-up examinations included high-resolution anoscopy,
anal
cytology/histology, HPV typing, and DNA load determination for HPV types 16, 18, 31, and 33.
During follow-up, 58% of all patients (11/19) developed new
anal
cytological abnormalities in previously normal, untreated
anal
regions.
[MeSH-major]
Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use.
Anus
Neoplasms / drug therapy.
Carcinoma
in Situ / drug therapy. DNA, Viral / drug effects. HIV Infections / complications. Papillomaviridae / genetics
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - Anal Cancer
.
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Hazardous Substances Data Bank.
Imiquimod
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18273049.001).
[ISSN]
1523-1747
[Journal-full-title]
The Journal of investigative dermatology
[ISO-abbreviation]
J. Invest. Dermatol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / DNA, Viral; 99011-02-6 / imiquimod
[Investigator]
Adam A; Schewe K; Weitner L; Aratesh K; Arendt G; Bartz C; Behrens G; Beichert M; Bieniek B; Cordes C; Bochow M; Brockmeyer N; Buchholz B; Bogner JR; Buhk T; Clad A; Dannecker M; Dupke S; von Einsiedel R; Esser S; Faetkenheuer G; Fischer K; Freiwald M; Friebe-Hoffmann U; Fenske S; Funk M; Ganschow R; Gingelmaier A; Glaunsinger T; Goebel FD; Gölz J; Grosch-Wörner I; Haberl A; Hamouda O; Harrer T; Hartmann M; Hartl H; Hölscher M; Hower M; Husstedt IW; Jansen K; Jäger H; Jessen H; Jessen A; Karwat M; Klausen G; Kirchhoff F; Knechten H; Köppe S; Kreuter A; Kuhlmann B; Langer P; Lauenroth-Mai; Lehmacher W; Lehmann M; Levin C; Lübke M; Maschke M; Marcus U; Mauss S; Meyerhans A; Meyer-Olson D; ter Meulen V; Michalik C; Moll A; Mosthaf FA; Mutz A; Neuen-Jacob E; Niehues T; Oette M; Paulus U; Plettenberg A; Potthoff A; Racz P; Racz K; Rasokat H; Rausch M; Reichelt D; Reitter A; Rieke A; Rockstroh J; Salzberger B; Schafberger A; Schauer J; Schlote F; Schmidt B; Schranz D; Scholten S; Schuler C; Schwab M; Schmidt W; Schmidt R; Schwarze S; Siffert W; Skaletz-Rorowski A; Sonnenberg-Schwan U; Sopper S; Spengler U; Staszewski S; Steffan E; Stellbrink HJ; Stoll M; Goecke T; Taubert S; Telschik A; Ulmer A; Ullrich R; Uberla K; Usadel S; Vogel M; Wagner R; Walter H; Warnatz K; Wasem J; Wiesel W; Von Weizsäcker K; Wieland U; Wintergerst U; Wolf E; Wolf H; Wünsche T; Wyen Ch; Zeitz M; Zylka-Menhorn V
47.
Allal AS, Bründler MA, Gervaz P:
Differential expression of anti-apoptotic protein Bcl-2 in keratinizing versus non-keratinizing squamous cell carcinoma of the anus.
Int J Colorectal Dis
; 2005 Mar;20(2):161-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Differential expression of anti-apoptotic protein Bcl-2 in keratinizing versus non-keratinizing
squamous cell carcinoma
of the
anus
.
BACKGROUND: Histologically, tumors of the
anal
region are either keratinizing (K) or non-keratinizing (NK)
squamous cell
carcinomas (SCCA).
METHODS: We performed an immunohistochemical analysis on 98 pre-treatment biopsies of patients with
anal
canal cancers.
The more distal the tumor is (
anal
margin
), the more frequently the keratinizing subtype is observed (87 vs. 23%, p=0.0002).
[MeSH-major]
Anus
Neoplasms / metabolism. Apoptosis.
Carcinoma
,
Squamous Cell
/ metabolism. Keratinocytes / pathology. Proto-Oncogene Proteins c-bcl-2 / biosynthesis
Genetic Alliance.
consumer health - Carcinoma, Squamous Cell
.
MedlinePlus Health Information.
consumer health - Anal Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Am Coll Surg. 1997 Nov;185(5):494-505
[
9358099.001
]
[Cites]
Pathology. 2002 Dec;34(6):573-8
[
12555997.001
]
[Cites]
Br J Cancer. 1998 Jul;78(2):210-4
[
9683295.001
]
[Cites]
Eur J Obstet Gynecol Reprod Biol. 2001 Aug;97(2):223-30
[
11451553.001
]
[Cites]
Swiss Med Wkly. 2003 Jun 28;133(25-26):353-9
[
12947531.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1989 Dec;17(6):1141-51
[
2599902.001
]
[Cites]
J Clin Oncol. 1996 Jul;14(7):2120-30
[
8683245.001
]
[Cites]
N Engl J Med. 1997 Nov 6;337(19):1350-8
[
9358129.001
]
[Cites]
Ann Oncol. 2003 Feb;14(2):214-9
[
12562647.001
]
[Cites]
J Clin Pathol. 1997 Aug;50(8):625-34
[
9301544.001
]
[Cites]
Gynecol Oncol. 2003 Oct;91(1):51-8
[
14529662.001
]
[Cites]
N Engl J Med. 2000 Mar 16;342(11):792-800
[
10717015.001
]
[Cites]
Curr Opin Oncol. 2000 Jul;12(4):345-52
[
10888420.001
]
[Cites]
J Clin Pathol. 1997 Jan;50(1):33-6
[
9059353.001
]
[Cites]
Cancer Res. 1999 Feb 1;59(3):753-7
[
9973228.001
]
[Cites]
Cancer. 1997 Aug 15;80(4):805-15
[
9264365.001
]
(PMID = 15688099.001).
[ISSN]
0179-1958
[Journal-full-title]
International journal of colorectal disease
[ISO-abbreviation]
Int J Colorectal Dis
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53
48.
Vieira FL, Vieira BJ, Guimaraes MA, Aarestrup FM:
Cellular profile of the peritumoral inflammatory infiltrate in squamous cells carcinoma of oral mucosa: Correlation with the expression of Ki67 and histologic grading.
BMC Oral Health
; 2008;8:25
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Cellular profile of the peritumoral inflammatory infiltrate in
squamous
cells
carcinoma
of oral mucosa: Correlation with the expression of Ki67 and histologic grading.
BACKGROUND:
Squamous
cells
carcinoma
is the most important malignant tumor with primary site in the oral cavity and, given the great exposure of mucosa and lips to the etiologic factors of this neoplasm, its incidence is high.
METHODS: In this study, oral mucosa samples of
squamous
cells
carcinoma
were analyzed, separated according to their histological classification as well as the phenotypical profile of the cells comprising the peritumoral inflammatory infiltrate was investigated by immunohistochemical method, in addiction, the
cell
proliferation index via protein Ki67 expression was determinated.
The B lymhocytes were the second most visualized leucocyte
cell
type followed by macrophages and neutrophils.
The immunohistochemical assessment of Ki-67 positive cells revealed a greater expression of this protein in samples of undifferentiated
squamous
cells
carcinoma
.
CONCLUSION: The results suggest that the cellular immune response is the main defense mechanism in
squamous
cells
carcinoma
of oral mucosa, expressed by the large number of T lymphocytes and macrophages, and that the greatest intensity of local response may be associated with the best prognosis.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
JAAPA. 2007 Oct;20(10):42-7
[
18019328.001
]
[Cites]
Oral Oncol. 2001 Feb;37(2):164-71
[
11167144.001
]
[Cites]
Acta Otorrinolaringol Esp. 2007 Oct;58(8):341-6
[
17949660.001
]
[Cites]
Int J Oral Maxillofac Surg. 2007 Aug;36(8):671-9
[
17643963.001
]
[Cites]
Minerva Stomatol. 2007 Jun;56(6):341-7
[
17625491.001
]
[Cites]
Pancreatology. 2006;6(5):450-3
[
16847382.001
]
[Cites]
Oncol Rep. 2006 Aug;16(2):329-34
[
16820911.001
]
[Cites]
Eur J Cancer. 2006 Apr;42(6):717-27
[
16520032.001
]
[Cites]
Braz J Otorhinolaryngol. 2005 Mar-Apr;71(2):181-7
[
16446915.001
]
[Cites]
Arch Pathol Lab Med. 2006 Jan;130(1):57-61
[
16390239.001
]
[Cites]
Br J Oral Maxillofac Surg. 2005 Dec;43(6):511-2
[
15908082.001
]
[Cites]
Cancer Immunol Immunother. 2005 Jul;54(7):671-6
[
15625605.001
]
[Cites]
Harefuah. 2005 Apr;144(4):243-5, 304, 303
[
15889605.001
]
[Cites]
Br J Oral Maxillofac Surg. 2005 Jun;43(3):253-5
[
15888363.001
]
[Cites]
J Periodontol. 2005 Mar;76(3):406-10
[
15857075.001
]
[Cites]
Laryngoscope. 2005 Apr;115(4):690-8
[
15805883.001
]
[Cites]
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Jan;99(1):64-70
[
15599350.001
]
[Cites]
Genes Dev. 1999 Jun 1;13(11):1382-97
[
10364156.001
]
[Cites]
Arch Pathol Lab Med. 1998 May;122(5):447-54
[
9593347.001
]
[Cites]
Aust Dent J. 1996 Apr;41(2):91-6
[
8670041.001
]
[Cites]
Br J Cancer. 1994 Mar;69(3):409-16
[
8123467.001
]
[Cites]
Anal Cell Pathol. 1989 Feb;1(1):25-39
[
2488698.001
]
[Cites]
Acta Pathol Jpn. 1993 Mar;43(3):99-106
[
8484337.001
]
[Cites]
Br J Oral Surg. 1983 Jun;21(2):136-46
[
6575816.001
]
[Cites]
Ann Oncol. 2004 Sep;15(9):1319-29
[
15319236.001
]
[Cites]
Hua Xi Kou Qiang Yi Xue Za Zhi. 2004 Apr;22(2):109-11
[
15190789.001
]
[Cites]
Shanghai Kou Qiang Yi Xue. 2002 Dec;11(4):350-2
[
14983378.001
]
[Cites]
Oral Oncol. 2003 Jul;39(5):459-69
[
12747970.001
]
[Cites]
J Biol Chem. 2002 Oct 11;277(41):38159-67
[
12138162.001
]
[Cites]
Exp Cell Res. 2001 Nov 1;270(2):259-67
[
11640889.001
]
[Cites]
Anticancer Res. 2007 Sep-Oct;27(5B):3661-6
[
17972532.001
]
(PMID = 18764952.001).
[ISSN]
1472-6831
[Journal-full-title]
BMC oral health
[ISO-abbreviation]
BMC Oral Health
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Other-IDs]
NLM/ PMC2556313
49.
Siekas LL, Aboulafia DM:
Establishing an anal dysplasia clinic for HIV-infected men: initial experience.
AIDS Read
; 2009 May;19(5):178-86
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Establishing an
anal
dysplasia clinic for HIV-infected men: initial experience.
Anal
dysplasia caused by human papillomavirus (HPV) infection is common in the HIV-infected population and is a precursor to
squamous cell carcinoma
of the
anus
(SCCA).
Herein, we describe our initial experience in assessing the frequency and severity of
anal
intraepithelial neoplasia (AIN) in a newly formed
anal
dysplasia clinic in Seattle.
We anticipate that the
anal
dysplasia clinic will enable our institution to participate in emerging HIV- and HPV-related AIN clinical trials.
[MeSH-major]
Anus
Neoplasms / etiology.
Carcinoma
in Situ / etiology.
Carcinoma
,
Squamous Cell
/ etiology. HIV Infections / epidemiology. Precancerous Conditions / etiology
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - Anal Cancer
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
AIDS Read. 2009 May;19(5):182-3
[
19554737.001
]
(PMID = 19554736.001).
[ISSN]
1053-0894
[Journal-full-title]
The AIDS reader
[ISO-abbreviation]
AIDS Read
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
50.
Michel A, Kopp-Schneider A, Zentgraf H, Gruber AD, de Villiers EM:
E6/E7 expression of human papillomavirus type 20 (HPV-20) and HPV-27 influences proliferation and differentiation of the skin in UV-irradiated SKH-hr1 transgenic mice.
J Virol
; 2006 Nov;80(22):11153-64
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
E6/E7 expression of human papillomavirus type 20 (HPV-20) and HPV-27 influences proliferation and differentiation of the
skin
in UV-irradiated SKH-hr1 transgenic mice.
Histological and immunohistochemical examination
of skin
samples revealed enhanced proliferation of the epidermal layers and papilloma formation in both transgenic strains in comparison to what was observed with nontransgenic mice.
Squamous cell carcinoma
developed in the HPV-20 E6/E7 transgenic line as well as in the HPV-27 E6/E7 transgenic line.
Several weeks after cessation of UV-B exposure, enhanced proliferation, as measured by BrdU incorporation, was maintained only in HPV-20 transgenic
skin
.
Keratin 6 expression was increased in the transgenic mice throughout all
cell
layers.
Expression of the differentiation markers involucrin and loricrin was reduced and disturbed. p63alpha expression was differentially regulated with high levels of cytoplasmic expression in clusters of cells in the granular layer of the
skin
in the transgenic lines 20 weeks after cessation of UV-B exposure, in contrast to uninterrupted staining in the nontransgenic lines. p53 was expressed in clusters of cells in nontransgenic and HPV-27 transgenic mice, in contrast to an even distribution in a higher number of cells in HPV-20 transgenic animals.
[MeSH-major]
Alphapapillomavirus / metabolism. Betapapillomavirus / metabolism.
Cell
Differentiation.
Cell
Proliferation. Oncogene Proteins, Viral / biosynthesis.
Skin
/ radiation effects.
Skin
/ virology
[MeSH-minor]
Animals. Bromodeoxyuridine / metabolism. Epidermis / metabolism. Epidermis / radiation effects. Epidermis / virology. Female. Histocytochemistry. Immunohistochemistry. Keratin-6 / biosynthesis. Male. Membrane Proteins / biosynthesis. Mice. Mice, Transgenic. Papilloma / pathology. Papilloma / virology. Papillomavirus Infections / virology. Phosphoproteins / biosynthesis. Protein Precursors / biosynthesis.
Skin
Neoplasms / pathology.
Skin
Neoplasms / virology. Trans-Activators / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis
Hazardous Substances Data Bank.
BROMODEOXYURIDINE
.
Mouse Genome Informatics (MGI).
Mouse Genome Informatics (MGI)
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Oncogene. 2000 Feb 10;19(6):821-6
[
10698500.001
]
[Cites]
Mol Carcinog. 2005 Jan;42(1):40-52
[
15547921.001
]
[Cites]
Am J Pathol. 2000 Dec;157(6):1975-81
[
11106570.001
]
[Cites]
Genes Dev. 2000 Dec 1;14(23):3065-73
[
11114894.001
]
[Cites]
J Invest Dermatol. 2001 Feb;116(2):330-8
[
11180011.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3156-61
[
11248048.001
]
[Cites]
Arch Dermatol. 2001 Mar;137(3):384
[
11255361.001
]
[Cites]
Int J Cancer. 2001 Mar 15;91(6):828-34
[
11275987.001
]
[Cites]
Am J Pathol. 2001 Oct;159(4):1247-53
[
11583952.001
]
[Cites]
Nat Rev Cancer. 2002 May;2(5):342-50
[
12044010.001
]
[Cites]
Mol Biol Cell. 2002 Jun;13(6):1857-70
[
12058054.001
]
[Cites]
Virology. 2002 Jul 5;298(2):240-7
[
12127787.001
]
[Cites]
J Biol Chem. 2002 Nov 1;277(44):42268-79
[
12200429.001
]
[Cites]
Br J Dermatol. 2003 Jul;149(1):64-73
[
12890196.001
]
[Cites]
J Virol. 2003 Oct;77(19):10186-201
[
12970404.001
]
[Cites]
Nat Rev Cancer. 2004 Jan;4(1):23-35
[
14681688.001
]
[Cites]
Genes Dev. 2004 Jan 15;18(2):126-31
[
14729569.001
]
[Cites]
Br J Dermatol. 2004 May;150(5):949-57
[
15149508.001
]
[Cites]
J Invest Dermatol. 2004 Jul;123(1):13-22
[
15191537.001
]
[Cites]
Cell Cycle. 2004 Apr;3(4):411-3
[
14976425.001
]
[Cites]
Carcinogenesis. 2004 Sep;25(9):1771-8
[
15105299.001
]
[Cites]
Anal Biochem. 1987 Apr;162(1):156-9
[
2440339.001
]
[Cites]
J Cell Biol. 1989 Jul;109(1):295-307
[
2473080.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2490-5
[
15699322.001
]
[Cites]
Cancer Res. 2005 Feb 15;65(4):1394-400
[
15735026.001
]
[Cites]
Mutat Res. 2005 Apr 1;571(1-2):91-106
[
15748641.001
]
[Cites]
Cell Cycle. 2005 May;4(5):689-96
[
15846070.001
]
[Cites]
J Virol. 2005 Dec;79(23):14899-908
[
16282489.001
]
[Cites]
J Invest Dermatol. 1999 Dec;113(6):1099-105
[
10594758.001
]
[Cites]
Am J Pathol. 2000 Jan;156(1):201-7
[
10623668.001
]
[Cites]
Cell. 1990 Aug 24;62(4):697-708
[
1696852.001
]
[Cites]
Cell. 1990 Dec 21;63(6):1129-36
[
2175676.001
]
[Cites]
J Virol. 1991 Jun;65(6):3335-9
[
1851881.001
]
[Cites]
Arch Virol. 1992;125(1-4):355-60
[
1642560.001
]
[Cites]
Proc Natl Acad Sci U S A. 1993 May 1;90(9):4216-20
[
8483937.001
]
[Cites]
Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5583-7
[
8390671.001
]
[Cites]
Curr Top Microbiol Immunol. 1994;186:157-75
[
8205840.001
]
[Cites]
J Virol. 1994 Jul;68(7):4358-68
[
7515971.001
]
[Cites]
Cell Growth Differ. 1994 Jun;5(6):667-75
[
7522035.001
]
[Cites]
Mol Cell Biol. 1994 Dec;14(12):8250-8
[
7969162.001
]
[Cites]
Cancer. 1995 Jan 15;75(2 Suppl):607-12
[
7804986.001
]
[Cites]
Arch Dermatol. 1995 Nov;131(11):1312-8
[
7503577.001
]
[Cites]
Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):274-8
[
8552621.001
]
[Cites]
J Natl Cancer Inst. 1996 Jun 19;88(12):802-11
[
8637046.001
]
[Cites]
Biochim Biophys Acta. 1996 Oct 9;1288(2):F55-78
[
8876633.001
]
[Cites]
J Biol Chem. 1997 Jan 17;272(3):2021-30
[
8999895.001
]
[Cites]
Arch Dermatol Res. 1996 Dec;289(1):28-34
[
9017132.001
]
[Cites]
Carcinogenesis. 1997 May;18(5):897-904
[
9163673.001
]
[Cites]
J Invest Dermatol. 1997 Sep;109(3):340-7
[
9284102.001
]
[Cites]
Clin Exp Dermatol. 1997 Jan;22(1):11-6
[
9330045.001
]
[Cites]
Int J Cancer. 1997 Nov 4;73(3):356-61
[
9359482.001
]
[Cites]
Virology. 1997 Dec 8;239(1):132-49
[
9426453.001
]
[Cites]
Virology. 1997 Dec 22;239(2):296-302
[
9434721.001
]
[Cites]
J Virol. 1998 Jun;72(6):5016-24
[
9573271.001
]
[Cites]
Mol Carcinog. 1998 Jul;22(3):167-74
[
9688142.001
]
[Cites]
Nature. 1999 Apr 22;398(6729):708-13
[
10227293.001
]
[Cites]
Mol Carcinog. 1999 Aug;25(4):231-40
[
10449029.001
]
[Cites]
Cancer Res. 1999 Sep 15;59(18):4591-602
[
10493513.001
]
[Cites]
Semin Cancer Biol. 1999 Dec;9(6):413-22
[
10712888.001
]
(PMID = 16971438.001).
[ISSN]
0022-538X
[Journal-full-title]
Journal of virology
[ISO-abbreviation]
J. Virol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Keratin-6; 0 / Membrane Proteins; 0 / Oncogene Proteins, Viral; 0 / Phosphoproteins; 0 / Protein Precursors; 0 / Trans-Activators; 0 / Trp63 protein, mouse; 0 / Tumor Suppressor Protein p53; 0 / loricrin; 60108-77-2 / involucrin; G34N38R2N1 / Bromodeoxyuridine
[Other-IDs]
NLM/ PMC1642157
51.
Satoh S, Nakashima T, Watanabe K, Toda S, Kuratomi Y, Sugihara H, Inokuchi A:
Hypopharyngeal squamous cell carcinoma bordering ectopic gastric mucosa "inlet patch" of the cervical esophagus.
Auris Nasus Larynx
; 2007 Mar;34(1):135-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Hypopharyngeal
squamous cell carcinoma
bordering ectopic gastric mucosa "inlet patch" of the cervical esophagus.
We report here a case of hypopharyngeal
squamous cell carcinoma
bordering on IP of the cervical esophagus.
METHODS: A 44-year-old female underwent partial pharyngectomy, total laryngectomy, cervical esophagectomy, and bilateral neck dissection under
the diagnosis
of hypopharyngeal
carcinoma
.
RESULTS: Resected specimens of the hypopharynx revealed a well-differentiated
squamous cell carcinoma
in the ulcerative tumorous lesion (3.5 cm x 0.5 cm).
A brown patch (2 cm x 1.5 cm) bordering the
anal
aspect of the tumor comprised ectopic gastric mucosa of fundic type epithelium.
CONCLUSION: The hypopharyngeal
squamous cell carcinoma
likely developed in association with chronic irritation due to gastric acid from the IP.
To our knowledge, this is the first reported case of
squamous cell carcinoma
related to IP.
[MeSH-major]
Carcinoma
,
Squamous Cell
/ pathology. Choristoma / pathology. Esophageal Diseases / pathology. Gastric Mucosa. Hypopharyngeal Neoplasms / pathology
Genetic Alliance.
consumer health - Carcinoma, Squamous Cell
.
MedlinePlus Health Information.
consumer health - Esophagus Disorders
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16949237.001).
[ISSN]
0385-8146
[Journal-full-title]
Auris, nasus, larynx
[ISO-abbreviation]
Auris Nasus Larynx
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Netherlands
52.
Shi X, Yuan X, Tao D, Gong J, Hu G:
Analysis of DNA ploidy, cell cycle and Ki67 antigen in nasopharyngeal carcinoma by flow cytometry.
J Huazhong Univ Sci Technolog Med Sci
; 2005;25(2):198-201
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Analysis of DNA ploidy,
cell
cycle and Ki67 antigen in nasopharyngeal
carcinoma
by flow cytometry.
The expression of DNA ploidy, the
cell
cycle and Ki67 antigen in nasopharyngeal
carcinoma
(NPC) were studied and their relationship with the clinical biological behaviors and prognosis of NPC was evaluated.
Biopsied specimens of NPC were made into
cell
suspension.
By using cytometric double labeling Ki67 and DNA method, the expression of DNA ploidy, the
cell
cycle and Ki67 antigen were analyzed.
The S phase cells accounted for 0 to 54% in the
cell
cycle and the positive expression of Ki67 ranged from 0 to 52%.
The patients having a low expression of Ki67 or DNA aneuploid in tumor cells were not sensitive to chemotherapy, liable to metastasis to distant organs and had a poor prognosis, while Ki67 showed no correlation with DNA ploidy and the
cell
cycle.
[MeSH-major]
Carcinoma
,
Squamous Cell
/ immunology. DNA, Neoplasm / genetics. Ki-67 Antigen / immunology. Nasopharyngeal Neoplasms / immunology
Genetic Alliance.
consumer health - Nasopharyngeal carcinoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Ai Zheng. 2002 Jun;21(6):644-50
[
12452067.001
]
[Cites]
Br J Cancer. 1995 Jan;71(1):146-9
[
7819031.001
]
[Cites]
Anal Quant Cytol Histol. 1999 Aug;21(4):311-8
[
10560508.001
]
[Cites]
J Clin Oncol. 1997 Mar;15(3):1030-8
[
9060543.001
]
[Cites]
Int J Radiat Biol. 1999 Feb;75(2):143-53
[
10072175.001
]
[Cites]
J Exp Clin Cancer Res. 2001 Sep;20(3):371-6
[
11718217.001
]
[Cites]
J Pathol. 1997 May;182(1):62-7
[
9227343.001
]
[Cites]
Semin Oncol. 1994 Jun;21(3):330-9
[
8209264.001
]
[Cites]
Surgery. 1991 Nov;110(5):814-9
[
1948649.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 1998 Jul;7(7):597-603
[
9681528.001
]
[Cites]
Cytometry. 1994 Nov 1;17(3):258-65
[
7851161.001
]
(PMID = 16116972.001).
[ISSN]
1672-0733
[Journal-full-title]
Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban
[ISO-abbreviation]
J. Huazhong Univ. Sci. Technol. Med. Sci.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
China
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Ki-67 Antigen
53.
Haboubi N:
Anal cancer; do we all have a common treatment strategy?
Colorectal Dis
; 2009 Nov;11(9):891-2
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Anal
cancer
; do we all have a common treatment strategy?
[MeSH-major]
Adenocarcinoma / pathology.
Anus
Neoplasms / pathology.
Carcinoma
,
Squamous Cell
/ pathology
Genetic Alliance.
consumer health - Anal Cancer
.
MedlinePlus Health Information.
consumer health - Anal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19832862.001).
[ISSN]
1463-1318
[Journal-full-title]
Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
[ISO-abbreviation]
Colorectal Dis
[Language]
eng
[Publication-type]
Editorial
[Publication-country]
England
54.
Nadal SR, Manzione CR, Horta SH:
Comparison of perianal diseases in HIV-positive patients during periods before and after protease inhibitors use: what changed in the 21st century.
Dis Colon Rectum
; 2008 Oct;51(10):1491-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Comparison
of perianal
diseases in HIV-positive patients during periods before and after protease inhibitors use: what changed in the 21st century.
Thus, the immunologic status of such patients has been improving and we believe that changes in their
perianal
diseases also have been occurring.
RESULTS: In Group 1, the most common diseases were condylomas (24.7 percent), ulcers (21.8 percent), and
anal
fistulas (19.7 percent).
Tumors occurred in 2.5 percent, with Kaposi's sarcoma in 51.1 percent, and
squamous
-
cell carcinoma
in 27.6 percent.
The tumor incidence was 1.8 percent, with
squamous
-
cell carcinoma
in 59.4 percent and Kaposi's sarcoma in 23.2 percent.
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS Medicines
.
MedlinePlus Health Information.
consumer health - Rectal Disorders
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18670819.001).
[ISSN]
1530-0358
[Journal-full-title]
Diseases of the colon and rectum
[ISO-abbreviation]
Dis. Colon Rectum
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Protease Inhibitors
55.
Nilsson PJ, Lenander C, Rubio C, Auer G, Ljungqvist O, Glimelius B:
Prognostic significance of Cyclin A in epidermoid anal cancer.
Oncol Rep
; 2006 Sep;16(3):443-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Prognostic significance of Cyclin A in
epidermoid
anal
cancer
.
Ultimately aiming at a more individualized therapeutic approach in
epidermoid
anal
cancer
, this study explored the prognostic and predictive impact
of a
set of tumour markers.
From a population-based cohort of 276 patients with
epidermoid
anal
cancer
, treated according to prospective protocols, 215 pre-treatment biopsies were investigated using immunohistochemistry.
Cyclin A may be an indicator of radiosensitivity and a valuable prognostic marker in
epidermoid
anal
cancer
.
[MeSH-major]
Anus
Neoplasms / metabolism. Biomarkers, Tumor / metabolism.
Carcinoma
,
Squamous Cell
/ metabolism. Cyclin A / metabolism
Genetic Alliance.
consumer health - Anal Cancer
.
MedlinePlus Health Information.
consumer health - Anal Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16865241.001).
[ISSN]
1021-335X
[Journal-full-title]
Oncology reports
[ISO-abbreviation]
Oncol. Rep.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Greece
[Chemical-registry-number]
0 / Antigens, CD31; 0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / Cyclin A; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Tumor Suppressor Protein p53
56.
Devaraj B, Cosman BC:
Expectant management of anal squamous dysplasia in patients with HIV.
Dis Colon Rectum
; 2006 Jan;49(1):36-40
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Expectant management of
anal squamous
dysplasia in patients with HIV.
PURPOSE:
Anal squamous
dysplasia is commonly found in patients with HIV infection.
This study reviews a series of patients with HIV and an abnormal
anal
examination who had
squamous
dysplasia and who have been followed with physical examination alone and with repeat biopsies as necessary for new or suspicious lesions.
METHODS: We reviewed the charts of 40 HIV-positive men who had
squamous
dysplasia of the
anal
canal and
anal
margin
, focusing on history, physical findings, histologic
diagnosis
, and the occurrence of invasive
squamous
-
cell carcinoma
.
RESULTS: Forty HIV-positive men (mean age, 39 years) were followed for
anal squamous
dysplasia.
Three patients developed invasive
carcinoma
while under surveillance, and these were completely excised or cured with chemoradiation.
In a group of patients followed expectantly, most did not develop invasive
cancer
, and in those who did, early cancers could be identified and cured.
Physical examination surveillance for invasive
carcinoma
may be acceptable for following patients with HIV and biopsy-proven
squamous
dysplasia.
[MeSH-major]
Anus
Neoplasms / surgery.
Carcinoma
,
Squamous Cell
/ surgery. Colectomy / methods. Decision Making. HIV / immunology. HIV Antibodies / immunology. HIV Infections / complications
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - Anal Cancer
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Dis Colon Rectum. 2006 Oct;49(10):1648-9; author reply 1649-50
[
16972138.001
]
(PMID = 16283561.001).
[ISSN]
0012-3706
[Journal-full-title]
Diseases of the colon and rectum
[ISO-abbreviation]
Dis. Colon Rectum
[Language]
eng
[Publication-type]
Case Reports; Comparative Study; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / HIV Antibodies
57.
Ge MJ, Wu QC, Wang M, Zhang YH, Li LB:
Detection of disseminated lung cancer cells in regional lymph nodes by assay of CK19 reverse transcriptase polymerase chain reaction and its clinical significance.
J Cancer Res Clin Oncol
; 2005 Oct;131(10):662-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Detection of disseminated lung
cancer
cells in regional lymph nodes by assay of CK19 reverse transcriptase polymerase chain reaction and its clinical significance.
RT-PCR) that can be used to detect disseminated tumor cells (DTCs) in regional lymph nodes (LNs) in patients with lung
cancer
and to evaluate its clinical significance.
Serial dilution study for LC-5 cells (a lung
squamous cell
line) was performed to detect sensitivity of the molecular protocol.
Regional LNs (n = 261) and primary lung
cancer
tissue (n = 40) were obtained from 40 patients with lung
cancer
who underwent lobectomy or pneumonectomy.
They were randomly categorized into two groups: group I (
LN
-based study, n = 20) and group II (patient-based study, n = 20).
Each
LN
was halved.
One half
of a LN
was subjected to histological examination (HE) and the other half was subjected to RT-PCR amplification of CK(19) mRNA.
RESULTS: CK(19) mRNA expressed in all tumor tissues as well as LC-5, PAa cells (a lung adenocarcinoma
cell
line), but not in normal control LNs.
Serial dilution study for LC-5 cells demonstrated that CK(19) mRNA was detectable at a concentration as low as 10 LC-5 cells in 1x10(7)
LN
cells.
There was no significant difference between the detecting result of single
LN
and that of mixed LNs (P > 0.05).
According to the results of regional LNs in 40 patients by molecular assay, the presence of the CK(19) product in LNs was related to tumor size (chi(2) = 5.76, P < 0.025) as well as
cell
differentiation of the tumor (chi(2) = 7.08, P < 0.01).
Molecular detection of DTCs in LNs is a supplement for current tumor staging in lung
carcinoma
.
[MeSH-major]
Biomarkers, Tumor / analysis. Keratins / biosynthesis. Lung Neoplasms /
diagnosis
. Lymphatic Metastasis /
diagnosis
. Reverse Transcriptase Polymerase Chain Reaction
[MeSH-minor]
Aged.
Cell
Line, Tumor. Female. Humans. Male. Middle Aged. RNA, Messenger / analysis. Sensitivity and Specificity. Survival Analysis
Genetic Alliance.
consumer health - Lung Cancer
.
MedlinePlus Health Information.
consumer health - Lung Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 1998 Jun 10;15(3):170-2
[
9621128.001
]
[Cites]
Chest. 1998 Jun;113(6):1526-32
[
9631789.001
]
[Cites]
Clin Cancer Res. 2001 May;7(5):1350-7
[
11350905.001
]
[Cites]
J Thorac Cardiovasc Surg. 2001 Nov;122(5):900-6
[
11689794.001
]
[Cites]
Jpn J Thorac Cardiovasc Surg. 2001 Sep;49(9):545-51
[
11577444.001
]
[Cites]
Cancer Res. 2000 Nov 15;60(22):6472-8
[
11103815.001
]
[Cites]
J Clin Oncol. 2001 Feb 15;19(4):1128-36
[
11181678.001
]
[Cites]
Proc Natl Acad Sci U S A. 1985 Sep;82(18):6133-7
[
2994062.001
]
[Cites]
J Clin Oncol. 2002 Jul 1;20(13):2930-6
[
12089221.001
]
[Cites]
Ann Thorac Surg. 1998 Nov;66(5):1715-8
[
9875777.001
]
[Cites]
J Exp Clin Cancer Res. 2000 Sep;19(3):375-81
[
11144532.001
]
[Cites]
Clin Cancer Res. 2000 Jun;6(6):2326-32
[
10873083.001
]
[Cites]
Eur J Cardiothorac Surg. 2001 Sep;20(3):481-8
[
11509267.001
]
[Cites]
Cancer Lett. 2000 Nov 10;160(1):115-23
[
11098092.001
]
[Cites]
Clin Chem. 1996 Sep;42(9):1369-81
[
8787692.001
]
[Cites]
Ann Thorac Surg. 2002 May;73(5):1558-62
[
12022549.001
]
[Cites]
Eur J Cancer. 2005 Jan;41(2):306-12
[
15661557.001
]
[Cites]
Clin Cancer Res. 2001 Dec;7(12):4041-8
[
11751499.001
]
[Cites]
J Thorac Cardiovasc Surg. 2002 Mar;123(3):484-91; discussion 491
[
11882819.001
]
[Cites]
Eur J Cell Biol. 1988 Dec;47(2):300-19
[
2468493.001
]
[Cites]
Zhonghua Zhong Liu Za Zhi. 2002 Jan;24(1):41-3
[
11977636.001
]
[Cites]
Ann Thorac Surg. 2001 Jun;71(6):1772-7; discussion 1777-8
[
11426746.001
]
[Cites]
Br J Cancer. 1996 Nov;74(10):1639-42
[
8932347.001
]
[Cites]
Anal Biochem. 1987 Apr;162(1):156-9
[
2440339.001
]
[Cites]
Am J Pathol. 1993 Apr;142(4):1111-8
[
7682761.001
]
[Cites]
JSLS. 1998 Oct-Dec;2(4):331-6
[
10036123.001
]
[Cites]
J Clin Oncol. 2001 Mar 1;19(5):1437-43
[
11230489.001
]
[Cites]
Ann Surg. 2002 Jan;235(1):133-9
[
11753052.001
]
[Cites]
Cancer Res. 1995 Jun 15;55(12):2640-4
[
7540108.001
]
[Cites]
Clin Cancer Res. 2000 Nov;6(11):4176-85
[
11106229.001
]
(PMID = 16047189.001).
[ISSN]
0171-5216
[Journal-full-title]
Journal of cancer research and clinical oncology
[ISO-abbreviation]
J. Cancer Res. Clin. Oncol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / RNA, Messenger; 68238-35-7 / Keratins
58.
Herat A, Whitfeld M, Hillman R:
Anal intraepithelial neoplasia and anal cancer in dermatological practice.
Australas J Dermatol
; 2007 Aug;48(3):143-53; quiz 154-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Anal
intraepithelial neoplasia and
anal
cancer
in dermatological practice.
Anal
intraepithelial neoplasia is considered to be a precursor lesion of invasive
anal
cancer
.
Human papillomaviruses are considered to be an important aetiological agent in both
anal
intraepithelial neoplasia and
anal
cancer
.
Dermatologists are likely to encounter these conditions among the differential diagnoses to be considered in high-risk patients presenting with
perianal
and
anal
lesions.
Anal
cancer
rates are also increasing among the HIV-infected and HIV-non-infected population.
The successful treatment of
anal
intraepithelial neoplasia may reduce the risk of subsequent development of
anal
cancer
.
However, current therapies for
anal
intraepithelial neoplasia may be associated with treatment-related morbidity and are not well validated.
It is currently not proven that they reduce the likelihood of the development of
anal
cancer
.
Nevertheless, screening for
anal
intraepithelial neoplasia is being advocated for high-risk groups and may become standard dermatological care for these patients.
In view of recent developments in the understanding of this condition, this article reviews the current understanding of
anal
intraepithelial neoplasia and its treatment from a dermatological perspective.
[MeSH-major]
Anus
Neoplasms.
Carcinoma
in Situ.
Carcinoma
,
Squamous Cell
. Papillomavirus Infections
[MeSH-minor]
Diagnosis
, Differential. HIV Infections / complications. Humans. Papillomaviridae / pathogenicity
Genetic Alliance.
consumer health - Anal Cancer
.
MedlinePlus Health Information.
consumer health - Anal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17680964.001).
[ISSN]
0004-8380
[Journal-full-title]
The Australasian journal of dermatology
[ISO-abbreviation]
Australas. J. Dermatol.
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
Australia
[Number-of-references]
115
59.
Ciobotaru B, Leiman G, St John T, Hyman N, Ramundo M, Grace C:
Prevalence and risk factors for anal cytologic abnormalities and human papillomavirus infection in a rural population of HIV-infected males.
Dis Colon Rectum
; 2007 Jul;50(7):1011-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Prevalence and risk factors for
anal
cytologic abnormalities and human papillomavirus infection in a rural population of HIV-infected males.
PURPOSE: This study was designed to determine the prevalence and risk factors for
anal squamous
intraepithelial lesions and human papillomavirus infection in a rural population of HIV-infected males.
Anal
Papanicolaou smear and human papillomavirus screening for oncogenic types were performed.
Ninety (60 percent) males had abnormal
anal
cytology, including atypical cells of unknown significance 40 (26 percent), low-grade
squamous
intraepithelial lesions 28 (19 percent), and high-grade
squamous
intraepithelial lesions 22 (15 percent).
Binary logistic regression adjusted risks for abnormal
anal
cytology included: males who have sex with males (P<0.001), human papillomavirus infection (P<0.001), history of anogenital warts (P=0.014), and the mean lowest CD4 count (abnormal cytology, 158 (standard deviation, 135), negative cytology, 208 (standard deviation, 180; P=0.017)).
Twenty-two patients with high-grade
squamous
intraepithelial lesions underwent colorectal surgical examination and anoscopy.
Two (10 percent) were found to have invasive
squamous
-
cell carcinoma
and three (15 percent) others had mass lesions with high-grade
squamous
intraepithelial lesions.
CONCLUSIONS:
Anal squamous
intraepithelial lesions and oncogenic human papillomavirus are highly prevalent in males infected with HIV and living in a rural setting.
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - Rectal Disorders
.
MedlinePlus Health Information.
consumer health - Rural Health Concerns
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17429713.001).
[ISSN]
0012-3706
[Journal-full-title]
Diseases of the colon and rectum
[ISO-abbreviation]
Dis. Colon Rectum
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
60.
Ortiz CM, Ito T, Hashimoto Y, Nagayama S, Iwai A, Tsunoda S, Sato F, Martorell M, Garcia JA, Perez A, Shimada Y:
Effects of small interfering RNAs targeting fascin on human esophageal squamous cell carcinoma cell lines.
Diagn Pathol
; 2010;5:41
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Effects of small interfering RNAs targeting fascin on human esophageal
squamous cell carcinoma cell
lines.
BACKGROUND: Fascin induces membrane protrusions and
cell
motility.
Fascin overexpression was associated with poor prognosis, and its downregulation reduces
cell
motility and invasiveness in esophageal
squamous cell carcinoma
(ESCC).
Using a stable knockdown
cell
line, we revealed the effect of fascin on
cell
growth,
cell
adhesion and tumor formation.
We established a stable transfectant with downregulated fascin from KYSE170
cell
line.
RESULTS: The fascin downregulated
cell
lines showed a slower growth pattern by 40.3% (p < 0.01) and detachment from collagen-coated plates by 53.6% (p < 0.01), compared to mock cells, suggesting that fascin plays a role in
cell
growth by maintaining
cell
adhesion to the extracellular matrix.
CONCLUSIONS: These findings suggest that fascin overexpression plays a role in tumor growth and progression in ESCC and that
cell
death caused by its downregulation might be induced by
cell
adhesion loss.
[MeSH-major]
Carcinoma
,
Squamous Cell
/ genetics. Carrier Proteins / genetics. Esophageal Neoplasms / genetics. Microfilament Proteins / genetics. RNA Interference. RNA, Small Interfering / metabolism
[MeSH-minor]
Amino Acid Chloromethyl Ketones / pharmacology. Animals. Apoptosis. Caspase Inhibitors. Caspases / metabolism.
Cell
Adhesion.
Cell
Line, Tumor.
Cell
Proliferation. Collagen / metabolism. Cysteine Proteinase Inhibitors / pharmacology. Humans. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Time Factors. Transfection. Tumor Burden. Xenograft Model Antitumor Assays
Genetic Alliance.
consumer health - Carcinoma, Squamous Cell
.
MedlinePlus Health Information.
consumer health - Esophageal Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Lung Cancer. 2003 Nov;42(2):203-13
[
14568688.001
]
[Cites]
Thyroid. 2009 Jul;19(7):735-42
[
19485776.001
]
[Cites]
N Engl J Med. 2003 Dec 4;349(23):2241-52
[
14657432.001
]
[Cites]
Biochem Soc Trans. 2004 Jun;32(Pt3):421-5
[
15157151.001
]
[Cites]
Anal Biochem. 1987 Apr;162(1):156-9
[
2440339.001
]
[Cites]
Proc Natl Acad Sci U S A. 1989 Feb;86(4):1254-8
[
2919174.001
]
[Cites]
Cancer. 1993 Feb 15;71(4):1368-83
[
8435813.001
]
[Cites]
Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):9115-9
[
8415664.001
]
[Cites]
Biotechniques. 1993 Sep;15(3):532-4, 536-7
[
7692896.001
]
[Cites]
Nat Cell Biol. 2000 May;2(5):249-56
[
10806474.001
]
[Cites]
Br J Cancer. 2000 Oct;83(7):870-3
[
10970687.001
]
[Cites]
Oncogene. 2000 Oct 5;19(42):4864-75
[
11039904.001
]
[Cites]
J Immunol. 2001 Jan 1;166(1):338-45
[
11123310.001
]
[Cites]
Am J Physiol Gastrointest Liver Physiol. 2001 Jan;280(1):G75-87
[
11123200.001
]
[Cites]
Clin Exp Metastasis. 2000;18(1):83-8
[
11206843.001
]
[Cites]
Cell Motil Cytoskeleton. 2001 Feb;48(2):109-20
[
11169763.001
]
[Cites]
Nature. 2001 May 17;411(6835):375-9
[
11357145.001
]
[Cites]
Am J Pathol. 2002 Apr;160(4):1239-49
[
11943709.001
]
[Cites]
Bioessays. 2002 Apr;24(4):350-61
[
11948621.001
]
[Cites]
J Clin Invest. 2002 Apr;109(8):987-91
[
11956233.001
]
[Cites]
Am J Clin Pathol. 2002 Jul;118(1):52-9
[
12109856.001
]
[Cites]
J Cutan Pathol. 2002 Aug;29(7):430-8
[
12139639.001
]
[Cites]
Am J Pathol. 2003 Jan;162(1):69-80
[
12507891.001
]
[Cites]
Clin Cancer Res. 2003 Jan;9(1):243-9
[
12538476.001
]
[Cites]
Surg Oncol. 2003 Jul;12(1):1-7
[
12689665.001
]
[Cites]
J Cell Biol. 1994 Feb;124(4):619-26
[
8106557.001
]
[Cites]
Curr Opin Cell Biol. 1994 Feb;6(1):105-9
[
8167015.001
]
[Cites]
Semin Cell Biol. 1994 Jun;5(3):165-74
[
7919230.001
]
[Cites]
J Virol. 1994 Nov;68(11):7320-8
[
7933116.001
]
[Cites]
Cancer Res. 1995 Jul 1;55(13):2752-5
[
7796399.001
]
[Cites]
Ann Surg Oncol. 1996 Jan;3(1):100-5
[
8770310.001
]
[Cites]
J Cell Biol. 1996 Sep;134(5):1271-81
[
8794867.001
]
[Cites]
J Cell Biol. 1998 Oct 5;143(1):121-33
[
9763425.001
]
[Cites]
Br J Dermatol. 1999 Aug;141(2):218-23
[
10468791.001
]
[Cites]
Oncology. 2004;67(3-4):262-70
[
15557788.001
]
[Cites]
Cancer. 2005 Mar 15;103(6):1154-64
[
15712207.001
]
[Cites]
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
[
15761078.001
]
[Cites]
Clin Cancer Res. 2005 Apr 1;11(7):2597-605
[
15814639.001
]
[Cites]
Biochem Biophys Res Commun. 2005 Nov 11;337(1):355-62
[
16185662.001
]
[Cites]
Nat Rev Cancer. 2006 May;6(5):392-401
[
16572188.001
]
[Cites]
Cancer Res. 2006 May 15;66(10):5487-94
[
16707478.001
]
[Cites]
J Clin Pathol. 2006 Sep;59(9):958-64
[
16524962.001
]
[Cites]
Invest Ophthalmol Vis Sci. 2006 Dec;47(12):5267-75
[
17122112.001
]
[Cites]
J Biomed Sci. 2009;16:100
[
19917110.001
]
[Cites]
Cell Signal. 2007 Apr;19(4):761-71
[
17113264.001
]
[Cites]
Apoptosis. 2007 Dec;12(12):2221-31
[
17879163.001
]
[Cites]
Oncogene. 2007 Nov 8;26(51):7194-203
[
17525740.001
]
[Cites]
Hum Pathol. 2009 Feb;40(2):174-80
[
18835624.001
]
[Cites]
J Cell Biol. 2003 Nov 24;163(4):847-57
[
14623871.001
]
(PMID = 20565981.001).
[ISSN]
1746-1596
[Journal-full-title]
Diagnostic pathology
[ISO-abbreviation]
Diagn Pathol
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Amino Acid Chloromethyl Ketones; 0 / Carrier Proteins; 0 / Caspase Inhibitors; 0 / Cysteine Proteinase Inhibitors; 0 / Microfilament Proteins; 0 / RNA, Small Interfering; 0 / benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone; 146808-54-0 / fascin; 9007-34-5 / Collagen; EC 3.4.22.- / Caspases
[Other-IDs]
NLM/ PMC2907320
61.
Sotlar K:
[Human papillomavirus infection. Pathology and molecular pathology].
Pathologe
; 2008 Nov;29 Suppl 2:153-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Cervical
cancer
is the second most frequent female malignoma worldwide and accounts for about 500,000 cases every year.
Persistent infections with a group of 15 so-called high-risk human papillomaviruses (HR-HPV) are the cause of cervical carcinogenesis of
squamous cell
carcinomas and for most of the adenocarcinomas.
The resulting loss of
cell
cycle control sets the basis for additional, as yet only incompletely discovered, genetic and epigenetic changes, finally leading to invasive growth.
In addition to cervical
cancer
, HPV infections are responsible for the development of genital warts (condyloma) and a number of vaginal, vulvar, and
anal
intraepithelial neoplasias.
[MeSH-major]
Adenocarcinoma / pathology.
Carcinoma
,
Squamous Cell
/ pathology. Cervical Intraepithelial Neoplasia / pathology. Papillomavirus Infections / pathology. Uterine Cervical Neoplasms / pathology
[MeSH-minor]
Adolescent. Adult.
Cell
Transformation, Neoplastic / genetics.
Cell
Transformation, Neoplastic / pathology. Child. Female. Humans. Middle Aged. Papillomaviridae / genetics. Papillomavirus Vaccines / administration & dosage. Young Adult
MedlinePlus Health Information.
consumer health - Cervical Cancer
.
International Agency for Research on Cancer - Screening Group.
diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas
.
International Agency for Research on Cancer - Screening Group.
diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Lancet. 2004 Nov 6-12;364(9446):1678-83
[
15530628.001
]
[Cites]
J Natl Cancer Inst. 2005 Jul 20;97(14):1066-71
[
16030304.001
]
[Cites]
J Infect Dis. 2007 Jun 1;195(11):1582-9
[
17471427.001
]
[Cites]
J Clin Virol. 2005 Mar;32 Suppl 1:S16-24
[
15753008.001
]
[Cites]
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
[
15761078.001
]
[Cites]
Cancer Res. 2006 Nov 1;66(21):10630-6
[
17062559.001
]
[Cites]
Rev Med Virol. 2006 Mar-Apr;16(2):83-97
[
16287204.001
]
[Cites]
Clin Sci (Lond). 2006 May;110(5):525-41
[
16597322.001
]
[Cites]
N Engl J Med. 1999 Nov 25;341(22):1633-8
[
10572150.001
]
[Cites]
J Gen Virol. 1995 Apr;76 ( Pt 4):1057-62
[
9049358.001
]
[Cites]
Virology. 2005 Jun 20;337(1):76-84
[
15914222.001
]
[Cites]
J Virol. 2003 Oct;77(19):10186-201
[
12970404.001
]
[Cites]
N Engl J Med. 2003 Feb 6;348(6):518-27
[
12571259.001
]
[Cites]
Virology. 2004 Jun 20;324(1):17-27
[
15183049.001
]
[Cites]
Lancet. 1978 Aug 26;2(8087):463-5
[
79818.001
]
[Cites]
Br J Cancer. 2003 Jul 7;89(1):101-5
[
12838308.001
]
[Cites]
Lancet. 2007 Sep 8;370(9590):890-907
[
17826171.001
]
[Cites]
N Engl J Med. 1998 Feb 12;338(7):423-8
[
9459645.001
]
[Cites]
Int J Cancer. 2007 Aug 1;121(3):621-32
[
17405118.001
]
[Cites]
Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1654-8
[
7878034.001
]
[Cites]
Cancer Res. 1999 Dec 15;59(24):6132-6
[
10626803.001
]
[Cites]
J Pathol. 2006 Jan;208(2):152-64
[
16362994.001
]
[Cites]
Nat Rev Cancer. 2007 Jan;7(1):11-22
[
17186016.001
]
[Cites]
Lancet. 2001 Jun 9;357(9271):1831-6
[
11410191.001
]
[Cites]
Verh Dtsch Ges Pathol. 2005;89:195-200
[
18035691.001
]
[Cites]
J Virol. 2003 Dec;77(24):13125-35
[
14645569.001
]
[Cites]
J Med Virol. 2004 Sep;74(1):107-16
[
15258976.001
]
[Cites]
J Natl Cancer Inst. 1990 Sep 19;82(18):1477-84
[
2167986.001
]
[Cites]
J Virol. 1997 Mar;71(3):2449-56
[
9032382.001
]
[Cites]
J Infect Dis. 2005 Jun 1;191(11):1796-807
[
15871111.001
]
[Cites]
Am J Epidemiol. 2003 Feb 1;157(3):218-26
[
12543621.001
]
[Cites]
J Natl Cancer Inst. 2005 Apr 20;97(8):577-86
[
15840880.001
]
[Cites]
Int J Cancer. 2006 Dec 1;119(11):2677-84
[
16991121.001
]
[Cites]
J Natl Cancer Inst. 2005 Jul 20;97(14):1072-9
[
16030305.001
]
(PMID = 18820920.001).
[ISSN]
1432-1963
[Journal-full-title]
Der Pathologe
[ISO-abbreviation]
Pathologe
[Language]
ger
[Publication-type]
English Abstract; Journal Article; Review
[Publication-country]
Germany
[Chemical-registry-number]
0 / Papillomavirus Vaccines
[Number-of-references]
34
62.
Esquibies AE, Zambrano E, Ziai J, Kesebir D, Touloukian RJ, Egan ME, Reyes-Múgica M, Bazzy-Asaad A:
Pulmonary squamous cell carcinoma associated with repaired congenital tracheoesophageal fistula and esophageal atresia.
Pediatr Pulmonol
; 2010 Feb;45(2):202-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Pulmonary
squamous cell carcinoma
associated with repaired congenital tracheoesophageal fistula and esophageal atresia.
We report a 19-year-old man with pulmonary
squamous cell carcinoma
(SCC) who had a history of vertebral,
anal
, cardiac, tracheal, esophageal, renal, and radial limb defects (VACTERL) association and tracheoesophageal fistula (TEF) + esophageal atresia (EA) repair as an infant.
Children that undergo TEF + EA repair may have an increased risk for developing
cancer
as they reach adulthood.
[MeSH-major]
Abnormalities, Multiple / surgery.
Carcinoma
,
Squamous Cell
/ etiology. Esophageal Atresia / surgery. Lung Neoplasms / etiology. Postoperative Complications / etiology. Tracheoesophageal Fistula / surgery
Genetic Alliance.
consumer health - Carcinoma, Squamous Cell
.
Genetic Alliance.
consumer health - Esophageal Atresia
.
Genetic Alliance.
consumer health - Tracheoesophageal fistula
.
MedlinePlus Health Information.
consumer health - After Surgery
.
MedlinePlus Health Information.
consumer health - Lung Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
(c) 2010 Wiley-Liss, Inc.
(PMID = 20054858.001).
[ISSN]
1099-0496
[Journal-full-title]
Pediatric pulmonology
[ISO-abbreviation]
Pediatr. Pulmonol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
63.
Jethwa P, Lake SP:
Using topical negative pressure therapy to resolve wound failure following perineal resection.
J Wound Care
; 2005 Apr;14(4):166-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Elective resection of the rectum and perineum in a patient with recurrent
squamous cell carcinoma
of the
anus
resulted in significant wound failure.
Full healing was achieved with topical negative pressure, with no recurrence of the
cancer
.
[MeSH-minor]
Anus
Neoplasms / surgery.
Carcinoma
,
Squamous Cell
/ surgery. Humans. Male. Middle Aged. Recurrence. Suction / methods. Treatment Failure
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15835227.001).
[ISSN]
0969-0700
[Journal-full-title]
Journal of wound care
[ISO-abbreviation]
J Wound Care
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
England
64.
Bakotic WL, Willis D, Birdsong G, Tadros TS:
Anal cytology in an HIV-positive population: a retrospective analysis.
Acta Cytol
; 2005 Mar-Apr;49(2):163-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Anal
cytology in an HIV-positive population: a retrospective analysis.
OBJECTIVE: To retrospectively evaluate cellularity and correlate the presence of columnar cells with specimen interpretation in conventionally prepared
anal
cytologic smears from an HIV-positive population.
STUDY DESIGN: Two cytopathologists and 1 senior cytotechnologist, blinded to the original
diagnosis
, screened 114 samples from 110 patients collected between 1997 and 2002.
The relationships between
diagnosis
and presence of columnar cells, visible
anal
lesions, concurrent HIV viral load and CD4+ T-
cell
counts were assessed.
RESULTS: The cytologic findings were as follows: 7, unsatisfactory (6%); 29, negative (25%); 25, atypical
squamous
cells of undetermined significance (22%); and 53, dysplasia (47%) (42
anal
intraepithelial lesion 1 [37%] and 11
anal
intraepithelial lesion 2/3 [10%]).
CONCLUSION: A highly significant association between the presence of columnar cells and
anal
intraepithelial lesion (p<0.001) and a significant association between the presence of columnar cells and atypical cytology when a visible lesion was absent (p=0.0019) were found.
No significant relationship was found between the presence/degree of dysplasia and CD4+ T-
cell
counts or HIV viral load.
[MeSH-major]
Anal
Canal / pathology.
Anus
Neoplasms / pathology.
Carcinoma
/ pathology. Epithelial Cells / pathology. HIV Infections / complications. HIV Seropositivity / complications
[MeSH-minor]
Adult. CD4 Lymphocyte Count.
Cell
Biology / standards. Female. HIV / immunology. Humans. Immunocompromised Host. Male. Mass Screening. Middle Aged. Predictive Value of Tests. Retrospective Studies. Unsafe Sex. Viral Load
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - Anal Cancer
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - HIV/AIDS in Women
.
COS Scholar Universe.
author profiles
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15839621.001).
[ISSN]
0001-5547
[Journal-full-title]
Acta cytologica
[ISO-abbreviation]
Acta Cytol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
65.
Goldstone SE, Kawalek AZ, Huyett JW:
Infrared coagulator: a useful tool for treating anal squamous intraepithelial lesions.
Dis Colon Rectum
; 2005 May;48(5):1042-54
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Infrared coagulator: a useful tool for treating
anal squamous
intraepithelial lesions.
PURPOSE: The incidence of invasive
anal squamous carcinoma
in men who have sex with men is rising, particularly in those with human immunodeficiency virus.
As in the cervix the high-grade
squamous
intraepithelial lesion is thought to be an invasive
squamous cell carcinoma
precursor.
Cervical high-grade
squamous
intraepithelial lesions are treated by removing the squamocolumnar transition zone.
This is not possible in
the anus
, where treatment is often surgical and is accompanied by significant pain and morbidity.
Better office-based techniques to treat
anal
high-grade
squamous
intraepithelial lesions are needed.
We employed the infrared coagulator in an office setting to ablate high-grade
squamous
intraepithelial lesions.
Procedures were performed with local anesthesia on patients with discrete high-grade
squamous
intraepithelial lesions.
Follow-up consisted of
anal
cytology with high-resolution anoscopy and biopsy of suspicious areas every three to six months.
However, 44 patients (65 percent) developed a new or persistent high-grade
squamous
intraepithelial lesion within a median time of 217 days (range 27-566 days) after infrared coagulation.
No patient developed
squamous
-
cell carcinoma
, had a serious adverse event, or developed
anal
stenosis.
CONCLUSIONS: The infrared coagulator is a safe, office-based modality for treating
anal
high-grade
squamous
intraepithelial lesion in human immunodeficiency virus-positive men who have sex with men.
[MeSH-major]
Anus
Neoplasms / surgery.
Carcinoma
,
Squamous Cell
/ surgery. HIV Seropositivity. Infrared Rays / therapeutic use. Light Coagulation / methods. Precancerous Conditions / surgery
MedlinePlus Health Information.
consumer health - Anal Cancer
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Dis Colon Rectum. 2006 Oct;49(10):1648-9; author reply 1649-50
[
16972138.001
]
(PMID = 15868241.001).
[ISSN]
0012-3706
[Journal-full-title]
Diseases of the colon and rectum
[ISO-abbreviation]
Dis. Colon Rectum
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
66.
Goldstone SE, Kawalek AZ, Goldstone RN, Goldstone AB:
Hybrid Capture II detection of oncogenic human papillomavirus: a useful tool when evaluating men who have sex with men with atypical squamous cells of undetermined significance on anal cytology.
Dis Colon Rectum
; 2008 Jul;51(7):1130-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Hybrid Capture II detection of oncogenic human papillomavirus: a useful tool when evaluating men who have sex with men with atypical
squamous
cells of undetermined significance on
anal
cytology.
PURPOSE: In the cervix and
anus
, patients with atypical
squamous
cells of undetermined significance often do not have high-grade
squamous
intraepithelial lesions.
In women with atypical
squamous
cells of undetermined significance, Hybrid-Capture II testing for oncogenic high-risk human papillomavirus is performed and those without high-risk human papillomavirus often are observed.
We endeavored to determine whether Hybrid-Capture II testing would be beneficial in men who have sex with men with atypical
squamous
cells of undetermined significance.
METHODS: We performed a retrospective chart review of men who have sex with men with atypical
squamous
cells of undetermined significance who had high-resolution anoscopy and Hybrid-Capture II.
High-grade
squamous
intraepithelial lesions were found in 50 (17 percent): 23 (10 percent) who were HIV-negative and 27 (35 percent) who were HIV-positive men.
Five percent with high-grade
squamous
intraepithelial lesions would be missed.
[MeSH-major]
Alphapapillomavirus / genetics.
Anal
Canal / pathology.
Carcinoma
,
Squamous Cell
/ pathology. Homosexuality, Male. Papillomavirus Infections / pathology. RNA, Viral / analysis. Rectal Neoplasms / pathology
[MeSH-minor]
Adult. Biopsy. Colonoscopy.
Diagnosis
, Differential. Humans. Male. Middle Aged. Polymerase Chain Reaction / methods. Precancerous Conditions. Predictive Value of Tests. Prevalence. Retrospective Studies. Risk Factors. Sensitivity and Specificity. United States / epidemiology
MedlinePlus Health Information.
consumer health - HPV
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18481150.001).
[ISSN]
1530-0358
[Journal-full-title]
Diseases of the colon and rectum
[ISO-abbreviation]
Dis. Colon Rectum
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / RNA, Viral
67.
Damin DC, Rosito MA, Schwartsmann G:
Sentinel lymph node in carcinoma of the anal canal: a review.
Eur J Surg Oncol
; 2006 Apr;32(3):247-52
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Sentinel lymph node in
carcinoma
of the
anal
canal: a review.
AIMS: To review the studies investigating the efficacy of the sentinel lymph node (SLN) procedure in
anal
canal
carcinoma
and to evaluate its potential role in guiding a more selective approach for patients with the malignancy.
METHODS: A literature search in the PubMed database was preformed using the key words "sentinel lymph node" and "
anal
cancer
".
All indexed original articles (except case reports) on the SLN procedure in
cancer of
the
anal
canal were analysed.
The detection of occult metastases in clinically unsuspicious nodes represents an important improvement in the process of staging these patients, which has not been possible with any other method
of diagnosis
.
Although SLN procedure is still in an early phase of investigation in this type
of cancer
, it emerges as an objective method to guide individual therapeutic decisions.
[MeSH-major]
Anus
Neoplasms / pathology.
Carcinoma
/ secondary
MedlinePlus Health Information.
consumer health - Anal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16289647.001).
[ISSN]
0748-7983
[Journal-full-title]
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
[ISO-abbreviation]
Eur J Surg Oncol
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
England
[Number-of-references]
55
68.
Abbas A, Yang G, Fakih M:
Management of anal cancer in 2010. Part 1: Overview, screening, and diagnosis.
Oncology (Williston Park)
; 2010 Apr 15;24(4):364-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Management of
anal
cancer
in 2010. Part 1: Overview, screening, and
diagnosis
.
Although
anal
cancer
is a rare disease, its incidence is increasing in men and women worldwide.
Anal
cancer
is generally preceded by high-grade
anal
intraepithelial neoplasia (HGAIN), which is most prevalent in human immunodeficiency virus (HIV)-positive men who have sex with men.
Meta-analysis suggests that 80% of
anal
cancers could be avoided by vaccination against HPV 16/18.
Nearly half of all patients with
anal
cancer
present with rectal bleeding.
Pain or sensation
of a
rectal mass is experienced in 30% of patients, whereas 20% have no tumor-specific symptoms.
According to the Surveillance Epidemiology and End Results (SEER) database, 50% of patients with
anal
cancer
have disease localized to
the anus
, 29% have regional lymph node involvement or direct spread beyond the primary, and 12% have metastatic disease, while 9% have an unknown stage.
Clinical staging of
anal carcinoma
requires a digital rectal exam and a computed tomography scan of the chest, abdomen, and pelvis.
The 5-year relative survival rates are 80.1% for localized
anal
cancer
, 60.7% for regional disease, and 29.4% for metastatic disease.
Part 2 of this two-part review will address the treatment of
anal
cancer
, highlighting studies of chemoradiation.
[MeSH-major]
Anus
Neoplasms /
diagnosis
.
Anus
Neoplasms / prevention & control. Mass Screening
Genetic Alliance.
consumer health - Anal Cancer
.
MedlinePlus Health Information.
consumer health - Anal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20464850.001).
[ISSN]
0890-9091
[Journal-full-title]
Oncology (Williston Park, N.Y.)
[ISO-abbreviation]
Oncology (Williston Park, N.Y.)
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Number-of-references]
94
69.
Kim JW, Abramson DH:
Topical treatment options for conjunctival neoplasms.
Clin Ophthalmol
; 2008 Sep;2(3):503-15
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Over the past ten years, topical agents have been used by investigators to treat various premalignant and malignant lesions of the conjunctiva, such as primary acquired melanosis with atypia, conjunctival melanoma,
squamous
intraepithelial neoplasia and
squamous cell carcinoma
of the conjunctiva, and pagetoid spread of the conjunctiva arising from sebaceous
cell carcinoma
.
In this review, we present specific guidelines for treating both melanocytic and
squamous
neoplasms of the conjunctiva, utilizing the available data in the literature as well as our own clinical experience at the Memorial Sloan-Kettering
Cancer
Center.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Br J Ophthalmol. 1997 Jul;81(7):595-8
[
9290377.001
]
[Cites]
Ophthalmology. 1997 Dec;104(12):2085-93
[
9400769.001
]
[Cites]
Arch Ophthalmol. 1997 Jun;115(6):808-15
[
9194740.001
]
[Cites]
Arch Ophthalmol. 1996 Oct;114(10):1261-4
[
8859090.001
]
[Cites]
Ophthalmology. 1995 Sep;102(9):1263-9
[
9097762.001
]
[Cites]
Ophthalmology. 1995 Sep;102(9):1338-44
[
9097771.001
]
[Cites]
Ophthalmology. 2002 Nov;109(11):2129-33
[
12414427.001
]
[Cites]
Jpn J Ophthalmol. 2002 Mar-Apr;46(2):215-7
[
12062230.001
]
[Cites]
Am J Clin Oncol. 2002 Jun;25(3):248-55
[
12040282.001
]
[Cites]
Am J Ophthalmol. 2002 May;133(5):601-6
[
11992855.001
]
[Cites]
Ophthalmology. 2002 Mar;109(3):548-52
[
11874760.001
]
[Cites]
Ophthalmology. 2002 Mar;109(3):542-7
[
11874759.001
]
[Cites]
Br J Ophthalmol. 1993 Nov;77(11):751-3
[
8280698.001
]
[Cites]
Int Ophthalmol Clin. 1993 Summer;33(3):25-30
[
8407189.001
]
[Cites]
Acta Ophthalmol (Copenh). 1992 Jun;70(3):289-96
[
1636385.001
]
[Cites]
JAMA. 1991 Sep 11;266(10):1375-83
[
1715409.001
]
[Cites]
Trans Am Ophthalmol Soc. 1991;89:285-98; discussion 298-301
[
1808811.001
]
[Cites]
Ophthalmology. 1991 Mar;98(3):317-21
[
2023752.001
]
[Cites]
Surv Ophthalmol. 1989 May-Jun;33(6):477-90
[
2658172.001
]
[Cites]
Br J Ophthalmol. 2002 Jan;86(1):31-4
[
11801499.001
]
[Cites]
Cornea. 2002 Jan;21(1):6-11
[
11805499.001
]
[Cites]
Ophthalmology. 1994 Apr;101(4):759-62
[
8152772.001
]
[Cites]
Surv Ophthalmol. 1995 May-Jun;39(6):429-50
[
7660300.001
]
[Cites]
Br J Ophthalmol. 1994 Jul;78(7):520-8
[
7522545.001
]
[Cites]
Arch Ophthalmol. 1994 Sep;112(9):1145-6
[
8085957.001
]
[Cites]
Br J Ophthalmol. 1994 Apr;78(4):252-9
[
8199108.001
]
[Cites]
Arch Ophthalmol. 1994 Jan;112(1):22-3
[
8285885.001
]
[Cites]
Ophthalmology. 1989 Feb;96(2):147-66
[
2649838.001
]
[Cites]
Am J Ophthalmol. 1989 Apr 15;107(4):337-40
[
2929703.001
]
[Cites]
Doc Ophthalmol. 1986 Dec 30;64(1):31-42
[
3582100.001
]
[Cites]
Am J Ophthalmol. 1986 Jul 15;102(1):87-90
[
3728630.001
]
[Cites]
Ophthalmology. 1986 Feb;93(2):176-83
[
3951824.001
]
[Cites]
Invest Ophthalmol Vis Sci. 1985 Apr;26(4):580-3
[
3980172.001
]
[Cites]
Ophthalmology. 1984 Jun;91(6):673-8
[
6462625.001
]
[Cites]
Ophthalmic Surg. 1984 Apr;15(4):289-94
[
6728400.001
]
[Cites]
Arch Ophthalmol. 1983 May;101(5):782-6
[
6847469.001
]
[Cites]
J Urol. 1981 Oct;126(4):461-4
[
6793738.001
]
[Cites]
Arch Ophthalmol. 1980 Aug;98(8):1385-9
[
7417073.001
]
[Cites]
Trans Am Ophthalmol Soc. 1976;74:154-71
[
325854.001
]
[Cites]
Am J Ophthalmol. 1979 Jan;87(1):84-6
[
434057.001
]
[Cites]
Doc Ophthalmol. 1973 Feb 21;34(1):93-108
[
4706112.001
]
[Cites]
Ophthalmology. 2004 Sep;111(9):1755-61
[
15350333.001
]
[Cites]
Am J Ophthalmol. 2004 May;137(5):950-1
[
15126170.001
]
[Cites]
Br J Ophthalmol. 2004 May;88(5):718-9
[
15090432.001
]
[Cites]
Br J Ophthalmol. 2004 Jan;88(1):17-8
[
14693762.001
]
[Cites]
Am J Ophthalmol. 2003 Aug;136(2):375-7
[
12888073.001
]
[Cites]
Ophthalmology. 2003 May;110(5):1012-6
[
12750105.001
]
[Cites]
Cornea. 2003 Mar;22(2):114-7
[
12605043.001
]
[Cites]
Acta Ophthalmol Scand. 2002 Dec;80(6):674-5
[
12485296.001
]
[Cites]
Am J Ophthalmol. 2001 Oct;132(4):576-8
[
11589886.001
]
[Cites]
Br J Ophthalmol. 2001 Sep;85(9):1115-9
[
11520767.001
]
[Cites]
Ophthalmology. 2001 Jun;108(6):1093-8
[
11382635.001
]
[Cites]
Ophthalmology. 2000 Dec;107(12):2190-5
[
11097594.001
]
[Cites]
Arch Ophthalmol. 2000 Jul;118(7):885-91
[
10900099.001
]
[Cites]
Br J Ophthalmol. 2000 Mar;84(3):268-72
[
10684836.001
]
[Cites]
Cornea. 2000 Jan;19(1):1-6
[
10631999.001
]
[Cites]
Anal Quant Cytol Histol. 1999 Oct;21(5):387-96
[
10560521.001
]
[Cites]
Br J Ophthalmol. 2006 Jul;90(7):819-22
[
16672325.001
]
[Cites]
Graefes Arch Clin Exp Ophthalmol. 2005 Nov;243(11):1108-14
[
15940485.001
]
[Cites]
Cornea. 2005 May;24(4):443-8
[
15829803.001
]
[Cites]
Cornea. 2005 Apr;24(3):297-300
[
15778602.001
]
[Cites]
Am J Ophthalmol. 2005 Feb;139(2):229-34
[
15733981.001
]
[Cites]
Arch Ophthalmol. 2005 Jan;123(1):109-13
[
15642823.001
]
[Cites]
Am J Ophthalmol. 1963 Apr;55:811-5
[
13948673.001
]
[Cites]
Ophthalmology. 1999 Sep;106(9):1756-60; discussion 1761
[
10485547.001
]
[Cites]
Cornea. 1999 Jan;18(1):59-62
[
9894938.001
]
[Cites]
Am J Ophthalmol. 1997 Sep;124(3):397-9
[
9439368.001
]
[Cites]
Am J Ophthalmol. 1997 Sep;124(3):303-11
[
9439356.001
]
[Cites]
Ophthalmology. 1999 Jan;106(1):91-7
[
9917787.001
]
[Cites]
Surv Ophthalmol. 1998 Jan-Feb;42(4):321-50
[
9493274.001
]
(PMID = 19668748.001).
[ISSN]
1177-5467
[Journal-full-title]
Clinical ophthalmology (Auckland, N.Z.)
[ISO-abbreviation]
Clin Ophthalmol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
New Zealand
[Other-IDs]
NLM/ PMC2694026
[Keywords]
NOTNLM ; 5-Fluorouracil / Mitomycin-C / conjunctival neoplasms melanosis / topical therapies
70.
Pineda CE, Berry JM, Welton ML:
High resolution anoscopy and targeted treatment of high-grade squamous intraepithelial lesions.
Dis Colon Rectum
; 2006 Jan;49(1):126
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
High resolution anoscopy and targeted treatment of high-grade
squamous
intraepithelial lesions.
PURPOSE: The purpose of this video is to illustrate the use of high resolution anoscopy in
the diagnosis
and treatment of
anal
high-grade
squamous
intraepithelial lesions.
METHODS: Five patients with
anal
dysplasia were examined in the operating room with acetic acid and the operative microscope.
Acetic acid is generously applied to aide in the recognition of high-grade
squamous
intraepithelial lesions.
Acetowhite regions are examined under the operative microscope to further distinguish lesions as either low-grade
squamous
intraepithelial lesions or high-grade
squamous
intraepithelial lesions.
These lesions are selectively destroyed under direct visualization with an effort to maintain normal mucosa and
skin
to prevent stenosis.
Some pigmented lesions contain high-grade
squamous
intraepithelial lesions; the operative microscope is used in this setting to look for the vascular characteristics of high-grade disease.
RESULTS: The video reports five male patients treated for high-grade
squamous
intraepithelial lesions with the aide of high resolution anoscopy.
All lesions suspicious for high-grade
squamous
intraepithelial lesions based on observed vascular patterns were confirmed as such with permanent histopathology.
CONCLUSION: The use of acetic acid and the operative microscope with selective use of Lugol's solution accentuates the visual characteristics of high-grade lesions, enhancing the surgeon's ability to target treatment to high-grade
squamous
intraepithelial lesions.
High resolution anoscopy is useful in the targeted treatment of high-grade
squamous
intraepithelial lesions.
[MeSH-major]
Anus
Neoplasms / pathology.
Carcinoma
,
Squamous Cell
/ pathology. Colonoscopy / methods. Image Enhancement. Video-Assisted Surgery / methods
MedlinePlus Health Information.
consumer health - Anal Cancer
.
MedlinePlus Health Information.
consumer health - Colonoscopy
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16222485.001).
[ISSN]
0012-3706
[Journal-full-title]
Diseases of the colon and rectum
[ISO-abbreviation]
Dis. Colon Rectum
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
United States
71.
Theelen W, Speel EJ, Herfs M, Reijans M, Simons G, Meulemans EV, Baldewijns MM, Ramaekers FC, Somja J, Delvenne P, Hopman AH:
Increase in viral load, viral integration, and gain of telomerase genes during uterine cervical carcinogenesis can be simultaneously assessed by the HPV 16/18 MLPA-assay.
Am J Pathol
; 2010 Oct;177(4):2022-33
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Oncogenic human papillomavirus (HPV) infection is the most important risk factor in cervical carcinogenesis cases; high viral loads, viral integration into the host genome, and gain of the telomerase-related genes, TERT and TERC, are all factors associated with progression to
cancer
.
Only 5 out of 37 normal tissue samples or low-grade cervical lesions (ie, CIN1 and condyloma) showed either an HPV16 viral load higher than 25 copies per
cell
, viral integration, and/or gain of one of the telomerase-related genes, whereas for the high-grade cervical lesions, one or more of these risk factors was found in 25 of 30 cases.
Furthermore, the feasibility of the MLPA assay was shown for cytological samples, where in 57% of high-grade
squamous
intraepithelial lesion cases, the high-risk factors were detected using this assay.
[MeSH-major]
Human papillomavirus 16 / isolation & purification. Human papillomavirus 18 / isolation & purification. Papillomavirus Infections /
diagnosis
. Telomerase / genetics. Uterine Cervical Neoplasms /
diagnosis
. Viral Load. Virus Integration
[MeSH-minor]
Adult. Aged.
Carcinoma
,
Squamous Cell
/
diagnosis
.
Carcinoma
,
Squamous Cell
/ etiology.
Cell
Transformation, Neoplastic / genetics.
Cell
Transformation, Neoplastic / pathology. Cervical Intraepithelial Neoplasia /
diagnosis
. Cervical Intraepithelial Neoplasia / etiology. DNA, Viral / genetics. Feasibility Studies. Female. Humans. In Situ Hybridization, Fluorescence. Middle Aged. Nucleic Acid Amplification Techniques. Polymerase Chain Reaction. Uterus / metabolism. Uterus / pathology. Young Adult
MedlinePlus Health Information.
consumer health - Cervical Cancer
.
International Agency for Research on Cancer - Screening Group.
diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas
.
International Agency for Research on Cancer - Screening Group.
diagnostics - A practical manual on visual screening for cervical neoplasia
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Am Fam Physician. 2006 Jan 1;73(1):105-12
[
16417073.001
]
[Cites]
Cancer Genet Cytogenet. 2005 Feb;157(1):42-8
[
15676146.001
]
[Cites]
Vaccine. 2006 Aug 31;24 Suppl 3:S3/1-10
[
16949995.001
]
[Cites]
J Pathol. 2006 Dec;210(4):412-9
[
17054308.001
]
[Cites]
Int J Cancer. 2007 Feb 15;120(4):806-12
[
17131311.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):17-22
[
17220327.001
]
[Cites]
Gynecol Oncol. 2007 Sep;106(3):549-57
[
17568661.001
]
[Cites]
J Clin Virol. 2007 Dec;40(4):321-4
[
17981499.001
]
[Cites]
Cancer Res. 2008 Jan 1;68(1):307-13
[
18172324.001
]
[Cites]
Clin Biochem. 2008 Apr;41(6):423-8
[
18206116.001
]
[Cites]
BMC Biotechnol. 2008;8:57
[
18652663.001
]
[Cites]
J Clin Microbiol. 2008 Nov;46(11):3678-85
[
18799702.001
]
[Cites]
Obstet Gynecol. 2008 Dec;112(6):1419-44
[
19037054.001
]
[Cites]
Cytopathology. 2008 Dec;19(6):342-54
[
19040546.001
]
[Cites]
Int J Cancer. 2009 Jan 15;124(2):381-6
[
19003961.001
]
[Cites]
J Clin Microbiol. 2009 Feb;47(2):287-93
[
19036939.001
]
[Cites]
J Natl Cancer Inst. 2009 Feb 4;101(3):153-61
[
19176451.001
]
[Cites]
J Genet Genomics. 2009 Apr;36(4):257-65
[
19376486.001
]
[Cites]
J Clin Virol. 2009 Jun;45(2):100-4
[
19394266.001
]
[Cites]
J Obstet Gynaecol Res. 2009 Jun;35(3):503-6
[
19527390.001
]
[Cites]
Int J Cancer. 2010 Feb 15;126(4):959-75
[
19711394.001
]
[Cites]
Cancer Res. 1999 Dec 15;59(24):6132-6
[
10626803.001
]
[Cites]
Proc Soc Exp Biol Med. 2000 Mar;223(3):316-21
[
10719846.001
]
[Cites]
J Clin Microbiol. 2002 Mar;40(3):779-87
[
11880393.001
]
[Cites]
J Clin Microbiol. 2002 Mar;40(3):886-91
[
11880410.001
]
[Cites]
Nucleic Acids Res. 2002 Jun 15;30(12):e57
[
12060695.001
]
[Cites]
N Engl J Med. 2003 Feb 6;348(6):518-27
[
12571259.001
]
[Cites]
J Clin Pathol. 2003 Jul;56(7):532-6
[
12835300.001
]
[Cites]
Am J Pathol. 2003 Oct;163(4):1405-16
[
14507648.001
]
[Cites]
J Pathol. 2004 Jan;202(1):23-33
[
14694518.001
]
[Cites]
Gynecol Oncol. 2004 Mar;92(3):873-80
[
14984955.001
]
[Cites]
Anal Biochem. 1984 Feb;137(1):221-6
[
6731800.001
]
[Cites]
Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):479-84
[
8552665.001
]
[Cites]
J Clin Pathol. 1997 Jul;50(7):600-4
[
9306943.001
]
[Cites]
Int J Cancer. 2006 Sep 1;119(5):1095-101
[
16586444.001
]
(PMID = 20813962.001).
[ISSN]
1525-2191
[Journal-full-title]
The American journal of pathology
[ISO-abbreviation]
Am. J. Pathol.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / DNA, Viral; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
[Other-IDs]
NLM/ PMC2947296
72.
Ito B, Niwa Y, Ando N, Ohmiya N, Miyahara R, Ohashi A, Itoh A, Hirooka Y, Goto H:
Diagnosis of the depth of invasion of esophageal carcinoma using digital radiography.
Eur J Radiol
; 2005 Jun;54(3):377-82
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Diagnosis of
the depth of invasion of esophageal
carcinoma
using digital radiography.
OBJECTIVE: The purpose of our investigation was to determine the usefulness of digital radiography (DR) for diagnosing the depth of invasion of esophageal
carcinoma
.
Percent esophageal stenosis (PES) was based on the diameter across the lesion of maximal narrowing and the average of the normal oral and
anal
side diameters.
[MeSH-major]
Carcinoma
,
Squamous Cell
/ radiography. Esophageal Neoplasms / radiography. Radiographic Image Enhancement
MedlinePlus Health Information.
consumer health - Esophageal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15899339.001).
[ISSN]
0720-048X
[Journal-full-title]
European journal of radiology
[ISO-abbreviation]
Eur J Radiol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Ireland
73.
Nair KS, Naidoo R, Chetty R:
Expression of cell adhesion molecules in oesophageal carcinoma and its prognostic value.
J Clin Pathol
; 2005 Apr;58(4):343-51
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Expression of
cell
adhesion molecules in oesophageal
carcinoma
and its prognostic value.
Oesophageal
carcinoma
remains a disease of poor prognosis.
It has been established that the initial step in the metastatic cascade is the detachment of tumour cells from the primary tumour via dysregulation of normal
cell
-
cell
and
cell
-matrix interactions.
Distinct proteins known as
cell
adhesion molecules (CAMs) mediate these interactions.
This review provides a brief description of five families of CAMs (cadherins, integrins, CD44, immunoglobulin superfamily, and selectins) and highlights their altered expression in relation both to prognosis and tumour behaviour in
squamous cell carcinoma
and adenocarcinoma of the oesophagus.
[MeSH-major]
Cell
Adhesion Molecules / analysis. Esophageal Neoplasms / chemistry
[MeSH-minor]
Adenocarcinoma / chemistry. Antigens, CD44 / analysis. Cadherins / analysis.
Carcinoma
,
Squamous Cell
/ chemistry. Humans. Integrins / analysis. Neoplasm Metastasis. Prognosis. Selectins / analysis
MedlinePlus Health Information.
consumer health - Esophageal Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Histopathology. 1998 Jan;32(1):7-14
[
9522210.001
]
[Cites]
J Cell Physiol. 1998 Sep;176(3):482-94
[
9699501.001
]
[Cites]
Cancer. 1998 Sep 1;83(5):858-66
[
9731887.001
]
[Cites]
Chest. 1999 Dec;116(6 Suppl):463S-465S
[
10619509.001
]
[Cites]
Mol Pathol. 1999 Aug;52(4):189-96
[
10694938.001
]
[Cites]
Mol Pathol. 1999 Aug;52(4):208-13
[
10694941.001
]
[Cites]
Int J Oncol. 2000 Apr;16(4):677-82
[
10717234.001
]
[Cites]
Int J Oncol. 2000 Apr;16(4):725-9
[
10717240.001
]
[Cites]
Genes Dev. 2000 Aug 1;14(15):1837-51
[
10921899.001
]
[Cites]
Br J Surg. 2000 Aug;87(8):992-1005
[
10931041.001
]
[Cites]
J Cell Biol. 2000 Aug 7;150(3):567-80
[
10931868.001
]
[Cites]
Int J Oncol. 2000 Oct;17(4):701-5
[
10995880.001
]
[Cites]
Breast Cancer. 2000 Jan;7(1):19-26
[
11029766.001
]
[Cites]
Cell Biol Int. 2001;25(1):61-9
[
11237409.001
]
[Cites]
Clin Chem. 2001 Apr;47(4):624-30
[
11274010.001
]
[Cites]
Oncol Rep. 2001 Sep-Oct;8(5):981-5
[
11496302.001
]
[Cites]
Clin Cancer Res. 2001 Nov;7(11):3519-25
[
11705871.001
]
[Cites]
J Clin Invest. 2002 Apr;109(8):999-1006
[
11956235.001
]
[Cites]
J Cell Biol. 1991 Sep;114(5):1059-68
[
1874786.001
]
[Cites]
Annu Rev Biochem. 1991;60:155-90
[
1883195.001
]
[Cites]
J Clin Lab Anal. 1991;5(5):344-66
[
1941355.001
]
[Cites]
J Cell Biol. 1991 Dec;115(6):1751-61
[
1757472.001
]
[Cites]
Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2292-6
[
1372439.001
]
[Cites]
Cell. 1992 Apr 3;69(1):11-25
[
1555235.001
]
[Cites]
Cell. 1992 Apr 17;69(2):225-36
[
1568244.001
]
[Cites]
J Pathol. 1992 May;167(1):77-82
[
1625062.001
]
[Cites]
J Pathol. 1992 Jun;167(2):187-91
[
1378891.001
]
[Cites]
Cell. 1992 Jul 24;70(2):293-301
[
1638632.001
]
[Cites]
Lancet. 1992 Oct 31;340(8827):1053-8
[
1357452.001
]
[Cites]
Br J Cancer. 1992 Oct;66(4):629-34
[
1384639.001
]
[Cites]
J Cell Biol. 1993 Feb;120(3):577-85
[
8381117.001
]
[Cites]
Lancet. 1993 Mar 20;341(8847):725-6
[
8095628.001
]
[Cites]
Am J Pathol. 1993 Apr;142(4):981-6
[
7682766.001
]
[Cites]
Am J Pathol. 1993 Apr;142(4):987-93
[
7682767.001
]
[Cites]
J Surg Oncol. 1993 Jun;53(2):78-83
[
8501910.001
]
[Cites]
Br J Cancer. 1993 Jul;68(1):122-4
[
7686390.001
]
[Cites]
J Cell Biol. 1993 Jul;122(2):431-42
[
8320265.001
]
[Cites]
Br J Cancer. 1993 Aug;68(2):428-32
[
8347502.001
]
[Cites]
Cancer Res. 1993 Sep 15;53(18):4197-203
[
7689929.001
]
[Cites]
J Biol Chem. 1993 Oct 25;268(30):22883-94
[
8226797.001
]
[Cites]
Nature. 1993 Dec 16;366(6456):630-1
[
7505052.001
]
[Cites]
Nature. 1993 Dec 16;366(6456):695-8
[
7505053.001
]
[Cites]
Cancer Res. 1994 Jan 1;54(1):291-6
[
8261454.001
]
[Cites]
Cell. 1994 Jan 28;76(2):301-14
[
7507411.0